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ABSTRACT 
 The Huntingtin interacting protein 1 (HIP1)-platelet-derived growth factor beta 
receptor (PDGFβR) fusion oncogene (H/P), resulting from a somatic t(5;7) translocation, 
causes expression of a constitutively active tyrosine kinase and is associated with 
myelomonocytic leukemia.  To gain an understanding of the mechanism of 
leukemogenesis, we generated a mouse model with a conditional H/P knockin allele. We 
found that activation of this allele in vivo in hematopoietic cells of adult mice was not 
sufficient to induce leukemia. However, co-induction with a conditional human t(8;21) 
AML1-ETO (A/E) knockin allele resulted in a fully penetrant, rapid onset aggressive 
myeloproliferative disease.  The leukemic cells were completely recombined and were 
uniformly Gr-1 positive.  This leukemia was associated with a decreased frequency of 
hematopoietic stem cells (HSC) in the bone marrow and was sensitive to tyrosine kinase 
inhibition by imatinib.  Imatinib treatment normalized white blood cell counts and 
restored bone marrow stem cell frequency but unexpectedly increased the ability of the 
leukemia to be transferred to syngeneic recipients.  We show that a leukemia-initiating 
cell (LIC) persists in vivo during imatinib therapy, shares phenotypic characteristics with 
HSCs, and does not depend on H/P signaling for survival. Mobilization of the LIC was 
unable to enhance sensitivity to imatinib. This first example of a conditional knockin 
mouse model of a leukemogenic tyrosine kinase has facilitated the identification of an 
A/E cooperating mutation and has shed surprising light on the differential response of 
xi 
 
different leukemia cells to imatinib targeted therapy. The persistence of an LIC 
corroborates clinical data and provides a model system for testing of novel therapies. The 
disparity between different cancer cells in the same tumor is an issue that needs to be 
resolved and from such models as that described here the resolution of this issue is now 
more tractable. 
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CHAPTER 1 
 
 
 
INTRODUCTION 
 
 
 
Summary 
Constitutively activated receptor tyrosine kinases have been discovered in 
many forms of cancer, most predominantly hematopoietic neoplasms. One such 
mutation is the t(5;7) reciprocal translocation discovered in patients with chronic 
myelomonocytic leukemia (CMML)
1
. This translocation fuses the majority of the 
Hip1 gene to the transmembrane and tyrosine kinase coding-domains of the Pdgfβr 
gene. This chapter summarizes the information known about the HIP1 family and its 
role in cancer, the transforming properties of the HIP1/PDGFβR fusion protein, 
mouse modeling of chronic myeloid leukemia, and therapeutic challenges in CML. 
 
HIP1 
 Huntingtin interacting protein 1 (HIP1), the mammalian homologue of yeast 
Sla2p, was discovered by yeast two-hybrid screen as an interacting partner with 
huntingtin (htt), the protein that is mutated in Huntington’s disease (HD)2. The 
interaction between HIP1 and htt was found to be inversely correlated with the 
polyglutamine length in htt and this decreased interaction is hypothesized to play a 
2 
 
role in HD pathogenesis. Hip1 encodes a 116-kDa cytoplasmic protein that is 
expressed in select mouse tissues, specifically brain and lung
3
. HIP1 contains 
phosphoinositide, AP2, clathrin and actin binding domains and has been implicated as 
a co-factor in clathrin-mediated endocytosis of membrane bound receptors (Figure 
1.1A)
4-8
. Previous work in our laboratory has demonstrated that HIP1 binds to and 
stabilizes epidermal growth factor receptor (EGFR), increasing downstream 
signaling
9
. Moreover, overexpression of HIP1 transforms 3T3 mouse fibroblasts to 
grow in an anchorage-independent fashion and form tumors in nude mice
9
. HIP1 has 
also been found to associate with c-Kit, PDGFβR, FGFR4, AMPARs, and NMDARs 
but the precise role of HIP1 in clathrin-mediated endocytosis remains unclear 
(unpublished data)
4,10,11
. We have shown that HIP1 is expressed at high levels in 
many human cancers including those derived from the prostate, lung, ovary, colon, 
breast, brain and lymphoid tissue
12-14
. Moreover, HIP1 expression was found to be a 
negative prognostic factor in prostate cancer
12
. HIP1 has also been shown to be 
necessary for prostate and breast tumorigenesis in mouse model systems
15,16
. Adult 
Hip1 null mice display a complex degenerative phenotype characterized by 
kypholordosis, shortened lifespan, testicular degeneration, micro-opthalmia and 
cataracts
3,17
. The phenotype of this mouse clearly demonstrates that Hip1 has an 
important role in normal cellular homeostasis. Chapter 2 of this thesis describes the 
discovery and characterization of a cryptic splicing event that occurs in a targeted 
Hip1 mutant mouse that partially restores HIP1 protein functions as well as breast and 
prostate tumorigenesis in models of these cancers that are inhibited by HIP1 
deficiency.  
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HIP1/PDGFβR 
 Prior to the discovery that HIP1 expression is altered in solid tumors, Hip1 
was cloned as the chromosome 7 locus in a t(5;7)(q33;q11.2) translocation with the 
platelet-derived growth factor β receptor (PDGFβR) gene in a patient with CMML1. 
This in-frame chromosomal translocation fuses amino acids 1-950 of HIP1 with the 
transmembrane and tyrosine kinase domains of the type III receptor tyrosine kinase 
PDGFβR (Figure 1.1B). Only 18 C-terminal amino acids of HIP1 are excluded from 
the fusion protein. Seventeen other translocations involving the Pdgfβr gene have 
been identified in CMML and most patients demonstrate the common clinical 
features of leukocytosis, eosinophilia, variable dysplastic monocytosis and 
splenomegaly
18
. The other fusion partners of Pdgfβr, including TEL(ETV6), 
H4/D10S170, Rabaptin-5 and CEV14, are unrelated in function but share in common 
motifs which are thought to facilitate ligand-independent oligomerization of the 
fusion proteins
19
.  HIP1 contains a leucine zipper motif, a domain that has been 
shown to mediate homodimerization
20. The reciprocal PDGFβR/HIP1 fusion protein 
or transcript was not identified in the original patient and the other reciprocal 
translocations are not thought to play a role in leukemic transformation
1
.  
The fusion protein HIP1/PDGFβR (H/P) is cytoplasmic, constitutively 
phosphorylated and causes IL3-independent growth of the pro-B cell line Ba/F3
21
. 
These transformed cells have constitutively activated STAT5 and tyrosine 
phosphorylation of an as yet unidentified protein, p130. Interestingly, the leucine 
zipper domain was not found to be necessary for H/P oligomerization but rather, the 
terminal 55 amino acids of the HIP1 portion (corresponding to the actin-binding 
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TALIN homology domain) were necessary for oligomerization. In contrast to 
findings with other X/P fusions, additional HIP1 sequences were found to be 
necessary for transformation of Ba/F3 cells. Specifically, deletion of amino acids 
690-752 of HIP1 led to abrogation of transforming ability in Ba/F3 cells and this was 
associated with the loss of association with and tyrosine phosphorylation of p130. 
There are no known functional motifs with sequence homology in this region. It is 
unclear whether these residues are necessary for transformation of hematopoietic cells 
in vivo. Other PDGFβR fusions such as TEL/PDGFβR (T/P) have been shown to rely 
on STAT5 activation for transforming properties in vitro and in vivo 
22,23
. While there 
is clearly a role for the 5’ fusion partner in X/P translocations, most of the available 
data suggests that these oncogenic fusion proteins induce CMML via hyperactivity of 
the PDGFβR downstream signaling pathways 21,23. The principal pathways that have 
been shown to play a role in X/P mediated transformation are Ras/MAPK, PI3K, 
PLCγ and STAT5a/b.  
 
 
Modeling CML in mice 
Modeling hematopoietic neoplasms in mice, specifically the chronic myeloid 
forms, has been challenging for various reasons. One of the first approaches that 
gained popularity was transplantation of bone marrow cells that have been 
retrovirally transduced with the oncogene of interest 
24,25
. This approach utilizes the 
MSCV LTR promoter to express high levels of oncogene in immature hematopoietic 
progenitors. Hematopoietic cells are isolated from donor mice that have been pre-
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treated with the chemotherapeutic agent 5-flurouracil (5FU) and then cultured in 
cytokine-enriched media short term. Some of the known X/PDGFβR (X/P) fusions 
(Tel/P, Rabaptin-5/P) have been tested by this bone marrow 
transduction/transplantation assay (BTT) and these have all resulted in fatal 
myeloproliferative disease (MPD) closely resembling human CML and/or 
CMML
26,27
. Chapter 3 describes our use of the H/P oncogene in the BTT assay and 
the induction of a similar MPD.  
Despite the success of the BTT method in validating the leukemogenic 
potential of fusion tyrosine kinases, the system has multiple flaws that prevent its 
usefulness for evaluating the complexities of disease progression or measuring 
responsiveness to therapies. First, the MSCV LTR promoter does not restrict 
oncogene expression levels and supraphysiologic levels of the oncoproteins are 
almost always detected in recipient mice. In fact, transplant mice often develop a fatal 
myeloproliferative disease so rapidly after transplant that blastic transformation or 
investigation of therapeutic benefits cannot be observed before the mice die. Second, 
due to the random nature of retroviral integration, additional mutations are introduced 
into the genome. Third, short-term culture of hematopoietic cells during retroviral 
transduction may select for the most “leukemic” clones prior to transplant. Fourth, 
while the 5FU pretreatment does enrich for hematopoietic stem cells, the exact 
identity of the infected cell/cells is often unclear. While the 5’ fusion partners’ are not 
believed to play a critical role in the functionality of fusion RTKs, their regulatory 
elements would presumably affect expression of the novel gene (i.e. Tel regulatory 
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elements would control the T/P expression profile, Hip1 regulatory elements would 
control the H/P expression profile).  
To improve on these drawbacks, recent reports have used a gene “knockin” 
strategy to express fusion oncogenes under the spatial and temporal control of 
endogenous mouse promoters
28
. Loxp-flanked transcriptional stop cassettes are 
introduced upstream of the knocked-in oncogene, and Cre transgenic mice can then 
be used to limit expression to specific subsets of cells. The mouse hematopoietic 
system follows a hierarchical model driven by a rare, pluripotent stem cell (Figure 
1.2, HSC) which gives rise to all blood cell types
29
.  Many cell types in the 
hematopoietic system, including the HSC, can be prospectively isolated based on the 
expression of unique surface marker combinations. These “phenotypically” identified 
cells can be “functionally” validated by transplant and cell culture assays. The 
conditional knockin system is a powerful approach that combines the comprehensive 
knowledge of mouse hematopoiesis with gene targeting. Chapter 3 describes the 
generation and analysis of a conditional knockin of H/P into the mouse Hip1 locus. 
Importantly, we and others have found striking differences between the phenotypes 
generated by the BTT system and conditional knockin mice.   
 
Tyrosine kinase inhibitor therapy in CML 
 Most cases of chronic myeloid leukemia (CML) are the result of a somatic 
t(9;22) translocation that produces the fusion oncogene BCR/ABL. Similar to the X/P 
fusions in CMML, BCR/ABL has constitutive kinase activity and causes hyper-
production of mature myeloid cells that manifests clinically as splenomegaly and 
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leukocytosis. The advent of the molecularly targeted small molecule imatinib 
mesylate (IM) has revolutionized CML treatment
30
. Imatinib mesylate is a 2-
phenylaminopyrimidine derivative that competitively binds to the ATP-binding site 
of ABL, c-KIT, PDGFαR, and PDGFβR thus inhibiting kinase signaling. The use of 
IM as first-line therapy for new diagnosis CML with the t(9;22) translocation has 
improved the 5-year survival rate to 89%
31
. Nevertheless, with the passage of time, 
problems such as kinase domain drug resistance mutations and BCR/ABL transcript 
persistence have prevented the proclamation of “cure”. In vitro evidence suggests that 
the primitive “CML stem cell” is refractory to tyrosine kinase inhibitor (TKI) 
therapy
32
 and patients who stop therapy invariably relapse
33,34
. Eradication of CML 
necessarily requires eradication of the “CML stem cell” and concerted efforts are 
being taken to identify and characterize this malignant population. 
 
  The goal of this thesis was to investigate the mechanisms by which H/P 
induces chronic myelomonocytic leukemia with a focus on therapeutic strategies 
targeting H/P signaling. In Chapter 2, we describe our characterization of an 
unexpected splicing phenomenon that circumvented a gene targeting event to 
conditionally knockout Hip1. This information led to a better understanding of the 
complex Hip1 genetic locus that was used for the work that followed. In Chapter 3, 
we describe a novel mouse model of MPD induced by expression of the human 
tyrosine kinase oncogene H/P and the human transcription factor oncogene 
AML1/ETO (A/E) from their endogenous loci. We further demonstrate persistence of 
a leukemia-initiating cell (LIC) despite hematologic response to tyrosine kinase 
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inhibition. In Chapter 4, we further characterize the H/P;A/E-driven MPD and 
investigate the potential mechanisms of LIC persistence.  
 
  
9 
 
` 
 
 
 
 
 
 
Figure 1.1: Huntingtin Interacting Protein 1 (HIP1) and the HIP1/PDGFβR 
fusion protein 
A. Structure of mammalian HIP1 depicting the binding domains for lipids (ANTH), 
AP2, clathrin and actin (TALIN). Also depicted are the coiled coil and leucine zipper 
domains and the breakpoint in the t(5;7) translocation.  
B. Top, Platelet-derived growth factor β receptor (PDGFβR) structure depicting 
extracellular PDGF binding domain, transmembrane domain (TMD) and split kinase 
domain (KD). PDGF binding induces dimerization and kinase activity. Bottom, 
HIP1/PDGFβR fusion protein dimerizes independently of ligand stimulation, leading 
to constitutive kinase activity. 
10 
 
 
 
 
 
Figure 1.2: Simplified schematic model of normal hematopoietic development.  
Rare, pluripotent, self-renewing hematopoietic stem cells (red) differentiate into committed myeloid 
and lymphoid progenitors (blue) which differentiate into all mature blood cell types. Abbreviations: 
LT-HSC - Long-term HSC, ST-HSC - Short-term HSC, MPP – multipotent progenitor, CMP – 
committed myeloid progenitor, CLP – committed lymphoid progenitor. GMP – 
granulocyte/macrophage progenitor, MEP – megakaryocyte/erythrocyte progenitor. See text and 
methods for surface marker combinations  
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CHAPTER 2 
 
A Novel Use of a Cryptic Splice Site in the Hip1 Gene Allows for the Expression of 
HIP1 in Select Normal and Neoplastic Tissues 
 
Summary 
Huntingtin Interacting Protein 1 (HIP1) is a 116 kDa endocytic protein that is 
necessary for the maintenance of several adult tissues in vivo.  Its complete deficiency, 
due to homozygosity of a null Hip1 allele, leads to degenerative adult phenotypes. HIP1 
deficiency also inhibits prostate tumor progression in the prostate cancer prone TRAMP 
mouse model.  To better understand how deficiency of HIP1 leads to such phenotypes, 
we carefully analyzed tumorigenic potential in mice homozygous for a Hip1 mutant 
allele, designated Hip1
Δ3-5
, which is predicted to result in a frame-shifted, nonsense 
mutation in the N-terminal region of the coding sequence.  In contrast to our previous 
studies using the Hip1 “null” allele, an inhibition of prostate tumorigenesis was not 
observed as a result of the homozygosity of the “nonsense” Δ3-5 allele.  Also, it did not 
inhibit breast tumorigenesis in the MMTV-Myc breast cancer-prone background. To 
more closely examine the contrasting results from the two different Hip1 mutant mice, 
we cultured tumor cells from homozygous Δ3-5 allele bearing TRAMP and MMTV-myc 
mice and discovered the presence of an approximately 110 kDa form of HIP1 in tumor 
cells.  Upon genomic DNA and cDNA sequencing of Hip1 from these tumors, we 
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determined that this 110 kDa form of HIP1 is the product of splicing of a cryptic U12-
type AT-AC intron.  This event results in the insertion of an AG dinucleotide between 
exons 2 and 6 and restoration of the original reading frame.  Remarkably, this mutant 
protein retains its capacity to bind lipids, clathrin, AP2, and EGFR providing a possible 
explanation for why tumorigenesis was not altered following this “knockout” mutation.  
The expression and activities of this mutant form of HIP1 provide clues for future studies 
investigating the contribution of HIP1 to the homeostasis of specific normal and 
neoplastic tissues at different developmental stages. 
 
Introduction 
Huntingtin Interacting Protein 1 (HIP1) was first identified by its ability to 
interact with huntingtin, the protein encoded by the gene that is mutated in Huntington’s 
disease
1,2
.  HIP1 and its only known mammalian relative, HIP1-related (HIP1r), were 
subsequently shown to specifically interact with clathrin, AP2
3-10
, and epidermal growth 
factor receptor (EGFR)
11
.  Thus, the HIP1 family is widely thought to be involved in the 
regulation of growth factor receptor endocytosis and signaling.  Additionally, HIP1 and 
HIP1r contain AP180 N-terminal homology (ANTH) inositol lipid-binding domains, 
which are specific to endocytic proteins
12,13
.  Finally, deficiency of HIP1 leads to spinal 
defects, testicular degeneration, cataracts, adult weight loss, and early death
14-16
. These in 
vivo phenotypes indicate that HIP1 is necessary for fundamental cellular and organismal 
homeostasis.  Despite their clear necessity in the maintenance of adult cells and tissues, 
the precise cellular and biochemical function(s) of this protein family are yet to be 
determined.  In fact, several attempts at understanding the effects of HIP1/HIP1r 
15 
 
deficiency on receptor endocytosis either in cultured cells or in vivo have not been 
successful
14,16,17
. 
In addition to its function in normal tissue maintenance, HIP1 has been widely 
implicated in tumorigenesis.  HIP1 was discovered to be an amino-terminal partner of 
PDGFβR, in the leukemogenic fusion resulting from a t(5;7) chromosomal 
translocation
18
.  HIP1 protein also has been found to be up regulated in multiple human 
tumor types including prostate, colon
19
, breast
20
, brain
11
, and lymphoid
21
 cancers.  
Additionally, HIP1 over-expression is prognostic in prostate cancer
19
.  Furthermore, 
heterologous human HIP1 over-expression can transform mouse fibroblasts
20
, an effect 
that we propose to be due to altered growth factor receptor endocytosis and subsequent 
signal transduction cascades.  
To examine the role of HIP1 in prostate cancer, we have previously used mutant 
mice that are deficient in HIP1 due to a spontaneous targeting event (Hip1
null
).  When 
these HIP1-deficient mice were crossed with the transgenic adenocarcinoma of mouse 
prostate (TRAMP) mice
22
, the HIP1-deficient progeny mice contained fewer and less 
aggressive prostate tumors than their littermate TRAMP control mice
23
.  We have 
expanded these studies by using a different tumor model system (MMTV-MYC model of 
breast cancer) and a “third generation” Hip1 knockout mouse allele (the Hip1Δ3-5) that 
does not provide the confounding issues associated with the above-described spontaneous 
“null” allele16, such as possible altered expression of HIP1-neighboring genes caused by 
the neomycin cassette.  In the present study, we report the surprising result that Hip1
Δ3-
5/Δ3-5 
are equally, if not more, prone to the development of prostate and breast tumors than 
Hip1 wild type mice.  Furthermore, we found that the tumor cells from the Hip1
Δ3-5/Δ3-5 
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genetic background express a truncated form of the Hip1 protein that is the result of a 
novel cryptic splicing event.  These results have important implications not only for the 
role of HIP1 and its interacting proteins in normal and neoplastic cell biology but also for 
the development and analysis of mouse model systems with specific targeting events. Our 
data emphasize the value of how sequencing the transcript that is actually produced by an 
engineered knock-out allele can reveal novel types of molecular compensation at the 
level of splicing. 
 
Materials and Methods 
Mice.   
Mx1cre (B6.Cg-Tg(Mx1-cre)1Cgn/J, The Jackson Laboratories), Hip1
null
, Hip1
loxp
, 
Hip1
Δ3-5
 
(16)
,  TRAMP (
22
, C57BL/6, The Jackson Laboratories) and MMTV-myc (
24
, 
MammJ/FVB, Gift from Lewis Chodosh) allele-containing mice were maintained and 
bred under SPF conditions as per UCUCA guidelines at the University of Michigan.  The 
TRAMP and MMTV-myc allele-containing mice were maintained on pure genetic 
backgrounds.  Since the other alleles were maintained on a mixed C57BL/6;129svj 
background, all experiments were performed using the appropriate littermate controls.   
Tumor analysis in MMTV-myc mice.   
MMTV-myc transgenic mice were mated onto Hip1
null/null
 and Hip1
Δ3-5/Δ3-5
 backgrounds 
and were palpated for breast tumors weekly.  Tumor size was measured with calipers.  
The mice were sacrificed at one year of age or if a tumor impeded movement or 
ulcerated. 
Tumor cell culture.   
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Fresh tumor samples from MMTV-myc and TRAMP mice were cut into 1 mm sections, 
added to DMEM containing 2.2 mg/ml collagenase (Sigma), and incubated for 1 hour at 
37
o
C with agitation every 10 minutes.  The digested samples were filtered through a 100 
μm nylon cell strainer (Falcon) then centrifuged at 1,000 rpm for 10 minutes.  The 
supernatant was removed, and the remaining cells were suspended in DMEM/10% FBS 
and plated onto 10 mm dishes.  Cells were passaged every 3 days into fresh media. 
Survival analysis in TRAMP mice.   
The Hip1
null/null
 and Hip1
Δ3-5/Δ3-5
 mice were maintained on a mixed C57BL/6;129svJ 
background, and the TRAMP mice were
 
maintained on a pure C57BL/6 background.  
Intercross matings of TRAMP and Hip1
null/null
 and Hip1
Δ3-5/Δ3-5
 mice were performed as 
previously described
23
.  Fourteen TRAMP;Hip1
Δ3-5/Δ3-5
, 13 TRAMP;Hip1
+/Δ3-5
, 18 
TRAMP;Hip1
+/null
, and 15 TRAMP/Hip1
null/null 
littermates were analyzed for tumors at 
6.5 months.  Prior to these necropsies, a group of mice from these cohorts either 
unexpectedly died or became moribund and required euthanasia.  This survival data for 
each of these observation groups was compared.
 
 
Genomic DNA sequencing.   
High-fidelity PCR amplification of the 3 kb genomic region between exons 2 and 6 of 
Hip1 from a MMTV-myc;Hip1
Δ3-5/Δ3-5
 tumor was performed.  The resulting products 
were cloned, and single-run complete sequencing was performed on two independent 
clones. 
Sequence analysis.   
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The alignment of sequences from wild type Hip1 cDNA or MMTV-myc;Hip1
Δ3-5/Δ3-5
 
tumor genomic DNA was analyzed using a combination of Sequencer version 4.5 
(GeneCodes) and the NCBI BLAST program. 
RNA isolation.   
Total RNA was isolated from cultured tumor cells, tissues, and early passage mouse 
embryonic fibroblast (MEF) extracts using the TRIzol reagent (Invitrogen). 
Reverse-transcriptase PCR (RT-PCR).   
RT-PCR was performed on total RNA using the SuperScriptTM One-Step RT-PCR 
system (Invitrogen) and primers specific to Hip1 exon 1 (5’-
ATGAAGCAGGTATCCAACCCGCTGCCC-3’, forward primer) and the exon 14/15 
junction (5’-ATTAGCCTGGGCCTTTCTTTCTATCTC-3’, reverse primer) of murine 
Hip1 cDNA.  Resulting products were separated on 0.8% agarose gels.  Products were 
extracted from the gel and amplified by nested PCR using primers specific to the exon 
1/2 junction (5’-TTCGAGCGGACTCAGACGGTCAGCGTC-3’-forward primer) and 
the exon 13/14 junction (5’-ATGGCCCGCTGGCTCTCAATCTTCATG-3’ reverse 
primer) of murine Hip1 cDNA.  Products were again run on 0.8% agarose gels, extracted, 
and directly sequenced using the PCR primers that were used for the amplification.  PCR 
products that did not yield readable sequence were cloned using the TOPO TA Cloning 
Kit for Sequencing (Invitrogen).  Multiple clones were selected, and plasmid DNA was 
isolated and sequenced. 
Northern blot analysis of mouse embryonic fibroblast (MEF) mRNA.   
Poly (A) RNA was isolated from total RNA using the Poly(A) Purist MAG protocol 
(Ambion).  Then, 5μg of this poly(A) RNA was separated on a 1% agarose gel with 6% 
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formaldehyde, stained with ethidium bromide, transferred to Nytran membrane 
(Schleicher & Schuell), and cross-linked.  The membrane was prehybridized in a buffer 
containing 5X SSC, 5X Denhardt solution, 1% sodium dodecyl sulfate (SDS) (wt/vol), 
and 100 g of denatured salmon sperm DNA/ml for 3 h at 65C.  For the mouse Hip1 
Northern probe, an 850-bp EcoR1 and Not1 digested fragment encoded by mHip1 exons 
10-14 was used.  The probe was 
32
P labeled using a random-primed labeling kit 
according to manufacturer’s directions (Roche).  The blot was hybridized overnight at 
65C, washed twice in 2X SSC for 20 min, once in 1X SSC for 10 min, and twice in 0.1X 
SSC for 10 min.  The blot was exposed for 4 to 5 days on Kodak Biomax film.  The 
mRNA abundance was normalized with the signal for glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH).         
Tissue preparation and western blot analysis.   
Tissue harvesting, preparation, and immunoblotting of tissues was performed as 
previously described
17
.  A polyclonal anti-HIP1 (1:5,000, UM354) antibody was used to 
detect HIP1 expression in MMTV-myc, TRAMP and Mx1-Cre mice, and polyclonal
 
anti-
actin (1:1000, Sigma) antibody was used as a control.  
polyIpolyC (pIpC)-treatment of Mx1-cre mice.   
Mice were injected intraperitoneally with 250 ug/mouse of polyinosinic-polycytidylic 
acid (pIpC, Sigma, St. Louis, MO) every other day for 7 or 14 days as previously 
described
25,26
.   
Bone marrow culture.   
Mouse bone marrow cell monocytic culture was carried out as previously described 
(Bradley, 2007), except that RPMI-1640 media and M-CSF (1 ng/ml, Sigma, St. Louis, 
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MO)
 
was used and femur bone marrow was plated onto 100 mm dishes.
 
 One week later, 
cells were directly lysed in the dishes and collected for protein analysis. 
 
Co-immunoprecipitation of HIP1 and EGFR and endocytic factors.   
Full-length and mutant EGFR and HIP1 cDNA constructs in pcDNA3 have previously 
been described
11
.  A 15-cm dish of 70% confluent 293T cells was transfected with 20 μg 
of HIP1 cDNA and 20 μg of EGFR cDNA using Superfect reagent (Qiagen).  Twenty-
four hours post-transfection, the cells were lysed using an all-purpose lysis buffer [50 
mmol/L Tris (pH7.4), 150 mmol/L NaCl, 1% Triton X-100, 1.5 mmol/L MgCl2, 5 
mmol/LEGTA, 10% glycerol, Complete EDTA-free protease inhibitor tablets (Roche), 
30 mmol/L sodium pyrophosphate, 50 mmol/L sodium fluoride, and 100μmol/L sodium 
orthovanadate].  Five milligrams of protein were incubated with pre-immune serum, 
polyclonal anti-HIP1 serum (UM323), or sheep polyclonal anti-EGFR (Upstate).  One 
hundred microliters of a 3:1 slurry of protein G-sepharose beads (GE Healthcare) in lysis 
buffer were then incubated with the lysate-antibody mixture at 4ºC for 60 min with 
rotation.  The protein G pellets were washed four times with 1 mL of lysis buffer.  The 
entire pellet was dissolved in SDS sample buffer, boiled for 5 min, separated on 7% SDS-
PAGE, and transferred to nitrocellulose membranes.  Antibodies used for western blot 
analysis were the anti-HIP1/4B10 antibody (mouse monoclonal, human anti-HIP1 
immunoglobulin G1, 400 ng/mL), anti-adaptin-α antibody (rabbit polyclonal, BD 
Biosciences), anti-clathrin heavy chain TD-1 antibody (kind gift of Linton Traub, 
University of Pittsburgh), and an anti-EGFR antibody (sheep polyclonal antibody, 
Upstate Biotechnology, Charlottesville, VA). 
Generation of HIP1 expression constructs.   
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Generation of the pcDNA3/FL HIP1 expression construct was reported previously
19
.  
PCR mutagenesis using pcDNA3-FL HIP1 as a template was used to generate the insert 
for the pcDNA3/hHIP1Δ3-5/insAG expression construct.  Two initial PCR products were 
generated using two separate pairs of primers.  The first primer pair consisted of a 
forward primer specific to exon 1 (5’-AGGGAGACCCAAGCTTGGTA-3’including a 
KpnI restriction site) and an engineered reverse primer (5’-
GGGATTCTTTCTGGCGTGTTTTTCCTT-3’) consisting of sequence from exon 2, an 
AG dinucleotide, and sequence from the 5’ portion of exon 6.  The second primer pair 
consisted of an engineered forward primer (5’-
AACACGCCAGAAAGAATCCCAGGTTCC-3’) consisting of sequence from the 3’ 
portion of exon 2, an AG dinucleotide, and sequence from exon 6 and a reverse primer 
specific to exon 14 (5’-TTCTATCTCAGACAGGCTCC-3’; just 3’ of the EcoRI 
restriction site at position 1290 of the coding sequence).  The resulting PCR products 
were used as templates in a second PCR reaction to generate the hHIP1Δ3-5/insAG 
insert.  The hHIP1Δ3-5/insAG insert was cloned into pcDNA3-FL HIP1 using the KpnI 
and EcoRI restriction sites.  
Generation and purification of GST-fusion proteins.   
The 5’ portions of pcDNA3/FL HIP1 and pcDNA3/hHIP1Δ3-5/insAG were cloned into 
pGEX4T.1 to generate GST-HIP1wt (amino acids 1-430) and GST-HIP1Δ3-5 (amino 
acids 1-337) expression constructs, respectively.  The HIP1wt and HIP1Δ3-5 inserts 
cloned into the pGEX4T.1 vector were generated by PCR amplification using the forward 
primer, 5’-CCGGAATTCATGGATCGGATGGCCAGC-3’, and the reverse primer, 5’-
CCGCTCGAGACAGTCGTCGGCCGCCTGC-3’ and pcDNA3/FL HIP1 and 
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pcDNA3/hHIP1Δ3-5/insAG as templates.  Constructs were verified by sequencing.  The 
GST-HIP1wt and GST-HIP1Δ3-5 fusion proteins were expressed in E. coli strain BL21 
following induction with 0.1mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) for 2 h 
at 37
o
C.  Bacteria were pelleted and resuspended in PBS containing protease inhibitors 
(Roche Diagnostics).  Resuspended cells were lysed by sonication, and Triton X-100 was 
added to a final concentration of 2%.  The mixture was centrifuged at 12,000 x g for 10 
min.  Following centrifugation, the supernatant was added to glutathione sepharose 4 
beads (50% slurry) and incubated at room temperature for 30 min.  The beads were 
washed 3 times with PBS and elution buffer (50mM Tris-HCL, 10mM reduced 
glutathione [pH 8.0]) to elute the fusion proteins.  Eluted proteins were dialyzed in PBS 
at 4
o
C for 2 h and again overnight.  Dialyzed proteins were concentrated using Aquacide 
(Calbiochem), and protein concentrations were determined by SDS-PAGE and 
Coomassie blue staining.  Proteins were further analyzed by western blot analysis using 
an anti-GST antibody (Cell Signaling Technologies) and an anti-HIP1 antibody 
(UM354). 
Lipid-binding assay.   
Lipid-binding assays using PIP strips and PIP arrays (Echelon) were performed according 
to manufacturer’s protocol.  Briefly, either PIP strips or PIP arrays were incubated 
overnight at 4
o
C with 12.5 µg of purified protein in TBST with 1% milk.  Binding was 
detected using anti-GST antibody (1:5000) or UM354 (1:2000) in TBST with 1% milk.  
Anti-rabbit secondary antibodies conjugated to horse radish peroxidase (HRP) were used 
at 1:5000 (for anti-GST) or 1:2000 (for UM354) in TBST with 1% milk. 
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Results 
Germ line deletion of Hip1 exons 3 thru 5 leads to a phenotype similar to that of 
Hip1
null 
mice.   
The Hip1 gene has a complex structure consisting of 32 exons spread over 220 
kilobases.  To examine the role Hip1 plays in development and disease, we have 
generated a series of Hip1
16
 and Hip1r
17
 mutant alleles.  The original Hip1
null 
allele was 
serendipitously generated in an attempt to knock the human HIP1/PDGFβR fusion cDNA 
into the mouse Hip1 genomic locus
16
.  Using this null allele, we previously reported that 
HIP1 deficiency leads to a complex degenerative mouse phenotype
16
 and impaired tumor 
progression in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice
23
.  
Because of the complex structure of this original allele and the resultant multi-tissue 
phenotype, we generated a conditional Hip1 mutant allele (Hip1
loxp
).  To do this, we 
generated a targeting vector to introduce loxP sites flanking Hip1 exons three through 
five, which encode a significant portion (80%) of the ANTH domain.  As predicted, cre-
mediated recombination of these loxP sites resulted in the deletion of exons 3-5 as well as 
the neomycin selection cassette
16
.  The resulting allele (Hip1
Δ3-5
) contains not only a 
deletion of most of the ANTH domain sequences but also a frame-shifted, nonsense 
mutation that fuses exon 2 to exon 6.  Protein expressed from this mutant allele is 
predicted to be a truncated amino terminal 10 kDa protein lacking the ANTH, clathrin-
binding, AP2-binding, coiled-coil, and Talin homology domains (domains that span the 
remaining 90% of the coding sequence; Figure 2.1).  
Previously, mice homozygous for the Δ3-5 allele were found to exhibit 
degenerative phenotypes similar to the Hip1
null/null
 mice (e.g., kypholordosis and testicular 
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degeneration/infertility).  However, there were two differences in the phenotypes 
associated with these mice.  First, the Hip1
Δ3-5/Δ3-5
 mice did not have cataracts.  Second, 
the Hip1
Δ3-5/Δ3-5
 mice did not display perinatal lethality
16
.  These differences suggested 
that either the Hip1
Δ3-5
 allele is not a complete null allele or that the serendipitous Hip1
null
 
allele affects neighboring genes and that those effected genes (rather than Hip1) are 
necessary for embryogenesis and lens homeostasis.   
 
Breast and prostate tumorigenesis is not inhibited in Hip1
Δ3-5/Δ3-5 
mice. 
Since HIP1 is known to transform mouse fibroblasts
20
 and is over-expressed in 
multiple human cancers
19
, it has been hypothesized to play a role in tumorigenesis.  We 
have previously demonstrated that HIP1 deficiency inhibits prostate tumor progression in 
TRAMP mice
23
.  To examine further the involvement of HIP1 in tumor development, we 
analyzed the effect of HIP1 deficiency on breast tumorigenesis using the MMTV-myc 
mammary tumor model
24
.  Because of its less complex structure but similar phenotype to 
the Hip1
null
 allele, we have used the Hip1
Δ3-5 
allele in our subsequent studies of the role of 
HIP1 in tumorigenesis.  MMTV-myc and TRAMP transgenic mice were generated in 
both the Hip1 “null” and Δ3-5 genetic backgrounds.  The MMTV-myc mice were 
sacrificed prior to or at 12 months of age and analyzed for the appearance and 
progression of breast tumors (Figure 2.2).  Consistent with our previous results using the 
TRAMP mice, the HIP1 “null” background inhibited tumorigenesis induced by the 
MMTV-myc transgene
23
 such that none of the 6 Hip
null/null
;MMTV-myc mice (0%) 
analyzed developed breast tumors. In contrast, 3 of 16 Hip
+/null
;MMTV-myc mice 
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(18.8%) analyzed developed breast tumors.  This trend supports the hypothesis that HIP1 
deficiency inhibits breast tumorigenesis (Figure 2.3A). 
 The use of the Δ3-5 allele (compared to the null allele) to generate a HIP1 
deficient background resulted in a different effect on tumorigenesis.  For the MMTV-myc 
mice, 8 of 18 (44%) Hip1
Δ3-5/Δ3-5 
mice and 19 of 37 (51%) Hip1
+/Δ3-5 
mice developed 
palpable breast tumors (Figure 2.3A).  This level is significantly higher than the 19% 
breast tumor incidence in MMTV-myc mice with the Hip1
+/null
 backgrounds and the 0% 
incidence in the Hip1
null/null
 background.  Additionally, we only observed breast tumor 
metastasis in mice that contained the Δ3-5 allele (Figure 2.3B).  Both multiple 
synchronous primary breast tumors (Figure 2.3C) as well as multiple metastatic foci 
(Figure 2.3D) were observed in Hip1
+/Δ3-5
 and Hip1
Δ3-5/Δ3-5
 mice. 
The TRAMP;Hip1
Δ3-5
 mice produced similar results with a smaller cohort of mice 
available for tumor analysis (Figure 2.4).  We initially planned to compare larger groups 
of 6-month-old heterozygous and homozygous TRAMP;Hip1
Δ3-5 
mice.  This plan was 
based on the results of three independent prior TRAMP experiments that demonstrated 
that Hip1
null/+ 
and Hip1
+/+
 mice developed prostate cancer at a similar frequency and to a 
similar extent in the TRAMP background and survived to at least 6 months of age.  As 
expected, when we performed this fourth TRAMP experiment we observed that 84% 
(15/18) and 93% (14/15) of the TRAMP mice that were heterozygous and homozygous 
for the null allele, respectively, survived to 6 months of age (Figure 2.5A).  
Unexpectedly, Hip1
Δ3-5
;TRAMP mice (both heterozygotes and homozygotes) began to 
die spontaneously by 4 months of age and only 35% (5/14) of the homozygotes and 69% 
(9/13) of the heterozygotes survived to the 6 month point.  This reduction in survival 
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associated with the Hip1
Δ3-5 
allele was not due to the effects of the         Hip1
Δ3-5/Δ3-5 
degenerative phenotype (e.g., kypholordosis, dwarfism, etc.) as it was observed in both 
the heterozygotes and the homozygotes.  In the TRAMP mice that were available for 
tumor analysis we found that 4 of the 5 surviving homozygous Hip1
Δ3-5
 allele bearing 
TRAMP mice had gross prostate tumors (80%) and 3 of those 4 tumor bearing mice 
displayed gross evidence for multiple synchronous primary tumors in different lobes of 
the prostate (Figure 2.5B).  In comparison, there was no evidence for multiple primary 
tumors in the Hip1
+/Δ3-5
 (7 of these 9 (75%) mice had prostate cancer), Hip1
+/null
 (6 of the 
18 (33 %) mice had prostate cancer) or Hip1
null/null
 (5 of the 15 (33%) had prostate 
cancer) TRAMP mice. 
 
A novel cryptic splicing event allows for expression of a large mutant HIP1 protein.   
The difference in tumor incidence in the Hip1
null/null
 mice and the Hip1
Δ3-5/Δ3-5
 mice 
suggests either that (1) the original null allele alters the expression of neighboring genes 
and that it is those genes that influence tumorigenesis or (2) the Δ3-5 allele is not a 
completely null allele.  To investigate these two possibilities, we examined normal and 
tumor tissues from TRAMP and MMTV-myc mice with the Δ3-5 allele for the 
expression of polypeptides that react with HIP1-specific antibodies.  Extracts from these 
tissues were analyzed by western blotting for the presence of either full-length or 
truncated HIP1 protein using a polyclonal rabbit antibody (UM354) specific for the 
amino-terminal end of the HIP1 protein (Figure 2.6A).   Additionally, tumor tissue was 
dissociated and cultured so that tumor cells from these mice could be analyzed.  Results 
of this analysis indicated that a truncated protein approximately 10 kDa smaller than the 
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wild type HIP1 protein was expressed in the Hip1
Δ3-5/Δ3-5
 tumor-derived cultured cells 
(Figure 2.6A, lanes 1 and 2 versus lanes 3 and 4).  Extracts derived from the bulk of the 
tumor as well as other select tissues from these mice showed the expected lack of 
expression (lanes 5-10). 
In the construction of the Δ3-5 allele, exons 3 through 5 were deleted not only to 
disrupt the ANTH domain but also to ensure that the splicing of exon 2 with exon 6 or 
any of the other exons downstream of exon 6 would result in a frame shift that would 
lead to premature truncation at the amino terminal end of the protein.  Therefore, the 
presence of a truncated HIP1 protein in these tumor cells that is only 10 kDa smaller than 
the wild type protein was quite surprising.  To identify the mRNA that encodes for this 
truncated HIP1 protein, we performed reverse transcriptase polymerase chain reaction 
(RT-PCR) using total RNA derived from TRAMP and MMTV-myc tumor-derived 
cultured cells.  Primers specific to the exon 1 and the exon 14/15 junctions of the HIP1 
cDNA sequence (NCBL BLAST-Accession # NT_039314) were used in the initial RT-
PCR reaction.  We detected a PCR product of the expected size (1.6 kb) in tumor-derived 
cells generated from wild type mice and from mice heterozygous for the Δ3-5 allele 
(Figure 2.6B).  An additional band approximately 300 bp smaller (i.e., 1.3 kb) than 
expected was observed in both heterozygous and homozygous mice.  These bands were 
excised from the gel, PCR amplified using nested primers, and the products were 
sequenced.  The cDNA sequence for the nested 1.6 kb product was identical to that of the 
wild type Hip1 cDNA.  Interestingly, the sequence of the nested 1.3 kb product contained 
exon 2 fused to exon 6 with a dinucleotide AG insertion in the junction. This dinucleotide 
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insertion put the exon 2/6 fusion in frame (Figure 2.7) such that it encodes for an only 
slightly truncated HIP1 protein (Figure 2.6C).  
To examine further the above-described HIP1 mutant protein, we sequenced the 
Hip1 gene from genomic DNA derived from cultured tumor cells.  Surprisingly, we did 
not detect a mutation.  However, careful analysis of the genomic sequence revealed two 
unique findings to explain the aberrant protein and transcript expression.  First, we found 
that intron 2 uses a rare “AT-AC” U12 dependent splicing mechanism.  This type of 
intron, which represents approximately 1% of the introns in the mammalian genome
27
, 
consists of 5’AT and 3’AC splice sites.  Second, we found that the intron 5 splice 
acceptor (a typical AG) is immediately preceded by an AC.  This ACAG sequence allows 
for the incorporation of an AG dinucleotide into the coding sequence of the mRNA 
transcript and serendipitous maintenance of the original reading frame.  The predicted 
size of this mutant protein is 106 kDa, which is very similar to the size of the observed 
protein product. 
 
Mutant HIP1Δ3-5insAG protein expression in embryonic and adult lung and brain 
tissues.   
The presence of this AG dinucleotide insertion that placed exons 2 and 6 in frame 
in both Δ3-5 heterozygous and Δ3-5 homozygous cells led us to re-evaluate whether or 
not Hip1 protein is expressed in normal tissues.  We isolated select normal cells and 
tissues from wild type, Δ3-5 heterozygous, and Δ3-5 homozygous mice and analyzed 
them for the presence of the Hip1Δ3-5insAG protein product.  Using northern blot 
analysis of embryonic fibroblast RNA (Figure 2.8A), we found that the truncated 
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message was evident in homozygous mice when analyzed beside wild type RNA.  Using 
RT-PCR, we also found that tissue from the brains, lungs, and kidneys of Δ3-5 
heterozygous and homozygous mice contained the HIP1Δ3-5insAG mRNA (Figure 
2.8B).  No PCR product representing the Hip1Δ3-5 mRNA was observed in wild type 
mice. We also found that extracts from cultured, early passage embryonic fibroblasts and 
embryonic brain contained easily detectable truncated HIP1Δ3-5insAG protein product 
(Figure 2.9).  In contrast, nearly all adult tissues, with the exceptions of the lung and 
brain (Figure 2.8), displayed very low levels of HIP1 polypeptide expression. Either the 
diminished expression or the lack of function of the HIP1Δ3-5insAG product could 
explain why these mice display a degenerative phenotype similar to that of the original 
homozygous “null” mice.  In addition to the altered expression levels of the HIP1 
peptides in various tissues, we noted that the migration of the HIP1 protein in the 
embryonic brain was quite different from that in the adult brain.  Analysis of the Hip1 
protein product in embryonic, newborn, pre-weaned, and adult mice indicated that this 
differential expression correlates with developmental stage, with the product in the adult 
brain migrating distinctly slower or co-migrating with the wild type form of HIP1.  The 
molecular explanation of this striking developmental correlation remains to be 
determined. 
Next, using the original Hip1
loxp/loxp
 mice
16
, we generated a tissue-specific Δ3-5 
recombinant allele.  By crossing the Hip1
loxp
 mice with mice carrying an interferon 
inducible Mx1-Cre transgene, we generated mice that expressed the Δ3-5 allele only in 
cells of the adult hematopoietic system, liver, and kidney following pIpC-mediated 
induction of Cre expression
26,28
.  With these mice, we examined whether the gross 
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phenotype of the germ line Δ3-5 mouse could be recapitulated only in the isolated adult 
tissues.  Interestingly, western blot analysis of extracts from the spleen, liver, kidney 
(Figure 2.10A), and bone marrow (Figure 2.10B) of Mx1-Cre induced mice 
demonstrated that the expression of the truncated HIP1 protein was most prominent in the 
spleen and bone marrow and loss of HIP1 expression altogether was frequently observed 
in the normal liver and kidney but as expected not in brain, heart, eye, uterus, ovary or 
the GI tract (data not shown).  It is of interest that in the two tissues, liver and kidney, 
where we observed HIP1 protein deficiency due to a complete recombination event did 
not display the degenerative phenotype observed in the germ line recombined Δ3-5 mice.  
We therefore conclude that tissue specific HIP1 deficiency in the liver and kidney does 
not induce the knockout phenotype.  Unfortunately, we could not make this conclusion in 
the hematopoietic system as despite repeated attempts to induce interferon with pIpC, the 
complete recombination of the Hip1
loxp
 allele in the Mx1-cre mice was not achieved in 
hematopoietic tissues and, therefore, a significant amount of wild type Hip1 expression 
remained in the homozygotes.   
These findings also suggest the possibility that the truncated HIP1 protein may be 
preferentially expressed in dividing cells, including tumorigenic cells.  This prediction is 
supported by the finding that Δ3-5insAG protein was present in the fibroblasts and brains 
of Δ3-5 mouse embryos at E17.0 day. Furthermore, we discovered a gross liver tumor in 
an Mx1Cre;Hip1
loxp/+
 mouse (Figure  2.10C).  The tumor from this mouse expressed a 
truncated Δ3-5 protein product while the surrounding “normal” liver did not.  
Additionally, we identified a trend in which the spleen sizes of the Hip1 floxed, Mx1cre, 
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pIpC-treated mice increased, although frank hematopoietic malignancies were not 
observed (data not shown). 
 
The HIP1Δ3-5insAG protein retains its ability to bind lipids, clathrin, AP2, and 
EGFR.   
We have observed some slight phenotypic differences between the Hip1
Δ3-5/Δ3-5 
mice and 
the Hip1
null/null
 mice
16
.  These differences included absence of cataracts or perinatal death 
in the Hip1
Δ3-5/Δ3-5 
mice, increased mortality from tumors in the TRAMP;Hip1
Δ3-5
 mice 
relative to the TRAMP;Hip1
null/null
 mice, no decrease in breast or prostate tumorigenesis 
in Hip1
Δ3-5
 allele bearing backgrounds (although there was a trend toward more tumors), 
and a liver tumor in a young, conditional Hip1
Δ3-5
 heterozygous mouse.  Given these 
differences, we examined whether the Hip1Δ3-5insAG protein product possesses all or a 
subset of its cellular activities that promote normal and neoplastic cell 
proliferation/survival by assessing its ability to bind to lipids, endocytic factors, and 
EGFR.   
Because this truncated protein retains its clathrin-, AP2-, and EGFR-binding 
regions, we predicted that the Hip1Δ3-5insAG protein product would have the ability to 
bind these proteins.  To test this hypothesis, we expressed the HIP1
Δ3-5/insAG
 cDNA in 
293T cells, immunoprecipitated the mutant protein with an anti-HIP1 polyclonal antibody 
(UM323, bleed 8/2002), and immunoblotted the precipitates to determine the presence or 
absence of the endocytic proteins and EGFR. As expected, the truncated mutant protein 
bound EGFR, clathrin and AP2 (the alpha subunit) (Figure 2.11A, lanes 11 and 15).  In 
contrast, expression of a human HIP1 mutant cDNA construct that lacks the AP2- and 
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clathrin-binding domains did not bind these endocytic proteins.  Also, it should be noted 
that the interaction between HIP1 and EGFR was apparently enhanced by the deletion of 
either the sequences encoded for by exons 3-5 or the domains that bind to endocytic 
proteins, suggesting that the interaction of HIP1 with EGFR is not indirectly mediated by 
the its binding with clathrin and/or AP2. 
Since 80% of the sequence of the lipid binding ANTH domain is deleted from the 
HIP1Δ3-5insAG protein, we predicted that this mutant would likely not retain its lipid 
binding activity.  Interestingly, most of the key residues that are important for the direct 
binding of the ANTH domain-containing proteins to PI(4,5)P2 were retained in the Δ3-5 
protein product (key residues are bold in Figure 1)
12,13
.  However, one key residue 
(homologous to K76 of epsin) that has been shown to be important in binding to the 
Ins(1,4,5)P3 head group
13
 is deleted in the truncated Δ3-5 protein.  To determine whether 
the Δ3-5 protein product retained its lipid-binding capacity, we examined lipid binding 
using recombinant GST-HIP1
wt
 and GST-HIP1
Δ3-5/insAG
 fusion proteins.  We generated 
and glutathione-sepharose purified GST-fusion proteins that contained the first 430 and 
370 amino acids of the HIP1
wt
 and HIP1
Δ3-5/insAG
 proteins, respectively (Figure 2.11B).  
The purified proteins were separated by SDS-PAGE and Coomassie stained to quantitate 
the amount of recombinant protein.  The purified recombinant proteins were also 
analyzed by western blot to ensure interaction with anti-GST and anti-HIP1 antibodies.  
Next, the purified proteins were incubated with Echelon-generated PIP strips to examine 
whether the fusion proteins were capable of binding lipids.  Both the wild type and the 
HIP1
Δ3-5/insAG
 mutant fusion proteins bound PtdIns(3)P predominantly (Figure 2.12).  
These results were confirmed using PIP arrays (Echelon), which were used to further 
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examine the differential abilities of these proteins to bind to lipids.  Interestingly, these 
truncated fusion proteins displayed a higher specific binding to PtdIns(3)P than to 
polyphosphorylated inositol lipids.  On the other hand, our previous studies using the 
full-length HIP1 expressed in 293T cells indicated that its lipid binding preference was 
polyphosphorylated 3-phosphoinositides
29
.  Our contradictory results may be due to 
either the absence of the carboxyl-terminal end of the protein, differences in proteins 
expressed in bacteria versus mammalian cells or differences in the materials used in the 
various assays.  Additional biochemical analyses are necessary to clarify this issue.  
Nevertheless, the specific inositol lipid binding capacity of the ANTH domain is retained 
in the Hip1Δ3-5insAG protein.     
 
Discussion 
 We have previously demonstrated that the HIP1 family of proteins are 
biologically important since both single Hip1
15,16
 and double Hip1/Hip1r
14
 knockout 
mice have adult degenerative phenotypes and HIP1 protein expression is altered in 
multiple cancers
19
.  However, the exact function of this protein family remains unclear, 
and more detailed cellular and biochemical analyses are needed to validate predicted 
functions and identify novel ones.  In the current study, we describe a novel form of HIP1 
that is expressed in vivo as the result of a novel cryptic splice event between a 5’ AT-AC 
intron (intron 2) and a 3’ GT-AG intron (intron 5).  These results are important for both 
technical and functional reasons.  First, it illustrates an unpredicted cryptic splicing event 
in a previously predicted “loss of function” gene targeting event, and, second, this type of 
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cellular natural selection may provide clues to the function of HIP1 in normal and 
neoplastic cells.   
The technical aspects of these findings have provided us a very important lesson. 
The targeting event that we initially designed led to a mutation in the AT-AC intron 2.  
The rare splicing event that we observed reflects preferential splicing between splice sites 
of the same class.  The identification of rare U12-dependent intron splicing sites or AT-
AC introns will be important for all proteins with similar genetic structures
27
.  This 
finding has also raised an intriguing possibility that such splicing events might occur in 
normal cells leading to the expression of unexpected polypeptides.  Interestingly, the rare 
AT-AC intron 2 is conserved in both the human and mouse Hip1 genes.  This observation 
is consistent with previous reports that U12-type introns are usually conserved 
phylogenetically
30
.  It has been reported previously, that genes with                 non-
redundant, crucial cellular activities may have strong selective evolutionary pressure 
against the conversion of U12- to U2-type introns and, therefore, have retained them.  
HIP1 supports this assertion as HIP1 clearly has nonredundant, crucial activities as 
evidenced by the fact that its deletion in mice leads to dramatic adult phenotypes
14-16
. 
In terms of HIP1 function, it is evident that the expression of the truncated mutant 
protein in adult lung and brain tissue does not prevent the adult degenerative phenotypes, 
such as kypholordosis or testicular degeneration. The discovery here of concomitant 
expression of HIP1 sequences in the Hip1Δ3-5 homozygous mice and the degenerative 
phenotype suggests that this mutant protein may not be completely functional in normal 
cells.  In contrast, the presence of the truncated mutant protein in tumor cells may explain 
why tumorigenesis is not inhibited by the homozygosity of this allele.  This proposal is 
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supported by the finding that this mutant protein retains some of its functions (i.e., the 
ability to bind to lipids, clathrin, AP2, and EGFR).  These findings illustrate a 
prototypical example that provides insights into how mouse modeling may lead to 
insertion mutations and unpredicted, active protein products. 
The maintenance of AP2-, CHC-, EGFR- and lipid-binding functions in the 
truncated mutant HIP1 protein suggests that another HIP1 cellular function must 
contribute to the gross phenotype of the mutant mice.  This unknown function likely 
explains why we were unable to identify endocytic defects in either of the mutant mouse 
systems.  Future studies are required to understand the molecular modifications and 
sequences of the various forms of HIP1 that are expressed in different tissues at different 
times during mammalian development and how these different forms affect HIP1 
functions.   
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Figure 2.1:  Amino acid sequence of the HIP1 ANTH domain and schematic 
diagram of the HIP1 domain structure.   
The majority of the mouse ANTH domain is encoded by exons 3 to 5.  The amino acid 
sequence of the mouse ANTH domain (italicized,
12,13
) and a few additional carboxyl 
amino acids are shown in the box above the schematic diagram of the full-length protein.  
A line is drawn through the amino acids that are encoded by exons 3 to 5.  Residues in 
bold (K, K, KH, K) share homology with AP180 and epsin and are considered to be 
critical inositol lipid-binding residues.  The predicted protein product encoded by the 
Hip1
Δ3-5
 allele is 10 kDa and is shown schematically below the full length HIP1 diagram.  
The predicted protein product from the Hip1Δ3-5insAG cDNA is 106 kDa and is also 
shown schematically. 
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Figure 2.2: Tumorigenesis in MMTV-myc mice in the absence of HIP1. Percent 
tumor-free survival out to 5 weeks of age is shown for MMTV-Myc+ mice on various 
HIP1 knockout backgrounds. Mice were sacrificed when the tumor ulcerated or impeded 
movement. 
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Figure 2.3: Breast tumorigenesis in the presence of the Hip1Δ3-5 allele.  
A.  MMTV-myc transgenic mice were mated on to Hip1
null/null
 and Hip1
Δ3-5/Δ3-5
 
backgrounds.  Mice were dissected at one year of age, or earlier if a tumor was found.  
44% of Myc+;Hip1
Δ3-5/Δ3-5
 mice developed breast tumors, compared to none of the Myc+; 
Hip1
null/null
 mice.  51% of Myc+; Hip1
+/Δ3-5
 mice developed breast tumors, compared to 
19% of Myc+; Hip1
+/null
 mice.   
B.  None of the Hip1
+/null
 mice with tumors (N=3) exhibited metastasis of the breast 
tumors. 25% of Myc+;Hip1
Δ3-5/Δ3-5
 mice with tumors (N=8) and 26% of Myc+; Hip1
+/Δ3-5
 
mice with tumors (N=19) had metastasis of the breast tumors to organs including the 
lungs, liver, spleen and salivary gland.  
C. Multiple breast tumors and metastasis to lungs of a Myc+; Hip1
Δ3-5/Δ3-5
 mouse at 30 
weeks of age.   
D.  Metastasis of a breast tumor to the lungs of a Myc+;Hip1
+/Δ3-5
 mouse at 40 weeks of 
age. 
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Figure 2.4: Tumor incidence in mice with Hip1Δ3-5 and Hip1null alleles. MMTV-
myc transgenic and TRAMP mice were mated on the Hip1
null/null
 and Hip1
Δ3-5/Δ3-5
 
backgrounds and analyzed for tumor incidence. TRAMP mice that survived to 6 months 
of age were scored for gross prostate tumors. In each case the mice with the Δ3-5 allele 
were afflicted with more tumors. 
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Figure 2.5: TRAMP mice on different Hip1 mutant backgrounds. 
A. Survival curve of TRAMP mice in different Hip1 mutant backgrounds.  
B. Examples of bilateral synchronous prostate tumors. 
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Figure 2.6: Expression of Hip1 sequences in Hip1Δ3-5 mice.   
A.  Tumors from mice with breast (MMTV-myc) and prostate (TRAMP) cancer were 
grown in culture and analyzed by western blot for the presence of HIP1 polypeptides.  
Results from an MMTV-myc breast tumor sample are shown.  P=passage number. Even 
at zero passages (P0), the cultured cells from Δ3-5/Δ3-5 tumors expressed a slightly 
truncated form of HIP1 (Lane 4).  This product was not detected in the bulk tumor tissue, 
in the normal tissues tested of these mice, or in any cell types derived from mice 
heterozygous for the Δ3-5 allele (lanes 5-10). 
B.  RT-PCR of total RNA extracted from Δ3-5 allele-containing tumor-derived cultured 
cells resulted in the generation of wild type (WT) and mutant (Δ3-5) bands of expected 
sizes.   
C.  Partial Hip1Δ3-5 cDNA sequence alignment with wild type mouse Hip1 cDNA 
demonstrated an AG dinucleotide insertion between exons 2 and 6 of the Hip1Δ3-5 
cDNA sequence.  This insertion maintains the open reading frame of the transcript.  
Tumor cell line genomic DNA contains a recombined “AT-AC” intron. Genomic DNA 
isolated from a Myc breast tumor-derived cell line was sequenced in the region where the 
recombination occurred (box).  The sequence was compared to wild type Hip1 genomic 
DNA and no additional mutations were observed.  Note the recombinant intron flanked 
by exons 2 and 6 has a U12-dependent consensus branch point sequence (italicized) and a 
3’ AC dinucleotide (italicized) that serves as the cryptic splice site acceptor.  This 
splicing event results in an “AG insertion” in the transcript.  The region sequenced is 
indicated by the box that encompasses exons 2, 6 and intervening sequences including the 
single loxP site. 
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Figure 2.7: Partial Hip1Δ3-5 cDNA sequence alignment with wild type mouse Hip1 
cDNA. Shown is an alignment of cDNA sequence from the nested PCR reaction with the 
exon 2/3 and exon 5/6 junctions of mouse Hip1 mRNA reference sequence 
(NM_146001). Dots in the mouse Hip1 mRNA reference sequence denote identity with 
the Hip1 Δ3-5 cDNA sequence. Codons are represented by alternating bold/nonbold 
trinucleotide sequences. Note the AG dinucleotide insertion between exons 2 and 6 of the 
Hip1 Δ3-5 cDNA sequence, which maintains the open reading frame of the transcript. 
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Figure 2.8: Expression patterns of the Δ3-5insAG mRNA and its putative protein 
product.  
A.  Northern blot analysis using a probe specific for the 5’ end of the mouse Hip1 mRNA 
(nucleotides 1-1260) demonstrated the presence of a significant amount of a slightly truncated 
product in the RNA of mouse embryonic fibroblast (lane 2 versus lane 1).   
B.  Primers specific to the exon 1/2 junction (forward) and the exon 13/14 junction (reverse 
primer) of murine Hip1 cDNA were used to amplify the cDNA.  The resulting products were 
separated on a 1.0% agarose gel.  Water was used as the negative control (lane 1).  RNA from a 
TRAMP prostate cancer cell line generated from the prostate tumor tissue of a mouse that was 
heterozygous for the Hip1
Δ3-5
 allele was used as a positive control for both the wild type Hip1 and 
Hip1
Δ3-5/insAG
 mRNA transcripts (lane 2).  A 1.6 kb band indicates the presence of wild type Hip1 
mRNA transcripts while a 1.3 kb band indicates the presence of the mutant Hip1
Δ3-5/insAG
 mRNA 
transcripts.  Brain, lung and kidney tissues from wild type Hip1 mice (+/+) produced the 1.6 kb 
band but not a 1.3 kb band (lanes 3, 6 and 9).  Similar tissues from heterozygous Δ3-5 mice (+/Δ) 
produced both a 1.6 kb band and a 1.3 kb band (lanes 4, 7 and 10).  Only the 1.3 kb band was 
produced in brain, lung, and kidney tissues from homozygous Δ3-5 mice (Δ/Δ) (lanes 5, 8 and 
11). 
C.  Expression of the truncated product was most prominent in lung tissue although lesser 
amounts are detected in all other tissues tested.  Interestingly, brain tissue from Δ3-5 adult mice 
displayed significant amounts of a protein product that co-migrated with the wild type form.  This 
co-migration was not observed in the extracts from embryonic brains (described in panel D).  
Actin blotting was performed using an anti-actin monoclonal antibody (Sigma) as a control.    
D.  Postnatal day zero brains (isolated immediately after birth) have HIP1 banding patterns 
similar to those of embryos.  Pre-weaning stage brains have two distinct HIP1 bands, and the 
adult brains have a HIP1 band that co-migrates with the wild type band. 
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Figure 2.9: HIP1 Δ3-5/insAG 106 kDa protein is present in mouse embryonic brain 
and fibroblasts. Western blot analysis for HIP1 expression in the brains (left panel) and 
fibroblasts (right panel) of 17-day old mouse embryos of different genotypes 
demonstrated the presence of a slightly truncated HIP1 product. MEF cells of different 
genotypes were cultured from eleven individual embryos from the same mother. Only 5 
samples are shown here but all demonstrated similar banding patterns as related to the 
distinct genotypes. 
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Figure 2.10:  Conditional cre-mediated recombination of the floxed Hip1 allele leads 
to either HIP1 deficiency or expression of the truncated product depending on tissue 
analyzed.  
A.  Mx1-Cre transgenic mice carrying none (+//+; lanes 2 and 7), one (-/+; lanes 3 and 8) 
or two (-/-; lanes 4-6 and 9-11) of the floxed Hip1 alleles were treated with 3 injections of 
pIpC at 8-12 weeks of age then were retreated at 20 weeks of age.  Their organs were 
harvested at 28-32 weeks of age.  Organ extracts were separated on 6% SDS-PAGE and 
analyzed for HIP1 expression by western blotting (using the UM354 (1:5000) antibody). 
An extract of a wild type brain (lane 1) was included as a positive control of HIP1 
expression.  Near complete recombination (resulting in the deficiency of HIP1 protein) 
was observed in liver and kidney but not in thymus and spleen where residual wild type 
-5insAG product) was expressed.  As expected, 
eye, brain, and heart tissue showed no evidence for recombination since Mx1-cre is not 
induced in these tissues 
26
-5insAG truncated product 
was observed in lung tissue and may be a result of recombination in tissue macrophages, 
which are abundant in the lung tissue.   
B. Mice were untreated (lanes 1, 2, 9 and 10) or treated at 6 weeks of age with pIpC (6 
doses IP every other day; lanes 3-6 and Lanes 11-14).  A small group was treated with 
pIpC again at 20 weeks of age (3 additional doses every other day; lanes 7, 8 and 15, 16).  
The mice were sacrificed at 6 months of age, and their tissues were analyzed for HIP1 
expression by western blot (UM354).  Complete deficiency of HIP1 was never observed 
in bone marrow despite continued pIpC injections whereas complete deficiency of HIP1 
was achieved was maintained in the liver without repeated recombination.  Interestingly, 
in the mouse without complete recombination in the liver (lane 14), there was no 
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truncated product in its cultured bone marrow (lane 6).   A small amount of the truncated 
product was observed in cultured bone marrow from some untreated mice (e.g. lane 1), a 
finding consistent with the possibility that the endogenous production of interferon (i.e. in 
response to viral infections) can activate Mx1-cre expression at low levels in mice in the 
absence of pIpC treatment.  As a loading control, actin blots were performed on 10% 
SDS-PAGE using a monoclonal anti-actin antibody (Sigma, St. Louis, MO).  
C.  Mice were treated with pIpC in two stages: first at 21 weeks of age (with 6 every 
other day doses) and second at 55 weeks of age (with 6 every other day doses).  Six 
treated mice (3 heterozygous and 3 homozygous) and 5 untreated mice were necropsied.  
At necropsy, a previously undetected liver tumor was discovered in a treated 
heterozygous mouse, and it was harvested for histological and protein expression 
analysis.  Increased amounts of truncated HIP1 expression were observed in the tumor 
tissue compared to surrounding “normal” liver tissue.  Since this was a heterozygous 
mouse, expression from the wild type allele was also detected. 
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Figure 2.11: HIP1Δ3-5insAG association with clathrin, AP2, EGFR and lipids. 
A.  HEK 293T cells were transfected with EGFR and/or various HIP1 constructs.  
Cells were lysed 24 hours post-transfection and polyclonal anti-HIP1 (UM323) and anti-
EGFR antibodies were used for immunoprecipitation.  The immunoprecipitates were 
separated on 6% SDS-PAGE gels and transferred to nitrocellulose for western blot 
analysis using the indicated antibodies.  Lanes 1-4: whole cell lysates.  Lanes 5-8: Pre-
immune immunoprecipitates.  Lanes 9-12: anti-HIP1 immunoprecipitates.  Lanes 13-16: 
anti-EGFR immunoprecipitates.  Note the association of AP2, CHC, and EGFR with 
HIP1 is preserved despite deletion of sequences encoded by exons 3-5.  Interestingly, the 
anti-EGFR antibody did not co-precipitate wild type HIP1 (top panel, lane 14) but did co-
precipitate the HIP1Δ3-5 and HIP1ΔLD mutant proteins (top panel; lanes 15 and 16).   
B.  Schematic diagrams of GST-5’HIP1 and GST-5’HIP1/Δ3-5 fusion proteins are 
shown.  Expression of these fusion proteins in E. coli BL21 was induced by treatment 
with 0.1 mM IPTG.  The cells were pelleted and lysed, and the fusion proteins were 
purified from the resulting extracts using glutathione sepharose 4 beads.  Ten microliters 
of a 1:10 dilution of the purified GST-5’HIP1 and GST-5’HIP1/Δ3-5 fusion proteins 
were run on a 10% polyacrylamide gel and immunoblotted with an anti-GST antibody 
(1:5000) or an anti-HIP1 antibody (UM354-1:2000) to ensure reaction of the proteins by 
the respective antibodies and to confirm their purity.  Similar amounts were run on a 
separate 10% polyacrylamide gel along with various known concentrations of BSA, and 
the gel was Coomassie stained to estimate the concentrations of the purified fusion 
proteins.   
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-5’HIP1 or GST-
5’HIP1/Δ3-5 protein in TBST with 1% milk were incubated with PIP arrays (Echelon) 
containing various concentrations of different phosphoinositides.  As with the PIP strips, 
both GST-5’HIP1 and GST-5’HIP1/Δ3-5 proteins bound preferentially to PtdIns(3)P.  
Lipid-protein interactions were detected using a polyclonal anti-GST antibody (Cell 
Signaling Technologies).  No signal was detected using antibody alone. 
 
 
 
 
 
 
 
 
 
 
Figure 2.12: Comparison of lipid binding specificity and relative affinity GST-
5’HIP1/Δ3-5 and GST-5’HIP1 using PIP strips. Protein solutions containing 10µg of 
either purified GST-5’HIP1 or GST-5’HIP1/Δ3-5 protein in TBST with 1% milk were 
incubated with PIP strips (Echelon) containing 15 different lipids at 100 pmol/spot. 
Lipid-protein interactions were detected using a polyclonal antibody (UM354) that 
recognizes both GST-5’HIP1 and GST-5’HIP1/Δ3-5 proteins. Both proteins bound 
preferentially to PI(3)P on the PIP strip.
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CHAPTER 3  
Persistence of Leukemia-Initiating Cells in a Novel Mouse Model of an 
Imatinib-Responsive Myeloproliferative Disorder  
 
Summary 
Despite remarkable responses to the tyrosine kinase inhibitor imatinib, CML 
patients are rarely cured by this therapy perhaps due to imatinib-refractoriness of 
leukemia-initiating cells (LICs). Evidence for this is limited because of poor engraftment 
of human CML-LICs in NOD-SCID mice and non-physiologic expression of oncogenes 
in retroviral transduction mouse models. To address these challenges, we generated mice 
bearing conditional knockin alleles of two human oncogenes: HIP1/PDGFβR (H/P) and 
AML1ETO (A/E). Unlike retroviral transduction, physiologic expression of H/P or A/E 
individually failed to induce disease, but co-expression of both H/P and A/E led to rapid 
onset of a fully penetrant, myeloproliferative disorder (MPD), indicating cooperativity 
between these two alleles.  Although imatinib dramatically decreased disease burden, 
LICs persisted, demonstrating imatinib-refractoriness of LICs.  
 
Introduction 
A number of chromosomal translocations that contribute to leukemogenesis in 
humans have been identified
1
.  For example, translocations that lead to the expression of 
a constitutively active platelet-derived growth factor beta receptor (PDGFβR) fusion 
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protein, such as HIP1/PDGFΒR (H/P)2, contribute to the development of chronic 
myelomonocytic leukemias (CMML)
3. Although these PDGFβR-driven leukemias are 
clinically sensitive to imatinib therapy
4
, the leukemias can still progress to acute myeloid 
leukemia (AML) or bone marrow failure over time. Progression to AML in chronic 
leukemias with tyrosine kinase mutations is associated not only with resistance to 
imatinib but also with additional genetic lesions such as the t(8;21)-associated 
AML1/ETO (A/E) fusion protein
5,6
.   
Molecularly-targeted cancer therapies, such as imatinib, have revolutionized 
patient care over the past twenty years. These drugs target molecular defects specific to 
cancer cells rather than simply targeting mitotically active cells. For example, the use of 
imatinib in CML patients has led to an enormous reduction in the five-year mortality 
associated with Bcr/Abl-positive CML
7
; however, only 5% of patients maintained on 
imatinib therapy are considered cured as defined by a molecular remission
8
. In fact, upon 
discontinuation of therapy, the disease aggressively relapses in the majority of patients
9
.  
These clinical observations suggest that while imatinib eliminates the bulk of CML cells, 
this drug may not eliminate the leukemia-initiating cells (LICs) that maintain the disease 
state.  
The CML-LIC, like normal hematopoietic stem cells (HSCs), is thought to have 
not only the properties of self renewal and differentiation but also a relative quiescence 
compared to the more differentiated leukemia cells
8
.  This quiescence has led to the 
hypothesis that the LIC is likely to be refractory to non-targeted therapies, such as 
chemo-or radio-therapy, which depend upon cell division for their cytotoxicity. In 
contrast, targeted therapies, such as imatinib, were thought to be more likely to eliminate 
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LICs compared to standard therapy approaches. Unfortunately, in the case of CML, the 
latter does not appear to be the case. Indeed, cell culture data have suggested that 
Bcr/Abl-expressing cells are refractory to imatinib therapy when quiescent and that 
awakening these cells increases their sensitivity to this drug
10
. The mechanism of this 
observed resistance and the in vivo confirmation of the relative refractoriness of 
CML-LICs to imatinib therapy compared to the bulk of neoplastic cells, however, has not 
yet been reported.  These types of in vivo studies have been difficult to accomplish due 
to poor engraftment of CML LICs into NOD-SCID mice and limitations inherent in the 
variability associated with studying human subjects.  
Modeling hematopoietic neoplasias in mice to study effects of therapies on cancer 
cells in vivo has also been challenging since the consequences of oncogene expression are 
different depending upon the techniques used to obtain expression. For instance, 
retroviral overexpression of A/E in hematopoietic cells leads to the formation of acute 
leukemias in some cases but not in others, and this variability may be due, in part, to 
expression of different isoforms
11
. This heterogeneity in outcome may also stem from 
variables inherent to retrovirus-mediated transduction, including copy number, 
expression level, integration site, the presence and identity of cooperating insertional 
mutations, and the identity of the infected cells. Furthermore, growth of 
retrovirally-infected cells may select for rare clones that have the highest levels of 
proliferation. In contrast to the retroviral model of A/E, Downing and colleagues 
developed a conditional knockin allele of A/E that was expressed from the mouse Aml1 
locus. Conditional expression of A/E under the control of native regulatory elements in 
the locus was never leukemogenic on its own. Treatment of disease-free conditional A/E 
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knockin mice with the DNA alkylating mutagen N-ethyl-N-nitrosourea (ENU) resulted in 
the development of acute leukemia
12
. These results suggest that the use of knockin alleles 
of oncogenes improves leukemia mouse modeling by achieving more realistic expression 
patterns; however, the A/E knockin model was still not entirely useful to leukemia 
investigators because these mice require unidentified cooperating mutations to develop a 
neoplastic phenotype.                              
In contrast to the existence of conditional knockin mouse models of the 
transcription factor oncogene A/E
12
 and other transcription factor oncogenes such as the 
MLL translocation fusions
13,14
, mouse models currently used to study tyrosine kinase 
oncogenes have been limited to retroviral transduction and transplantation assays
15,16
, a 
non-targeted transgenic of BCR/ABL
17,18
, and a non-conditional knockin mouse model of 
Flt3-Itd mutations
19,20
. Similar to the results described above for A/E, Flt3-Itd knockin 
animals demonstrated that knockin alleles of oncogenic tyrosine kinases likely yield 
different results than retrovirally-expressed alleles
19,20
. Thus, most conclusions as they 
relate to oncogene expression-induced leukemias to date have been based on 
non-physiologic expression of oncogenes.  Our understanding of leukemia biology will 
clearly benefit from studying the consequences of oncogene expression under the control 
of native regulatory elements.  
Since a knockin allele of an oncogenic PDGFβR kinase that is conditionally 
expressed under the control of native regulatory elements in adult hematopoietic 
progenitors is not yet available, we generated a conditional knockin allele of the H/P 
mutation and examined its ability to drive hematopoietic neoplasias.  We postulated that 
this allele would not only provide us with a more realistic model of X-PDGFβR-driven 
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hematopoietic neoplasias for investigation of targeted therapies such as imatinib but 
would also serve as a mechanism to test the hypothesis that tyrosine kinase oncogenes 
cooperate with transcription factor oncogene knockin alleles such as A/E. Since 
activating mutations in the PDGFR family of receptor tyrosine kinases (c-kit, flt3, and 
PDGFβR) have been found concurrently with the t(8;21) mutation in AML patients5,21, 
mutations in tyrosine kinase oncogenes and transcription factor oncogenes were likely to 
cooperate to produce the neoplastic phenotype
12
. Indeed, our studies to determine the 
consequences of H/P expression under the control of native regulatory elements in the 
adult animal provide a much improved model for characterizing tyrosine kinases in 
leukemogenesis and demonstrate that H/P cooperates with A/E to lead to a CML-like 
MPD that contains a rare population of LICs that are refractory to imatinib therapy.  
 
Materials and Methods 
Generation of Conditional H/P Knockin Mice  
The conditional H/P knockin allele, Hip1
LSL-H/P
, was generated by modifying the original 
H/P knockin target vector that contained a human H/P cDNA in frame with murine Hip1 
exon 2 
(22)
. Two custom vectors were constructed with desired multiple cloning sites 
(designated AMP1 with SpeI, EagI, EcoRI, NotI/EagI, BamHI, and SalI sites; and AMP2 
with NotI, KpnI, HindIII, and SalI sites).  The 5’ NotI/BamHI 8.2-kb fragment from the 
original H/P knockin vector was subcloned into the EagI/BamHI sites of AMP1 and 
named N/B7+KI.  Subsequently, the SpeI/EcoRI 7.2-kb fragment from N/B7+KI was 
ligated into the EcoRI/EcoRI 4-kb subclone from the original HIP1/PDGFR knockin 
target vector and into the AMP1 vector digested with SpeI and EcoRI (named p1N/RI/RI 
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5’).  Next, a 1.5-kb DNA fragment containing a transcription termination stop cassette 
flanked by loxP sites was inserted, as an AscI cassette, 5’ to the HIP1/PDGFR cDNA into 
the KpnI site of HIP1’s intron 2 (KpnI site modified to AscI by the paired oligos: 
5’–AACATTGGCGCGCCACAAGTCGTAC-3’ and 
5’-GACTTGTGGCGCGCCAATGTTGTAC-3’) and designated as p1N/RI/RI 5’ stop.  
This stop cassette contains the SV40 polyadenylation signal, thus preventing full-length 
transcripts from being made until the stop cassette is removed by Cre recombinase.  In 
addition, an ATG translation start site and 5’ splice donor are encoded to prevent correct 
expression of the HIP1/PDGFR fusion due to downstream transcription. The 3’ half of 
the target vector was constructed in the AMP2 vector by first subcloning the 4-kb HIP1 
exon 6 and 7 Hind H/B subclone into the HindIII site of AMP2 (designated p2H4).  A 
PGK-neomycin NotI/KpnI cassette lacking loxP sites was generated by PCR using the 
original target vector as a template and the following primers: 
5’-TTTGCGGCCGCTAGGTCTGAAGAGGAGTTTAC-3’ and 
5’-TTTGGTACCATTAAGGGTTCCGGATCGATC-3’. This NotI/KpnI neo PCR 
product was subcloned into p2H4 5’ of the HIP1 genomic DNA (named p3H4neo).  The 
final conditional H/P knockin target vector was generated by subcloning the p3H4neo 
NotI/SalI 5.5-kb fragment into the corresponding sites in p1N/RI/RI5’stop so as to fuse 
the neomycin resistance cassette and HIP1 3’ genomic DNA to the 3’ end of the 
polyadenylation signal for the H/P cDNA. The final targeting vector was ~21.5 kb.  
Electroporation into ES cells and screening by Southern blot for clones that were 
correctly targeted with the 3’ genomic probe was performed as described22.  
 
Southern Blot Analysis  
58 
 
Southern blot analysis to distinguish the targeted Hip1
LSL-H/P
 
allele and the wild-type 
allele was performed with the 3’ probe as described for the Hip1null allele22.  For 
recombination of the targeted allele, a hHIP1 cDNA probe (“5’ probe” encompassing 
HIP1 sequences up to the EcoRI site [nt 1260]; Figure 1) was used under the same 
conditions as those used for the 3’ genomic probe.  
Double and Triple Transgenic Mice  
Double transgenic Mx1-Cre;Hip1
+/LSL-H/P
 
mice were generated by crossing the 
Hip1
+/LSL-H/P
 
mice with mice transgenic for the Mx1-Cre gene (obtained from Jackson 
Labs 
23
). Triple transgenic Mx1-Cre;Hip1
+/LSL-H/P
;Aml1
+/LSL-A/E
 mice were generated by 
crossing the Mx1-Cre;Hip1
+/LSL-H/P
 mice with Aml1
+/LSL-A/E
 mice
12
. Expression of Cre 
(Sigma, St. Louis, MO) in a 100 ul of PBS at two-day intervals for two weeks as 
previously described
24
.  The pIpC activates interferon which activates the Mx1 
promoter. For this study a total of 69 triple transgenic mice were generated and 17 
(25%) had spontaneous recombination due to endogenous interferon mediated Mx1-Cre 
activation. We conclude this because double knockin mice that were Mx1-Cre negative 
never underwent recombination. Mice were mated onto a C57Bl/6 genetic background. 
Mice were housed in the Unit for Laboratory Animal Medicine at the University of 
Michigan and were monitored regularly for evidence of disease and abnormal 
peripheral blood cell counts.  
Hematopoietic Analysis  
Induced cohorts of 22 Mx1Cre; Hip1
+/LSL-H/P
 and 23 Mx1Cre; Hip1
+/+
 
littermate animals 
were bled on a monthly basis for determination of CBCs.  Numbers were pooled from 
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each time point. Induced double H/P;A/E knockin mice were bled on a weekly basis. 
Blood was collected into a tube containing EDTA (Sarstad, Inc) and analyzed with an 
850 HEMA-VET machine (CDC Technologies, Inc.). For the time course of peripheral 
smears from the double knockin mice, mice were pre-bled by sub-mandibular bleed 
prior to treatment with pIpC. Twenty-four hours after treatment, daily tail bleeds were 
initiated.  Smears were stained with Wright-Giemsa. Flow cytometric analysis, 
methylcellulose assays, and quantitation of HSCs from bone marrow and spleen were 
performed as described previously 
24
. The total number of 
CD150
+
CD48
-
CD41
-
Sca-1
+
c-kit
+
 
cells (HSCs) per mouse was calculated based on the 
frequency of this population in the bone marrow and spleen, the cellularity of the spleen 
and long bones, and the assumption that 15% of all bone marrow is within the long 
bones. Blood and other tissues do not contribute significantly to the overall size of the 
HSC pool.   
Mouse Genotyping 
Mouse tail DNA was used for PCR detection of the various germline alleles.  
Hip1
+/LSL-H/P
 
specific primers were 5’EcoRI 
(5’-CTGAGAGCCAGCGGGTTGTGCTGCAGCTGA-3’) and 3’EcoR1 
(5’-CTCCTTTAGCTTGCTATATCGCTGTTCATTGGC–3’). Cre allele primers were 
IMR567 (5’-ACCAGCCAGCTATCAACTCG-3’) and IMR568 (5’-
TTACATTGGTCCAGCCACC-3’). Aml1 primers were Int3.up (5’-
ATCAAATGATGACGACGG-3’), Ex5.low 
(5’-TGATGGCTCTATGGTAGGTGG–3’), and Int4.low 
(5’–CAGTTTAGGAAAACGGTGG–3’). The expected product sizes for Hip1
LSL-H/P 
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and Cre products were 200 base pairs. The Aml1 expected product (Int3.up and 
Int4.low primer pair) was 596 base pairs and, the A/E knockin product was 378 base 
pairs (Ex5.low and Int4.low primer pair). Pretreatment with a “gene releaser protocol” 
using 5 μl of gene releaser (Bioventrue, Inc.) mixed with 2 μl (100 ng/μl; 200 ng total) 
DNA was performed.                PCR analysis for Hip1
LSL-H/P
 recombination to 
Hip1
H/P
 (Figure 3.1G) was performed as follows. Genomic DNA was isolated from 
lysed peripheral blood samples or organs using standard protocols. Recombination of 
the floxed stop cassette was detected with the following primers: 
5’-CTATCCAAGGGACCTGATGG-3’ and 5’GCCAGTCCAAGGTGGATTTA -3’. 
The PCR conditions were as follows: 7 min at 94 ºC, 35 cycles of (30 sec at 94 ºC, 1 
min at 55 ºC, 1 min at 72 ºC), and 7 min at 72ºC. The predicted recombined product was 
336 base pairs, whereas the wild-type product was predicted at 200 base pairs. The 
non-recombined product, which contained the entire stop cassette, was 2 kilobases and 
not amplified under these conditions.  PCR analysis for A/E recombination was 
performed as described previously
12
.                                                                                                                             
Histology Analysis                                               
Tissue obtained at necropsy was
25
 fixed in 10% formalin/PBS.  Paraffin embedding 
and standard hematoxylin and eosin staining were performed by the University of 
Michigan Comprehensive Cancer Center Research and Histology and 
Immunoperoxidase Laboratory Core or Histoserv, Inc. MPO staining was carried out on 
deparaffinized and hydrated sections (xylene followed by 100-50% EtOH).  Antigen 
was retrieved with citrate buffer followed by incubation of the slide with 10% goat 
serum block and primary antibody (polyclonal anti-M PO, Abcam). Slides were blocked 
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for endogenous peroxidase with 0.3% peroxide. The secondary antibody was 
biotinylated goat anti-rabbit (1:200, Jackson Immuno Research). The signal was 
amplified using the ABC kit (Pierce) and visualized with the DAB kit (Vector labs).  A 
hematoxylin counterstained.  TUNEL assay was performed using the In Situ Cell 
Death Detection Kit (Roche), and non-specific esterase staining was achieved with the 
non-specific esterase staining kit (Sigma) following the manufacturers instructions. 
Imatinib experiments  
For the mouse treatment experiments, Imatinib mesylate capsules (Novartis, 100 mg) 
were crushed and dissolved in sterile PBS with 10% DMSO at a final concentration of 
20 mg/mL. The solution was filtered through a 0.1 uM syringe tip filter (Millipore). 
Mice were injected intraperitoneally once daily with 100 mg/kg.  Mice were treated in 
pairs (vehicle or imatinib) until a complete hematologic response (normalized WBC) 
was observed in the imatinib-treated mouse (7-10 days), and then both the vehicle and 
imatinib-treated mice bone marrow was transplanted into irradiated syngeneic lethally 
irradiated Ly5.2 recipient mice as described previously
24
. ENU mutagenesis  
Seven-to eleven-week-old Mx1-Cre positive H/P or wild type mice were 
intraperitoneally injected 6 times with 250 μg pIpC at two day intervals.  Mice were 
then subcutaneously injected with 4 doses of 1 μg G-CSF followed by a single IP dose 
of 50mg/kg ENU as described previously
12
. Mice were then observed for disease for 11 
months.  
Results 
Generation of H/P Conditional “Knockin” Mice  
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To model the human t(5;7) translocation, we engineered the human H/P cDNA into the 
mouse Hip1 locus downstream of a loxP-bracketed transcriptional stop cassette 
(Hip1
LSL-H/P
, Figure 3.1A). This conditional knockin allele allows use of specific Cre 
transgenic mice to guide tissue-specific expression together with the endogenous mouse 
Hip1 promoter to regulate the expression of the oncogenic fusion protein both spatially 
and temporally. We targeted ES cells to generate mice carrying the Hip1
LSL-H/P
 allele 
(Figure 3.1B).  Hip1
+/LSL-H/P
 mice were born at predicted Mendelian frequency and 
exhibited normal growth curves; however, these mice were distinguishable from 
wild-type littermates by the presence of gross microopthalmia and cataracts as seen 
previously in the heterozygous Hip1
+/null 
mice
22
.  The Hip1
+/LSL-H/P
 mice were crossed 
with transgenic Mx1-Cre mice. The Mx1 promoter is activated by interferon, which is 
induced by treatment with the synthetic double-stranded RNA, polyinosinic-polycytidylic 
acid (pIpC)
12,23,24
. The pIpC treatment leads to Cre expression in an array of 
hematopoietic and non-hematopoietic cells, but because the expression of the knockin 
allele depends on many of the natural regulatory elements of the HIP1 locus, we 
predicted that its expression would closely mimic that found in the original CMML 
patient. Southern blot analyses demonstrated that pIpC-induced recombination occurred 
in liver, kidney, and spleen but not in brain or testes (Figure 3.1C).  
 
Absence of Neoplasia in pIpC-Induced Mx1-Cre;Hip1
+/LSL-H/P 
Mice  
Mx1-Cre;Hip1
+/LSL-H/P
 
and Mx1-Cre;Hip1
+/+
 
littermate controls were treated with 
pIpC at 6 weeks of age (n=20 for each genotype) and monitored by peripheral blood 
analysis for eighteen months (Figure 3.1D).  Almost all of the animals survived to 1.5 
years of age without gross evidence of disease, although two moribund pIpC-induced 
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Mx1Cre;Hip1
+/LSL-H/P
 mice (three and nine months of age) were discovered. The three 
month-old had splenomegaly with a moderately effaced splenic structure (Figure 3.1E).  
The H/P fusion protein was detectable by western blot of lysates from cultured bone 
marrow cells from this mouse (Figure 3.1E, lane 2). The nine-month-old had a 
well-differentiated hepatocellular carcinoma (Figure 3.1F).  Interestingly, the neoplastic 
liver tissue exhibited complete recombination of the Hip1
LSL-H/P
 allele, but the kidney 
from this mouse maintained a 50% rate of recombination in the Hip1
LSL-H/P
 allele (Figure 
3.1F). The remaining mice appeared healthy up to 1.5 years of age without abnormalities 
in peripheral blood cell counts (data not shown).  
At the experimental endpoint of 1.5 years, the mice were sacrificed and 
necropsied for gross abnormalities. Eight pIpC-induced Mx1-Cre;Hip1
+/LSL-H/P
 mice 
(47%) and three Mx1-Cre;Hip1
+/+ 
mice (20%) were discovered to have enlarged spleens 
(>150 mg) upon necropsy. The histology of the enlarged spleens showed signs of 
myeloproliferation with enlarged red pulp.  MPD was histologically diagnosed from five 
of the H/P (29%) and one of the wild type (7%) enlarged spleens. An additional Mx1-
Cre;Hip1
+/LSL-H/P
 mouse had a liver tumor (Table 3.1). Flow cytometry and 
methylcellulose analyses of bone marrow from the 1.5-year-old pIpC-treated 
Mx1-Cre
;
Hip1
+/LSL-H/P
 mice did not display significant abnormalities (data not shown). 
Excision of the floxed stop cassette was detected by PCR in hematopoietic tissue from 
the 1.5-year-old mice, indicating that the lack of significant disease was not due to 
selective loss of cells with the recombined Hip1
H/P
 allele (Figure 3.1G). Since the pIpC-
treated Mx1-Cre
;
Hip1
+/LSL-H/P
 mice did not frequently develop hematopoietic 
malignancies even after 1.5 years, we conclude that physiologic H/P expression is not 
64 
 
sufficient to cause hematopoietic transformation. These results are in contrast with 
evidence from models that rely on retroviral bone marrow expression of tyrosine kinase 
oncogenes such as Bcr/Abl
16
, TEL/PDGFΒR15, and H/P (Figure 3.2).  In these animals, 
these oncogenes alone efficiently induce a lethal myeloproliferative disease similar to 
CML.  
The infrequent occurrence of neoplasms after a long latency in the mice bearing 
the H/P knockin allele suggests that additional genetic events are required to transform 
hematopoietic cells.  To begin to test this hypothesis, 7-11-week-old H/P mice were 
mutagenized with ENU to induce secondary mutations following pIpC induction of H/P 
recombination. A week after pIpC induction, the mice were treated with G-CSF for four 
days to induce myeloid proliferation, and the following day the mice were administered a 
single mutagenic dose of ENU (50 mg/kg). Since this dose of ENU efficiently induces 
only single base mutations
26
, we did not observe any neoplasias in mutagenized wild-type 
control animals as expected (0/12; Table 3.1). By contrast, 67% of the H/P-expressing 
mice died or developed disease by 10 months after treatment (17/24). Disease was scored 
as “present” when gross thymic tumors, splenomegaly, and/or spontaneous death were 
observed. Interestingly, histological and FACS analysis of the spleens demonstrated both 
myeloid and lymphoid neoplasias, suggesting that the H/P mutation does not specifically 
transform cells of the myeloid lineage. Finally, it remains unknown if disease penetrance 
in mice bearing the H/P knockin allele is modified by different genetic backgrounds since 
all of the studies presented here are on a pure C57/BL6 background.  
 
CML-Like MPD in pIpC-Induced H/P;A/E Mice 
The A/E mutation has been identified in many human tyrosine kinase-driven 
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leukemias
5,6,21
.  We, therefore, tested whether conditional co-expression of the H/P and 
A/E fusion oncogenes from their endogenous loci in adult mice led to hematopoietic 
transformation.  A previous report showed that Mx1-Cre-activated A/E expression from 
the mouse Aml1 locus is insufficient for leukemogenesis
12,27
. Dual conditional knockin 
mice were generated by intercrossing Mx1-Cre;Hip1
+/LSL-H/P
 mice with Aml1
+/LSL-A/E
 
knockin mice (Figure 3.3A).  The double knockin Mx1-Cre transgenic uninduced 
H/P;A/E mice, which were genotyped at weaning, were born and survived at a 
significantly lower than predicted Mendelian frequency (7.5% observed vs. 12.5% 
expected; p<0.001 Figure 3.4), indicating some embryonic or perinatal lethality. All 
surviving mice, however, were developmentally normal.  
To study the consequences of simultaneous H/P and A/E expression in adult 
bone marrow, we treated H/P;A/E mice with six doses of pIpC every other day 
beginning at six weeks of age. In contrast to wild-type and single knockin mice, 100% 
of the induced double knockin (H/P;A/E) mice developed a fully penetrant, aggressive 
MPD, some within days of initiation of pIpC treatment (Figure 3.3, 3.4). The 
CML-like disease was easily identifiable by severe myeloid leukocytosis (Figure 3.3D 
and 3.3E) and palpable hepatosplenomegaly as early as 72 hours following the start of 
pIpC induction (range 3-42 days; Figure 3.3F). White blood cell (WBCs) counts at the 
time of euthanasia were increased an average of 25-fold above wild-type levels with a 
range of 50-700 K/μL (Figure 3.3E).  While the white cell differential demonstrated a 
reversal of the normal 1:3 neutrophil-to-lymphocyte ratio (Figure 3.3E, right), an 
increase in absolute numbers of all lineages was also observed. Compared to wild-type 
or single knockin animals, spleen and liver weights of diseased H/P;A/E animals were 
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increased ten-fold and two-fold, respectively (Figure 3.3F, left).  Myeloid blasts were 
never observed at a frequency greater than 20% in bone marrow cytospins, precluding a 
diagnosis of acute leukemia (Figure 3.4D)
27
.  
In addition, histological analysis demonstrated a gross effacement of normal 
splenic architecture with expansion of the red pulp (comprised of sheets of mature and 
maturing granulocytic cells) and disappearance of organized follicles (Figure 3.3F, 
right hand panel). Mutant livers displayed similar mature myeloid cells surrounding 
portal cavities and infiltrating the parenchyma (Figure 3.3F, right hand panel).  Lung 
sections showed infiltration of alveolar wall spaces with these same mature myeloid 
cells (Figure 3.4E). Immunohistochemical analysis demonstrated that the majority of 
the myeloid cells in the spleen and liver were granulocytic rather than monocytic since 
the cells were myeloperoxidase-positive but non-specific esterase negative 
(Supplemental Figure 3 and data not shown).  TUNEL analysis did not demonstrate 
changes in the frequency of apoptotic cells.  In contrast, the neoplastic cells were often 
positive for the proliferation marker Ki67, whereas normal spleen and liver contained 
only rare Ki67-positive cells (Figure 3.5).  
While kidney, liver, and spleen displayed 50% recombination of H/P alleles in 
healthy single H/P knockin mice (Figure 3.1C), neoplastic double H/P;A/E knockin 
spleen samples consistently demonstrated complete recombination of the H/P allele, 
suggesting expansion of cells harboring the recombined allele (Figure 3.2C).  
Recombination of the H/P and A/E stop cassettes was also detected in peripheral blood 
by PCR (data not shown). Bone marrow cells from diseased H/P;A/E mice readily grew 
under monocytic (or myeloid) culture conditions, and the H/P protein was detected in 
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these cells by western blot (data not shown).  These data indicate that simultaneous 
activation of the H/P and A/E oncogenes confers a selective growth advantage to 
hematopoietic cells.  
We next examined the cellular characteristics of the spleen and bone marrow from 
a cohort of wild type, single knockin or double knockin mice 4-weeks post pIpC 
induction to more thoroughly analyze the hematopoietic neoplasias.  Spleen cellularity 
was sharply elevated in induced H/P;A/E mice (Figure 3.6A), whereas bone marrow 
cellularity was diminished (Figure 3.6B).  In both tissues, the frequency of 
Mac-1
+
Gr-1
+
 
myeloid cells was significantly increased (Figure 3.6A and B, right hand 
panels).  This expansion of differentiated myeloid cells was associated with a relative 
decrease in frequency of B, T, and erythroid cells in bone marrow and spleen (Figure 
3.7).  Although hematopoietic stem cell (HSC) frequency was significantly reduced in 
the bone marrow of both the single H/P knockin mice and the H/P;A/E mice (Figure 
3.6C, left hand panel), the absolute number of HSCs in the H/P;A/E spleen was 
significantly increased (Figure 3.6C, right hand panel), consistent with the onset of 
extramedullary hematopoiesis, which often occurs in the context of hematopoietic 
malignancies. The diminished frequency of HSCs in the single H/P knockin mice was not 
observed in the 1.5-year old single H/P knockin mice (data not shown) and was therefore 
not pursued further for this study.  In addition, the frequency of bone marrow cells that 
formed primitive GEMM colonies or GM colonies in methylcellulose was also 
significantly reduced by H/P;A/E induction (Figure 3.6D). Together, these cellular 
characteristics are consistent with the development of an MPD in induced H/P;A/E mice.  
It is possible that the diminished bone marrow HSC frequency was due to an 
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intrinsic effect of oncogene expression on HSC maintenance or due to an extrinsic effect 
of the leukemic cells on normal HSC survival (or both).  To test these possibilities in the 
H/P;A/E-expressing mice, we conducted a competitive bone marrow repopulation 
experiment. In this experiment, 1,000,000 bone marrow cells from uninduced 
Mx1Cre;H/P;A/E or Cre negative control mice (CD45.2) together with 500,000 wild-type 
cells from recipient-type bone marrow (CD45.1) were used as donor cells (Figure 3.8A 
shows schematic). Recipients (CD45.1) were analyzed for stable peripheral blood 
chimerism at 6 weeks post-transplant and then induced with pIpC. As expected, all of the 
Mx1Cre;H/P;A/E recipients developed a CML-like MPD that was grossly and 
histologically identical to that of the primary mice (Figure 3.9).  Two weeks after 
induction (during early stages of disease), groups of mice from Mx1Cre;H/P;A/E and 
control transplants were euthanized, and their bone marrows were analyzed for HSC 
distribution (n=3 each group). For both groups, HSCs were distributed in the expected 
2:1 ratio of CD45.2 donor-type to CD45.1 recipient-type (Figure 3.8B). However, the 
total numbers of recipient and donor-type HSCs were significantly decreased in the 
Mx1Cre+;H/P;A/E recipients compared to Cre-negative controls (Figure 3.8C). 
Together, these data indicate the presence of an extrinsic inhibitory effect of the 
H/P;A/E-expressing CML-like MPD on the HSC compartment.  
We next attempted to transplant the CML-like MPD from H/P;A/E mice into 
secondary recipients. The direct transfer of unfractionated primary neoplastic cells from 
diseased H/P;A/E mice to immunocompromised or syngeneic recipient mice was highly 
inefficient, consistent with prior studies that have found MPDs relatively difficult to 
transplant
27,19,28
. For example, when sublethally irradiated (1 x 240 rad) 
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NOD/SCID-IL2Rγ mice were retro-orbitally injected with unfractionated bone marrow 
cells (2 x 10
6
) from H/P knockin, A/E knockin, or diseased double H/P;A/E knockin 
animals. None of the recipients displayed evidence of disease for up to 20 weeks (data 
not shown). In lethally irradiated syngeneic CD45.1 recipients, up to 6x10
6 
whole bone 
marrow cells from multiple diseased donors (n=4) were also highly inefficient at 
transplanting the disease (Table 3.2, “vehicle”).  Similar results were obtained with 
unfractionated splenocytes. The relative inability of cells from animals with 
H/P;A/E-induced disease to transfer the neoplasias upon transplantation is consistent with 
the idea that the vast majority of CML cells have a limited capacity to proliferate
8,9,29
. 
Furthermore, these data also support the categorization of this hematopoietic neoplasias 
as a CML-like MPD rather than a transplantable leukemia
27
.  
To begin to identify the LIC from the diseased mice, we performed transplant 
experiments with FACS-purified HSCs. Although transplantation of HSCs from these 
mice did not transfer a florid CML-like MPD into syngeneic recipients, these cell 
transfers resulted in rapid death post-transplant in a high frequency of recipients (data not 
shown). This was despite the fact that sufficient “radioprotective” bone marrow cells 
were mixed with the purified HSCs for transplant success.  Histological analysis of the 
spleens from the deceased mice that received the purified HSC transplantation 
demonstrated myeloid infiltrates that were consistent with an MPD.  These data provide 
evidence that tumorigenic cells (or LICs) from the diseased H/P;A/E mice are highly 
enriched in the HSC fraction compared to unfractionated bone marrow or spleen.  
Imatinib Treatment Reduces Leukemic Burden but Enriches LICs 
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To determine whether PDGFβR signaling from H/P was critical to the maintenance of the 
H/P;A/E-induced neoplasias, a group of diseased mice were treated with imatinib or 
vehicle for 10-12 days by intraperitoneal injection (n=4 imatinib, n=3 vehicle).  All 
vehicle-treated H/P;A/E-induced mice exhibited progressive hepatosplenomegaly, 
effacement of splenic architecture, and myeloid infiltration of their livers and lungs. 
Imatinib therapy did not appear to exert any discernible effects on wild-type animals 
(data not shown). In contrast, imatinib treatment of H/P;A/E-induced mice led to a rapid 
response as evidenced by reduction of WBCs to wild-type levels (p=0.01, Figure 3.10A). 
Upon necropsy, significant decreases in spleen (p=0.0005) and liver (p=0.004) size were 
also observed (Figure 3.10B and data not shown). Histologically, splenic architecture 
was normalizing, and the liver appeared free of myeloid infiltrates (Figure 3.10C).  This 
rapid hematological response to imatinib is consistent with that observed following 
imatinib treatment in humans with CML
9
 and in mice with retroviral expression of 
tyrosine kinases such as BCR/ABL
30
 and TEL/PDGFβR15.  
We next analyzed the effect of imatinib on HSC frequency in H/P;A/E mice. 
Compared to vehicle-treated mice, bone marrow from imatinib-treated mice displayed a 
restoration of nearly normal HSC frequency in bone marrow (0.0026 +/-0.0018, p=0.05; 
Figure 3.10D and data not shown). Interestingly, in contrast to the reduction observed in 
spleen cellularity, bone marrow cellularity was not immediately restored, presumably due 
to the depletion of CML-like MPD cells from the bone marrow (Figure 3.10B). The 
increase in bone marrow HSC numbers concomitant with the depletion of neoplastic cells 
suggests the presence of a differential effect of imatinib on bulk tumor cells as compared 
to HSCs.  
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In order to begin to determine whether imatinib affected the frequency of LICs, 
we transplanted unfractionated bone marrow from vehicle-or imatinib-treated H/P;A/E 
mice into lethally irradiated syngeneic recipients along with a radioprotective dose of 
200,000 wild-type bone marrow cells.  We predicted that imatinib therapy would 
eliminate the limited transplantability of unfractionated bone marrow.  Transplants were 
performed after 10-12 days of imatinib therapy, when imatinib-treated mice displayed 
normalized WBC counts.  Regardless of the transferred cell number, bone marrow cells 
and splenocytes from imatinib-treated mice were consistently more likely to transfer 
disease than cells from vehicle-treated mice (Figure 3.11A, Table 3.2). The recipient 
disease was grossly and histologically similar to that in the donors, and no recipients 
showed evidence of progression to accelerated or blast crisis phases of the disease 
(Figure 3.11B).  The disease in recipient mice remained hematologically sensitive to 
imatinib therapy (Figure 3.11B), indicating that the transferred cells did not represent 
imatinib-resistant clones from the donor animals.  The increased transplantability of 
bone marrow LICs in H/P;A/E mice after imatinib treatment contrasted dramatically with 
the reduced neoplastic burden in these mice and suggested that LICs are less sensitive to 
imatinib than other neoplastic cells of the MPD. Further evidence for this refractoriness 
of the LICs was accumulated when a rapid return of the MPD disease state was observed 
following withdrawal of imatinib from H/P;A/E-expressing mice that were put into 
remission with imatinib therapy (data not shown). For example, we have continuously 
treated H/P;A/E mice for up to 26 days with imatinib and found that upon withdrawal of 
imatinib there was a rapid return of disease.  
Clear differences in long-term multilineage reconstitution activity were also 
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evident between recipients of vehicle-and imatinib-treated bone marrow samples (Figure 
3.11C). Only 60% of recipients of vehicle-treated bone marrow cells showed long-term 
multilineage reconstitution by donor cells, confirming the decrease in HSC frequency in 
untreated, induced H/P;A/E mice. In contrast, almost all recipients of bone marrow cells 
from imatinib-treated mice showed long-term multilineage reconstitution (Figure 3.11C).  
This correlation of increased functional HSC activity (reconstitution) with the increased 
transplantability of the MPD in imatinib treated mice is additional evidence (to the HSC 
transplant data) that the LIC is contained in the HSC fraction.  
Although we have not yet definitively purified the LIC in these mice, the evidence 
thus far indicates that LICs are found in the HSC compartment and are relatively 
refractory to imatinib. Interestingly, FACS-isolated HSCs from imatinib-treated mice 
upon transplantation into irradiated mice more frequently led to early lethality with an 
MPD compared to HSCs from vehicle-treated mice (data not shown), suggesting that the 
increased bone marrow transplantability observed in the imatinib-treated mice (Figure 
3.11) may not just induce a change in LIC frequency but may also modulate their 
tumorigenicity.  
A few possible mechanisms for how the LICs may be insensitive to imatinib 
while the bulk tumor cells readily respond to imatinib include the following: lack of 
expression of the H/P protein in the LICs despite recombination, extremely high levels of 
H/P expression that overwhelm “therapeutic” levels of the drug, or lack of addiction of 
these cells to H/P due to quiescence or other unknown “context” factors. We have 
gathered some evidence that indicates that H/P expressing cancer cells may or may not be 
addicted to H/P signaling depending on the milieu they are in. For example, H/P -
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expressing Ba/F3 cells are sensitive to imatinib (“addicted”) in the absence of IL-3; 
however, when IL-3 is present, the survival of these cells in the presence of imatinib is no 
different than wild type Ba/F3 cells (Figure 3.12). In this case we know that the H/P 
protein is expressed in the cells in the presence or absence of IL-3 so the relative 
resistance is not due to lack of H/P expression and instead is due to IL-3 induced 
environmental changes that cure the cells of their H/P addiction. Until we are able to 
purify enough LICs from H/P;A/E-expressing mice to characterize them, the precise 
mechanism of their imatinib refractoriness in vivo remains to be determined and the 
above list of possibilities comprise only a subset of avenues for future investigation of 
this complex issue.  
 
DISCUSSION 
The role of activating mutations of receptor tyrosine kinases (RTKs) in 
hematopoietic malignancies is well-established.  PDGFβR is one such RTK that is a 
frequent target in myeloid leukemias. More than fifteen different translocations have been 
identified in human CMML patients that lead to constitutively active fusion variants of 
PDGFβR31.  Accumulating evidence suggests that all PDGFR-containing translocations 
share many properties and are functionally interchangeable.  For example, one such 
translocation, t(5;7)(q33;q11.2), fuses the majority of the HIP1 gene to the 
transmembrane and catalytic domains of the PDGFβR gene2. Like all of the other 
PDGFΒR fusions, the H/P fusion protein is a constitutively active tyrosine kinase that is 
able to transform hematopoietic cells to factor-independent growth in culture
2
 and 
activate the PI3K, MAPK, PLC-gamma and STAT5 pathways
32
. The role of these 
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oncogenes in vivo has only been studied using the retroviral bone marrow transduction 
and transplantation assays. In the current study, we employed a previously described 
knockin strategy
12
 that couples a loxP bracketed transcriptional stop cassette with an 
inducible Cre transgene to generate a mouse in which lineage-specific expression of H/P 
can be temporally and spatially controlled.  This strategy allows us to bypass any 
embryonic lethality that results from the expression of H/P 
22
 and to directly determine 
the development of disease in the adult mouse in the presence or absence of other genetic 
lesions such as a conditional A/E knockin allele
12
.  
Following the generation of the Mx1-Cre;Hip1
+/LSL-H/P
 
mice, we found that these 
mice did not frequently develop hematopoietic malignancies following pIpC induction 
even after 1.5 years. H/P expression is, therefore, not sufficient to cause cancer, though 
a minority of mice did exhibit enlarged spleens and liver tumors suggesting that H/P 
expression may increase the risk of carcinogenesis. This finding contrasts starkly with 
bone marrow retroviral transduction and transplantation assays where retroviral 
expression of tyrosine kinase oncogenes such as H/P, TEL/PDGFβR15 and BCR/ABL16 
induced a lethal myeloproliferative disease similar to CML.  Importantly, since 
healthy, non-neoplastic tissues (kidney, liver, spleen) from pIpC-treated 
Mx1-Cre
;
Hip1
+/LSL-H/P
 
mice maintained Hip1
H/P
 
alleles, the possibility that 
Hip1
H/P
-containing cells were selected against over time is an unlikely explanation for 
the lack of disease after 1.5 years. Since use of endogenous regulatory elements to 
express the H/P oncogene did not lead to the myeloproliferative disease observed 
following retroviral expression of tyrosine kinase oncogenes, the cell type and/or 
oncogene levels are seemingly key variables to control when developing accurate 
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mouse models of human cancers.  
In contrast to the finding that expression of H/P alone did not result in 
transformation of hematopoietic cells in vivo, co-induction of H/P with A/E led to a florid 
MPD within days of induction. The disease rapidly disseminated throughout the animals. 
Thus, contrary to bone marrow transduction/transplantation models of tyrosine kinase 
oncogene and A/E oncogene cooperation that yield prolonged disease latency and 
predominantly acute leukemia
15,21
, this murine model provides direct evidence that 
expression of A/E in adult myeloid progenitors in vivo does not completely block 
differentiation but instead cooperates with H/P (and likely other PDGFβR fusion 
proteins) to induce an explosive myeloproliferative neoplasm. Moreover, these data 
confirm that A/E-induced leukemia is a multi-step process, in which secondary genetic 
alterations, such as H/P fusion protein generation, cooperate with A/E to induce full 
transformation. This report is the first to demonstrate that a human oncogene cooperates 
with the A/E knockin allele to produce transformation
12
.  
While a clear hematologic response to imatinib was observed in these double 
knockin mice, transplant and drug withdrawal experiments demonstrated that LICs were 
not eliminated by this therapy. In fact, imatinib treatment appeared to increase the disease 
transplantability and bone marrow reconstitution frequency (functional HSC activity) of 
unfractionated bone marrow. This H/P;A/E disease model highlights the need for 
therapies that not only target oncoproteins but also preferentially kill leukemogenic cells. 
The mechanism(s) of resistance of LICs to imatinib therapy is not yet understood, but 
possibilities such as limited expression of the oncogene, relative quiescence, or lack of 
addiction to the oncogene due to presence of other growth factors that support LIC 
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survival and proliferation are all currently under investigation.  
Not only do these mice model the neoplastic role of the growing family of 
PDGFΒR human translocations, but these animals represent the first conditional knockin 
model of a PDGFβR tyrosine kinase oncogene. Furthermore, these experiments provided 
intriguing new insights into how the different ways used to model leukemia in mice 
influence outcomes and conclusions.  We expected that activation of a single copy of 
H/P cDNA knocked into the endogenous Hip1 locus in the adult mouse would be 
sufficient to induce a chronic MPD. In addition, based on the report by Grisolano et 
al.
15,33
, we expected that co-induction of A/E with this H/P allele would result in an 
increased frequency or severity of the H/P-induced disease and would inhibit myeloid 
differentiation leading to acute leukemia. To our surprise, however, a very low frequency 
of neoplasias was observed in the single H/P knockin mice, and a shockingly high 
frequency (100% penetrance) and an essentially absent disease latency of an explosive 
MPD (rather than acute leukemia) was observed in the double knockin mice. This 
observation directly counters the prevailing idea that A/E functions via prevention of 
hematopoietic differentiation
33
. If this notion were true, the H/P;A/E knockin mice would 
be immediately blastic and have impaired differentiation. These findings raise the 
possibility that modeling leukemogenic events under the most genetically realistic 
conditions may help us identify novel environmental or genetic triggers that lead to the 
development of CML accelerated phase or frank blast crisis.  
In sum, the conditional activation of H/P in the hematopoietic system of adult 
mice leads to an explosive, mature, imatinib-sensitive MPD when co-expressed with A/E. 
Importantly, LIC activity was surprisingly enriched in induced H/P;A/E mice following 
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imatinib treatment as their bone marrow was able to transplant this imatinib sensitive 
MPD more readily than vehicle treated mice. This model will therefore serve as an 
invaluable tool for in depth studies of the therapeutic effect of PDGFβR (imatinib, 
MAPK inhibitors, rapamycin) and A/E (trichostatin A, SAHA) inhibitors as well as allow 
for further rigorous in vivo characterization of the cellular and molecular mechanisms of 
hematopoietic transformation and drug resistance.  
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Figure 3.1: Phenotype of pIpC induced Mx1.Cre;Hip1
+/LSL-HP
 mice.  
(A) Schematic of the first 8 of 32 exons of the murine Hip1 genomic locus (Hip1
+
), the 
targeted Hip1
LSL-H/P
 
knockin allele generated by homologous recombination, and the 
activated allele with a deleted stop cassette (Hip1
H/P
) following Cre-mediated 
recombination. The following features are indicated: stop cassette bracketed by loxP 
recombination sequences (LSL), partial human H/P cDNA, and cDNA or genomic 
hybridization probes. Just 3’ of the H/P cDNA is a poly A tail (light grey box) and 3’ of 
this was a neomycin selection cassette (dark grey box). (B) Southern blot analysis 
(genomic probe) of EcoRI-digested DNA from wild-type and Mx1Cre-Hip1
+/LSL-H/P
 (C) 
Southern blot analysis (cDNA probe) of EcoRV-digested DNA from multiple tissues 
shows partial recombination in the kidney, liver and spleen and no recombination in brain 
or testis tissue. (D) Complete blood counts (CBC) from wild-type and single knockin H/P 
mice were normal. A cohort of pIpC treated Mx1Cre;Hip1
+/LSL-H/P 
mice (n=18) and 
Mx1Cre;Hip1
+/+ 
mice (n=18) were observed until 18 months of age. Bleeds were taken 
pre-induction and then monthly post-induction. No significant differences were observed 
between the two groups in WBC counts or any shifts in differentials over the entire time 
coarse up to the final bleed. At eighteen months of age the mice were euthanized and 
necropsied to observe any disease either by gross observation or histologically. (E)  
Enlarged spleen (0.27gm) from the youngest morbid Mx1Cre;Hip1
H/P 
(tag #1156, 3 
months-old) shows myeloproliferation. Western blot analysis for H/P expression in this 
mouse was performed on bone marrow culture from the same mouse (lane 2) and from its 
control littermate (lane 1). The bone marrow cells were cultured for seven days in 
monocytic culture conditions prior to analysis (41). Anti-human HIP1 (UM323), 
anti-PDGFβR  (BD Bioscience), anti-mouse HIP1 (UM354), and anti-actin (Sigma) 
polyclonal antibodies were used to detect the human fusion protein, endogenous mouse 
HIP1, and actin as indicated. (F) A liver tumor from a 9-month-old Mx1Cre;Hip1
H/P
 
mouse (tag #1151) shows a well differentiated hepatocellular carcinoma histopathology. 
Southern blot analysis (cDNA probe) of EcoRV-digested DNA from kidney, “normal” 
gross liver, and liver tumor DNA from the second pIpC induced 
Mx1Cre;Hip1+/LSL-H/P (H/P) mouse that was moribund and sacrificed at nine months 
of age. Note that the DNA from the kidney was partially recombined (50%), allowing for 
demonstration of both alleles, while the liver tumor is fully (100%) recombined. (G) 
Analysis for recombination in tissues from 18 month old mice demonstrates that the 
Hip1
H/P 
allele was not lost over time. NC = negative control wild type DNA; PC = 
positive control for presence of the recombined allele. The 336 bp band is the recombined 
allele and the 200 bp band is the wild type allele.  
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Figure 3.2: MPD results in mice transplanted with MSCV.H/P infected bone 
marrow.  
(A) Kaplan-Meier plot demonstrating survival of mice after transplantation with bone 
marrow cells that express H/P. MSCV.neo represents empty vector (n=10) and 
MSCV.H/P is MSCV.neo with the H/P cDNA inserted after the LTR (n=10). In this 
experiment bone marrow cells were isolated from femurs of donor mice pretreated with 
5-FU. Cells were cultured in transplant medium for 48 h.  The cells were infected with 
two rounds of spinoculation using MSCV.neo or MSCV.H/P retroviral supernatants. 
Recipients were conditioned with 1,000 cGy and then transplanted with 10 million 
transduced bone marrow cells. (B) Peripheral blood smears from empty MSCV vector 
and MSCV.H/P retrovirally transduced and transplanted mice four weeks post 
transplantation.  Note the increased number of mature neutrophils (ring forms) in the 
MSCV.H/P containing mice.  
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Figure 3.3: Expression of H/P;A/E Leads to a CML-Like MPD  
(A) Schematic of the mating scheme that was used to produce the double knockin mice 
used in this study.  Also shown are the symbols used to designate the different 
genotypes. (B) The Kaplan-Meier curve depicts disease-free survival as a function of 
time in weeks since pIpC induction. The rapid decline in disease-free survival of H/P 
mice at 67 weeks reflects occult abnormalities discovered at necropsy (Table I).  (C) 
Southern blot analysis (cDNA probe) of EcoRV-digested DNA from multiple tissues 
from a pIpC-induced H/P;A/E mouse shows no recombination in the tail, partial 
recombination in the kidney and complete recombination in a neoplastic spleen. (D) 
Peripheral blood smears from control (WT) and diseased mice (H/P;A/E) are represented. 
(E) Complete blood counts (CBC) from wild-type (WT; n=9), H/P (n=11), A/E (n=3), 
and H/P;A/E (n=8) mice were determined prior to pIpC induction (pre-bleed) and then 
after pIpC induction once weekly to determine onset of disease.  Final WBCs at 
necropsy are displayed (left panel). H/P;A/E mice developed a severe myeloid 
leukocytosis (right panel; NE=neutrophil, LY=lymphs, MO=monocytes). Values are 
mean ± s.d. *denotes a significant difference (p<0.01) compared to WT mice.  (F) 
Massive hepatosplenomegaly in H/P;A/E mice.  All livers and spleens (left inset is a 
WT spleen, and right inset is a H/P;A/E spleen) from H/P;A/E mice were greatly 
enlarged at necropsy while kidneys were normal (WT n=9, H/P n=11, A/E n=3, H/P;A/E 
n=8; *p<0.01). Histological analysis of H&E-stained spleen and liver tissue from WT, 
H/P, A/E or H/P;A/E mice were examined (right hand panels). Magnification was 100x.  
Effacement of the normal follicular architecture of the spleen and infiltration of the liver 
was observed only in the H/P;A/E mice.  
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Figure 3.4: Generation and analysis of H/P;A/E-expressing mice.  
(A) PCR analysis for the presence of Mx1-cre, Aml1
LSL-A/E
 
and Hip1
LSL-H/P
 
alleles in mouse tail 
DNA. H/P;A/E mice were successfully generated as indicated by the presence of a Cre, H/P and 
A/E specific PCR products in lanes 4 and 6.  Lane 1 = no template control. Lanes 2, 3, and 5 
lack at least one of the three mutant alleles. The IL-2 primer pair was used as an internal control 
for DNA quality. (B) Embryonic/pre-weaning lethality occurs in the Mx1-cre transgenic double 
knockin mice. The frequency of mice with various genotypes is displayed. The expected 
frequency is 12.5% in all cases. *Indicates significantly different than expected. We have 
observed cases (16%, 7/43) of spontaneous recombination and CML-like disease in the adult 
H/P;A/E animals and this phenomenon may be responsible for this pre-weaning lethality. (C) 
Daily blood smears (right hand panels show representative series from an H/P;A/E mouse) were 
prepared from tail bleeds and demonstrated a myeloid leukocytosis with severe neutrophilia 
within 6 days of initiating a 2 week course of pIpC induction. (D)  Control (WT) and diseased 
H/P;A/E-expressing mice were sacrificed and 100 ul of single cell suspensions (each in a total of 
3 ml of HBSS/2%FBS) of spleen and total bone marrow (two tibias and two femurs)  were 
visualized for morphology and density after spinning the cells onto a coverslip (cytospin).  (E) 
Lung tissue from the induced H/P;A/E mice was infiltrated with leukemia cells.   
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Figure 3.5: Histology of H/P;A/E induced MPD 
Spleen and liver tissues from wild-type and double knockin mice were embedded in paraffin. 
H/E, MPO, Ki67, and TUNEL staining was then performed.  400x magnified images are 
displayed.   
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Figure 3.6: Abnormal immunophenotype of hematopoietic cells from the bone 
marrow and spleen of H/P;A/E mice  
Single cell suspensions of bone marrow and spleen cells from pIpC-induced Mx1-Cre 
transgenic mice (average 3 weeks after induction) that were either WT, H/P, A/E, or 
H/P;A/E were analyzed by flow cytometry. Representative flow cytometry profile of 
forward and side scatter of spleen cells (A) and bone marrow cells (B). These profiles 
illustrate the presence of a distinct, uniform population of enlarged cells (box) in the 
spleen and bone marrow of H/P;A/E mice.  Representative profile of the myeloid 
immunophenotype illustrates a significant increase in both mature granulocytic 
(Gr1
+
/Mac1
+
) and monocytic (Gr1
lo
/Mac1
+
) populations (A, B, left lower panels) in 
H/P;A/E mouse spleen and bone marrow. Values in the bar graphs are mean ± s.d. For 
WT (white bar), H/P (black bar), and A/E (light grey bar) mice, n=4.  For H/P;A/E (dark 
grey bar) mice, n=10. * denotes a significant difference (p<0.01) between H/P;A/E mice 
and WT, H/P, or A/E mice. (C) The frequency of CD150+CD48-CD41-Sca-1+c-kit+
 
HSCs in the bone marrow of H/P;A/E (dark grey bars) mice was significantly reduced.  
*denotes a significant difference between H/P;A/E and WT mice (p< 0.01). (D) The 
frequencies of CFU-GEMM and CFU-GM colonies were significantly diminished in the 
bone marrow from H/P;A/E mice (dark grey bar) compared to WT (white), H/P (black) 
or A/E (light grey) mice.  
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Figure 3.7: Flow cytometry analysis of bone marrow and spleen from induced 
Mx1-Cre;Hip1
LSL-H/P
;Aml1
LSL-A/E
 
mice.  
Mice at 6 weeks of age were induced with pIpC and two weeks later bone marrow and spleens 
were harvested and analyzed with FACS for various lineages as shown.  Lymphoid (B220 
and CD3) and erythroid (Ter119) lineages were diminished in frequency while the myeloid 
(Gr-1 and Mac1) lineage were increased.  
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Figure 3.8. Although an H/P;A/E-expressing MPD results from an intrinsic  
transforming effect, there is an extrinsic inhibitory effect on normal BM HSC 
frequency.  
(A) Irradiated (CD45.1) recipients were transplanted with twice as many donor (CD45.2) 
Mx1-Cre;H/P;A/E or control bone marrow cells to recipient (CD45.1) bone marrow cells. 
Six weeks after transplantation, recipient mice were treated with pIpC for two weeks to 
induce recombination. Mice were bled 4 weeks after induction to monitor disease 
progression. All of the mice transplanted with the Mx1-Cre;H/P;A/E bone marrow were 
with splenomegaly and leukocytosis similar to the primary disease whereas the H/P;A/E 
Cre negative donors were disease free (Supplemental Figure 5). (B) Cells from bone 
marrow 4 weeks post pIpc induction were analyzed for frequency of 
CD150+CD48-CD41-Sca-1+c-kit+
 
(SLAM HSCs) donor versus recipient cells. The 
donor cells accounted for 61% of HSCs in recipient mice as expected, whether the mice 
had been transplanted with control donor cells or H/P;A/E donor cells.  Values represent 
mean ± s.d. of 3 mice per treatment. (C) The absolute number of both donor-type 
(H/P;A/E) and recipient-type (WT) HSCs decreased significantly in HP/AE recipients 
when compared to control recipients. The total number of HSCs (donor-type + 
recipient-type) was also drastically reduced. *denotes significantly different (p<0.05) 
compared to control recipients.  
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Figure 3.9. MPD results in mice transplanted with uninduced bone marrow and 
then treated with pIpC.  
(A) Upon pIpC induction, recipients of uninduced Mx1Cre;Hip1
+/LSL-H/P
;AML1
+/LSL-A/E
 
bone marrow develop an CML-like MPD that mimics the disease of induced primary 
mice. The spleens of these “pre-induction” transplant recipients are enlarged and 
histologically effaced (right). (B) WBC counts rise dramatically within 4 weeks of pI-pC 
induction in these mice.  
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Figure 3.10: Imatinib Treatment Eliminates the Bulk of the Neoplasia  
(A) Imatinib normalized WBCs after 10 days of treatment (*p=0.01, vehicle vs. 
imatinib). (B) Imatinib-treated mice exhibited markedly reduced spleen cellularity 
(*p=0.01, vehicle vs. imatinib), but bone marrow cellularity was not immediately 
normalized. (C) Imatinib treatment began to restore splenic architecture and cleared 
myeloid infiltrates from the liver. (D) The frequency of HSCs was partially rescued in the 
bone marrow (p=0.05, imatinib vs. vehicle) but not in the spleen. Splenic HSC frequency 
was increased in imatinib –treated mice (presumably because leukemic burden was 
dramatically reduced, increasing the frequency of normal HSCs in the spleen), but the 
difference was not statistically significant. +/+ = untreated wild-type mice (n=7); vehicle 
= vehicle-treated pIpC-induced H/P;A/E mice (n=3); imatinib = imatinib-treated 
pIpC-induced H/P;A/E mice (n=4).  
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Figure 3.11: Imatinib Treatment Rescues HSC Activity but Also Increases the 
Frequency of LICs  
(A) Graded doses of 1x10
5
 
to 2x10
6
 
whole bone marrow cells (WBM) from pIpC-induced 
H/P;A/E CD45.2 mice that were treated with vehicle (n=4 donors, 38 recipients) or imatinib (n=3 
donors, 40 recipients) for 7-10 days were transplanted into lethally irradiated CD45.1 recipients 
along with 2x10
5
 
wild-type CD45.1 bone marrow cells.  Recipients of bone marrow cells from 
imatinib-treated mice developed CML at a greater frequency than recipients of vehicle-treated 
bone marrow cells. (B) Representative peripheral blood smears of pIpC-induced H/P;A/E donor 
mice treated with vehicle displayed an abundance of mature granulocytes (upper left, arrows), 
which were greatly reduced in imatinib-treated mice (lower left). This CML-like MPD was 
transplantable, with some recipients of vehicle-(middle, top) and imatinibtreated (middle, bottom) 
WBM developing a similar disease. Note the predominantly mature granulocytic cells in the 
bottom panels and the absence of blasts. The primary mice that were treated with imatinib 
displayed the most transplantable disease and the disease remained sensitive to imatinib treatment 
(right hand panels). (C) WBM from imatinib-treated mice more frequently gave rise to 
multilineage reconstitution (donor myeloid, B, and T cells) at 12 weeks post-transplantation 
compared to vehicle-treated mice (at 4 weeks: total n=29 for vehicle, n=27 for imatinib; at 12 
weeks: total n=27 for vehicle, n=18 for imatinib). Reconstitution was defined as the presence of 
greater than 0.3% donor type CD45.1 marker in B (B220), T (CD3), and myeloid (Mac1, Gr1) 
lineages. Black bars indicate multilineage reconstitution of Cre
neg
 H/P;A/E (control) bone marrow 
recipients (n=15).  
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Figure 3.12. Imatinib resistance of H/P-expressing BaF3 cells in the presence of 
IL-3.  
BaF3 cells that had been infected with MSCVneoH/P (BaF3-H/P) to transform them to 
IL-3 independent growth were used (Ross et al., 1997). 200,000 of the BaF3-H/P cells 
were plated in each well of a 12-well plate in RPMI +/-recombinant IL-3.  Vehicle 
(DMSO) or imatinib at various concentrations in DMSO (DMSO at 0.1% final volume) 
was added to the different wells. Cells were counted at 30 and 50 hours by manual 
counting of viable cells (trypan blue exclusion microscopy). The upper panel represents 
cells growing in the presence of IL-3. The lower panel presents the result of cells growing 
in the absence of IL-3. Veh = vehicle (0.1% DMSO). 10, 50 and 100 nM = imatinib at 
various combinations in 0.1% DMSO.  
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Table 3.1: Neoplasms in H/P mice 
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Table 3.2: Imatinib does not eliminate LICs from H/P;A/E induced MPD 
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CHAPTER 4 
 
Leukemia Initiating Cells revert to HSC Functionality in the Presence of Imatinib 
 
 
Summary 
Physiologic co-expression of the human oncogenes HIP1/PDGFβR (H/P) and 
AML1/ETO (A/E) from the endogenous mouse Hip1 and Aml1 loci results in an 
aggressive myeloproliferative disease (MPD)
1
. Despite a robust response to the tyrosine 
kinase inhibitor (TKI) imatinib mesylate, leukemia-initiating cells (LICs) persist in vivo. 
We used the H/P;A/E mouse model of MPD to investigate potential mechanisms of LIC 
persistence focusing on the putative necessity of oncogenic tyrosine kinase signaling for 
cell survival. In the presence of tyrosine kinase inhibition, LICs, which share surface 
marker expression with HSCs, are inhibited from generating an MPD but not from 
normal hematopoietic self-renewal and differentiation. Similar to in vitro studies with 
human CD34+ CML cells, imatinib induced an anti-proliferative but not an apoptotic 
response of H/P;A/E-LICs in vivo. Unlike in vitro data from CD34+ CML cells, 
mobilization of the H/P;A/E-LIC population into cell cycle did not enhance sensitivity to 
imatinib. These results suggest that LIC survival is independent of tyrosine kinase 
signaling and cannot be manipulated into kinase-addiction by mobilizing agents.  
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Introduction 
Despite suppression of disease with targeted TKI therapy, persistence of LICs is a 
significant clinical problem in the treatment of CML
2
. While most CML patients achieve 
hematologic and cytogenetic response within 5 years of therapy, only 4% of patients 
achieve a major molecular response as measured by absence of BCR/ABL transcripts 
using quantitative RT-PCR
3
. LICs are a source of potential disease relapse as evidenced 
by the fact that most patients who have discontinued imatinib therapy relapse
4-6
. 
Persistent cells harboring leukemogenic mutations may be susceptible to further genetic 
instability leading to development of resistant clones and/or disease progression. 
Understanding the mechanism of LIC persistence is of paramount importance in 
developing new therapeutic strategies for elimination of LICs.  
 Many mechanisms of LIC persistence have been proposed, but they can be 
described as either kinase-dependent or kinase-independent. Kinase-dependent 
mechanisms assume that the LIC relies on oncogenic kinase signaling for survival and 
leukemogenic potential. Examples of kinase-dependent mechanisms include kinase-
domain mutations, amplification of kinase transcript and reduction of intracellular TKI 
concentration. Kinase-independent mechanisms assume that the LIC may rely on 
oncogenic kinase signaling for leukemogenic potential, but not for survival. Examples of 
kinase-independent mechanisms include activation of other survival pathways and 
hijacking the normal stem cell property of quiescence.  
While there is some debate regarding the identity of the LIC in CML and whether 
it is phenotypically distinct from the hematopoietic stem cell (HSC), it is clear that these 
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two cells share many properties including self-renewal, pluripotency and quiescence
7
. 
This last property has been proposed as a potential mechanism by which LICs evade TKI 
therapy. In vitro data using the stem cell containing CD34
+
 fraction of human CML 
samples has shown that the quiescent population is insensitive to imatinib
8
. Further in 
vitro studies have shown that exposure of primitive quiescent CML cells to high growth 
factor conditions enhances their sensitivity to imatinib
9,10
. However, in vivo validation of 
these findings is lacking due to inadequate mouse models of CML.  
We have used the H/P;A/E knockin mouse model of MPD to investigate potential 
mechanisms of LIC persistence. We began by further characterizing the cellular and 
molecular alterations induced by H/P and A/E. We then used the chimeric transplant 
system to functionally and phenotypically demonstrate persistence of LICs. Finally, we 
have used this animal model to test the hypothesis that enhanced cycling of LICs will 
increase their sensitivity to imatinib.  
 
Materials and Methods 
Mice and competitive transplant model 
The Mx1-Cre;Hip1
+/LSL-H/P
;Aml1
+/LSL-A/E
 mouse has been described in the previous 
chapter
1
. Expression of Cre recombinase was induced by injecting mice intraperitoneally 
with 250 micrograms of pIpC (Sigma, St. Louis, MO) in 100 microliters of PBS at two-
day intervals (6 injections total)
11
. Vav1-iCre mice were crossed with Hip1
+/LSL-
H/P
;Aml1
+/LSL-A/E 
mutant mice. MRP8-Cre-GFP mice were generously supplied to us by 
Dr. Irv Weissman (Stanford University). Mice were routinely genotyped by RT-PCR 
(Transnetyx, Inc, Memphis, TN). All experimental mice were on a C57Bl/6 (CD45.2) 
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genetic background for transplant experiments. Mice were housed in the Unit for 
Laboratory Animal Medicine at the University of Michigan and were monitored regularly 
for evidence of moribundity and/or abnormal peripheral blood cell counts. For bone 
marrow transplant experiments, B6.SJL-Ptprc<a>Pepc<b>/BoyJ (SJL) recipient mice 
(CD45.1, Jackson Labs #002014) were administered 2 doses of 520 rads, separated by 3 
hours. Donor cells were transplanted retro-orbitally within 24 hours of the second dose of 
irradiation. For HSC transplants, cells were double-sorted using a FACS-AriaII, directly 
into individual wells of a 96-well V-bottom plate containing 5x10
5
 SJL whole bone 
marrow cells per well. For analysis of engraftment, peripheral blood was collected from 
the submandibular plexus and analyzed for CD45.1 and CD45.2 as previously 
described
11
.  
Flow cytometry 
Flow cytometric analysis (FACS), methylcellulose assays, and quantitation of HSCs from 
bone marrow and spleen were performed as described previously
11
. Cell analysis was 
carried out on a BD FACS-Canto and sorting was performed using a BD FACS-AriaII. 
Antibodies used for lineage exclusion were CD2, CD3, CD8, B220, ter119 and Gr1 
(eBiosciences, BD Biosciences).  
Cell cycle and apoptosis analysis 
Testing of BrdU incorporation was performed essentially per manufacturer’s instructions 
(BD Biosciences). Cells were stained for surface marker expression prior to fixation and 
DNAse treatment. Flow cytometric analysis of AnnexinV surface staining was also 
performed as described by the manufacturer (BD Biosciences).  
Drug administration 
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Imatinib was administered by oral gavage twice daily separated by 8-12 hours. Each dose 
was 100mg/kg of IM (obtained from the clinic) dissolved in water and filtered through a 
0.45 micron syringe filter. Nilotinib (Tasigna, Novartis) was dissolved in 
10%NMP/90%PEG-300 and administered once daily at a dose of 100mg/kg by oral 
gavage. The cyclophosphamide/G-CSF protocol for HSC mobilization has been 
previously described
12
. Recombinant human G-CSF (Neupagen, obtained from the clinic) 
was administered for four consecutive days by subcutaneous injection.  
   
Results 
Sequential activation of H/P followed by A/E leads to MPD. 
We have previously shown that 100% of Mx1-Cre;Hip1
LSL-HP
;Aml1
LSL-AE
 mice rapidly 
develop an aggressive MPD following simultaneous activation of the “knocked-in” 
human oncogenes
1
. We wondered whether the order of oncogene activation impacted the 
disease profile. Because heterozygous expression of A/E in the germline leads to an 
embryonic lethal phenotype characterized by complete absence of definitive 
hematopoiesis
13
, we did not attempt to generate mice with an A/E germline knockin 
allele. As an alternative, we chose to first activate H/P in the germline and then cross this 
global H/P knockin with the Mx1Cre conditional knockin allele of A/E. To achieve this, 
we first crossed mice carrying the Hip1
LSL-HP 
allele with the EIIA-Cre transgenic mouse 
(Jackson Labs). The adenovirus EIIA promoter induces Cre expression in a mosaic 
pattern in the early embryo, including germ cells
14
. Offspring of the EIIA-Cre;Hip1
LSL-HP 
founders that transmitted the recombined H/P allele (but not the Cre transgene) were 
designated H/P knockin mice (H/P-KI). Complete excision of the transcriptional stop 
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cassette was confirmed by PCR in various hematopoietic and non-hematopoietic tissues 
(data not shown).   Similar to pIpC-induced Mx1Cre-Hip1
LSL-H/P 
mice, germline H/P-KI 
mice did not develop hematopoietic or non-hematopoietic neoplasms during a one year 
observation period (n=16 H/P-KI mice, Table 4.1). ENU mutagenesis of these H/P-KI 
mice led to a low frequency of tumorigenesis that was not significantly different from 
that observed in ENU-treated control mice (n=18). These data suggest that H/P is 
insufficient for tumorigenesis in hematopoietic as well as non-hematopoietic tissues. The 
germline H/P-KI mouse was then crossed with the Mx1-Cre;Aml1
LSL-AE
 mouse. This 
triple transgenic mouse has the potential to express the H/P oncogene constitutively in all 
tissues and the A/E oncogene only in Mx1-restricted tissues following pIpC treatment. 
Following pIpC, 100% of H/P-KI;Mx1-Cre;Aml1
LSL-AE 
mice developed an MPD 
characterized by hepatosplenomegaly and neutrophilic leukocytosis (n=2, Table 4.1). 
The MPD in pIpC-induced H/P-KI;Mx1-Cre;Aml1
LSL-AE 
mice was grossly and 
histologically indistinguishable from the MPD in Mx1-Cre;Hip1
LSL-HP
;Aml1
LSL-AE
 mice. 
These data suggest that H/P activation preceding A/E activation in hematopoietic tissues 
does not influence the latency or type of myeloid leukemia that develops.   
 
Co-activation of H/P and A/E in hematopoietic stem cells is required for 
development of MPD. 
Upon pIpC induction, the Mx1 promoter drives expression of Cre recombinase in 
many hematopoietic cell types including the HSC
15
. Our previous data suggest that the 
LIC in the Mx1-Cre;H/P;A/E mouse MPD shares phenotypic characteristics with normal 
hematopoietic stem cells (HSC). To determine if activation of H/P and A/E in HSCs 
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rather than more differentiated cells is required for induction of MPD, we crossed the 
Hip1
LSL-HP
 and Aml1
LSL-AE 
alleles onto different Cre-transgenic backgrounds. First, we 
used the Vav1-iCre transgenic allele which limits Cre recombinase activity to endothelial 
and hematopoietic cells
16
. Vav1 regulatory elements have been shown to induce 
transgene expression throughout the hematopoietic system, presumably due to expression 
at the level of the HSC
17
. All Vav1-Cre;Hip1
LSL-HP
;Aml1
LSL-AE
 mice developed an MPD 
within 7 weeks of birth (n=3, Table 4.1). This MPD was characterized by 
hepatosplenomegaly and neutrophilic leukocytosis, similar to the Mx1-Cre induced 
disease. We next used the MRP8-Cre-IRES-GFP transgenic mouse which restricts Cre 
and GFP expression to granulocytes and a fraction of granulocyte/macrophage 
progenitors (GMPs) 
18
. By 12 weeks of age, none of the MRP8-Cre-IRES-GFP;Hip1
LSL-
HP
;Aml1
LSL-AE
 showed signs of disease (n=2). MRP8Cre expression was confirmed 
indirectly by detection of GFP fluorescence in peripheral blood leukocytes. The absence 
of myeloproliferation in these mice suggests that activation of the H/P and A/E 
oncogenes in HSCs is required for induction of the MPD.  
To test the functional capacity of the stem cell compartment in diseased Mx1-
Cre;Hip1
LSL-HP
;Aml1
LSL-AE
 mice (H/P;A/E), we conducted transplant experiments with 
sorted cells. Cells were sorted from the bone marrow compartment of Cre
neg
 or diseased 
H/P;A/E mice (C57Bl/6 strain, CD45.2, see Methods). Cells were then co-transplanted 
into lethally irradiated syngenic SJL recipients (SJL/J strain, CD45.1) along with a 
protective dose of wildtype SJL bone marrow cells. The hematopoietic stem cell 
population is found within Lin
-
Sca1
+
c-Kit
+
 (LSK) cells, a population that includes long-
term and short-term HSCs (LT-HSC, ST-HSC) as well as non self-renewing multipotent 
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progenitors (MPP) (Figure 1.2). None of the recipients of 3000 LSK cells developed 
disease or exhibited long-term multilineage engraftment from donor cells (Figure 4.1A). 
This suggests that LSK from the H/P;A/E induced MPD are depleted of HSC activity and 
are unable to transfer the MPD. As we have reported previously
1
, some recipients of LT-
HSCs (CD150
+
CD48
-
CD41
-
LSK) from diseased H/P;A/E mice die with evidence of 
MPD early after transplant. We have confirmed this result with further transplants and 
also find that LT-HSCs from diseased mice form smaller colonies in methylcellulose than 
control LT-HSCs (Figure 4.1B).  
 
Competitive transplant system to study H/P;A/E induced MPD.  
We previously employed a competitive transplant system, which permits analysis 
of large cohorts of mice that have only a fraction of their hematopoietic cell compartment 
expressing the H/P and A/E oncogenes (Figure 4.2). This system utilizes expression of 
two different isotypes of the pan-hematopoietic marker CD45 (CD45.1 and CD45.2) to 
differentiate between recipient and donor populations. Briefly, bone marrow from 
uninduced Mx1-Cre;H/P;A/E (H/P;A/E) or control Cre
neg
;H/P;A/E (Cre
neg
) mice was 
used as the donor population (C57Bl/6J strain, CD45.2) in a specific ratio  with wildtype 
bone marrow (SJL strain, CD45.1) and transplanted into lethally irradiated SJL/J 
recipients (see figures for ratios, minimum of 5x10
5
 total cells in each independent 
transplant). Cre
neg
;H/P;A/E donors were chosen to control for the heterozygous state of 
the Hip1 and Aml1 loci. After a 4-6 week engraftment period, recipient mice were 
examined for stable multi-lineage chimerism in the peripheral blood and absence of 
disease.  Only a small proportion of Cre
+
;H/P;A/E chimeric mice (~1%) develop 
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spontaneous disease (data not shown). Disease-free recipients were treated with pIpC to 
activate H/P and A/E expression in the donor cell population. Chimeric mice uniformly 
developed an MPD (range 28-56 days post pIpC), that appeared grossly and 
histologically similar to that of primary Mx1Cre;H/P;A/E mice. We did observe that 
primary mice developed more severe hepatosplenomegaly and consequently were more 
prone to becoming moribund. As with primary Mx1Cre;H/P;A/E mice, chimeric 
recipients (hereafter referred to as H/P;A/E) with MPD displayed a rapid hematologic 
response to imatinib therapy as depicted by the frequency of mature myeloid cells in the 
bone marrow (Figure 4.3A). White blood cells counts, spleen and liver size also returned 
to normal (data not shown).  This chimeric system is a more accurate model of human 
CML than primary H/P;A/E mice because the somatic mutations are limited to a subset of 
hematopoietic cells.  Furthermore, this system allows for the analysis of larger cohorts of 
mice with MPD.  
As mentioned above, the H/P;A/E MPD is characterized by expansion of the 
mature myeloid compartment in bone marrow. When diseased H/P;A/E mice are treated 
with imatinib, the frequency of Gr1
+
Mac1
+
 myeloid cells in the bone marrow space 
returns to Cre
neg
 control levels within days (Figure 4.3A). The mature myeloid 
compartment of Cre
neg
 control mice was unaffected by short or long-term imatinib 
treatment (data not shown).  This complete hematologic response is consistent with the 
therapeutic effects of imatinib therapy in human CML
2
.  We have previously shown that 
despite this sustained hematologic response to imatinib therapy, cells capable of 
transplanting the MPD to syngenic recipients persist in the H/P;A/E mouse
1
. We referred 
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to these cells as LICs and showed that at least some of this leukemia-initiating 
functionality is contained within the phenotypic LT-HSC population.  
 
Hematopoietic stem and progenitor cell abnormalities are rescued by imatinib.  
To begin to determine the mechanism of this LIC persistence, we first analyzed 
the frequency of stem and progenitor populations in vehicle and imatinib treated H/P;A/E 
mice. In mouse bone marrow, myeloerythroid colony-forming potential is found among 
c-kit
+
 cells that do not stain for IL7Rα or lineage markers.  Self-renewing hematopoietic 
stem cells (HSCs) can be removed from this analysis by exclusion of Sca1
+
 cells. This 
IL7Rα-Lin-Sca1-c-Kit+ (LK) population can be further separated into three distinct 
populations: a common myeloid progenitor (CMP) which is thought to differentiate into a 
granulocyte/monocyte progenitor (GMP) and a megakaryocyte/erythrocyte progenitor 
(MEP) (Figure 1.2). The separation of these myeloid progenitor subpopulations is based 
on CD34 and FcγRII/III expression as shown in Figure 4.1B19.  In the H/P;A/E disease, 
the frequency of LK cells in WBM was slightly decreased but this was not statistically 
significant (Figure 4.3C). There were however, statistically significant changes in the 
frequency of myeloid progenitor subpopulations. Although the overall frequency of 
GMPs did not change, the CMP and MEP frequencies were reduced by 17-fold and 4-
fold, respectively. Within the myeloid progenitor compartment, the proportion of 
CMP:MEP:GMP cells shifted dramatically and nearly 100% of LK cells expressed GMP 
markers (Figure 4.3C). Because GMPs express relatively less c-Kit than CMPs or MEPs, 
a decrease in overall c-Kit expression within the LK population was observed.   Imatinib 
restored most myeloid progenitors to wild type frequencies with the exception of overall 
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CMP frequency which remained suppressed. However, imatinib did increase the 
frequency of CMPs significantly above vehicle-treated mice and it is possible that further 
therapy would normalize this progenitor compartment. These dramatic alterations in the 
myeloid progenitor compartment, particularly the increase in relative GMP frequency, 
suggest a key role for these cells in the maintenance of the MPD. However, the absence 
of a persistent defect during imatinib therapy, in addition to the absence of disease in 
MRP8-Cre;H/P;A/E mice, suggests that the LIC does not share phenotypic characteristics 
with non self-renewing myeloid progenitors.  
Because of the lack of a persistent abnormal cell population in the myeloid 
progenitor compartment, we analyzed the hematopoietic stem cell compartment in 
imatinib treated mice. This population is most broadly defined as Lin
-
Sca1
+
c-Kit
+
 (LSK) 
cells and includes long-term and short-term HSCs (LT-HSC, ST-HSC) as well as non 
self-renewing multipotent progenitors (MPP) (Figure 1.1 and Figure 4.4A). Mice with 
the H/P;A/E induced MPD did not have a change in overall LSK frequency in the bone 
marrow. However, LSK cells in diseased mice had diminished c-Kit staining intensity 
and increased Sca1 staining relative to wildtype LSKs. While it is unclear what the 
functional consequences of these changes may be, it is intriguing to hypothesize that 
because c-Kit is a member of the same family of tyrosine kinase receptors as the 
PDGFβR (Type III), H/P signaling may provide negative feedback to c-Kit expression to 
circumvent redundant tyrosine kinase signaling.  We have previously demonstrated that 
the H/P;A/E MPD leads to a dramatic decrease in LT-HSC frequency (CD150
+
CD48
-
CD41
-
LSK) and that this defect is rescued by imatinib therapy
1
. Here we have confirmed 
this finding and have extended this analysis to include other LSK subpopulations such as 
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the Flt3
+
LSK which represents a non-self renewing multipotent progenitor (MPP). We 
observed a 5-fold reduction in MPP frequency (0.155% vs. 0.03% of live bone marrow 
cells, p<0.001, Figure 4.4B). There was a corresponding non-significant increase in Flt3
-
LSK, a population that includes LT-HSCs and ST-HSCs (0.154% vs. 0.221%). It is 
possible that this shift in Flt3 expression represents a decrease in the frequency of 
functional MPPs (via altered stem cell differentiation).  However, because Flt3 is a Type 
III receptor tyrosine kinase as well, it is possible that the decreased expression is due to a 
similar negative feedback mechanism as proposed for c-Kit. Importantly, treatment of 
diseased mice with imatinib for 10-36 days led to normalization of Flt3
+
LSK frequencies 
to wild type levels (Figure 4.4B). We did not observe any significant alterations in the 
stem and myeloid progenitor cell frequencies of Cre
neg
 control mice treated with imatinib 
or primary Mx1-Cre;H/P or Mx1-Cre;A/E single knockin mice (data not shown). 
 
Functional evidence for the persistence of MPD-initiating cells. 
 We previously utilized a transplant strategy to demonstrate persistence of LICs in 
the imatinib responding H/P;A/E mice. While this assay is useful for prospective 
isolation of putative LICs by flow cytometry, it may underestimate LIC persistence 
particularly if these cells are incapable of appropriate homing and engraftment. We 
reasoned that LIC persistence could be qualitatively ascertained by MPD relapse upon 
therapy withdrawal, thus avoiding a transplantation step. We withdrew imatinib therapy 
from a group of hematologically responding chimeric recipient mice. Within three weeks 
of imatinib withdrawal, there was relapse of the MPD in all mice (Figure 4.5A, n=8). 
These mice displayed progressive expansion of Gr1
+
Mac1
+
 peripheral blood leukocytes 
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within days after therapy withdrawal (data not shown). Mice sacrificed at 7-21 days after 
imatinib withdrawal had enlarged spleens relative to mice maintained on therapy. These 
relapsed mice also had significant decreases in LT-HSC frequency and similar myeloid 
progenitor alterations as observed in untreated mice (Figure 4.5A and data not shown). 
The relapsed MPD maintained sensitivity to imatinib as depicted in the sample WBC 
timeline for an individual mouse cycled on and off therapy (Figure 4.5B, left). This 
uniform disease relapse (and our previous data showing increased disease 
transplantability from imatinib treated mice) suggests that imatinib suppresses, but does 
not eliminate, the cell or cells that initiate and maintain the MPD. In a similar experiment, 
we treated chimeric recipient mice with imatinib 11 days after completion of pIpC (prior 
to evidence of MPD) (Figure 4.5B, right). All 5 mice in this suppression study 
maintained normal absolute white blood cell counts at 30 days after pIpC completion 
while 16 of 25 untreated mice developed MPD during that same period. Importantly, 
within 30 days of withdrawing imatinib, these mice all developed MPD. The ability of 
imatinib to suppress the emergence of florid MPD suggests that H/P signaling is critical 
for initiation of the disease.  
 
Phenotypic evidence for the persistence of MPD-initiating cells. 
Because imatinib returned stem, progenitor and mature cells populations to 
wildtype frequencies, we turned to the competitive transplant system to more precisely 
determine which donor cell types persist during imatinib therapy. Wild type C57Bl/6 
(CD45.2) and wild type SJL (CD45.1) mice were analyzed in parallel to set the 
appropriate gates for CD45 expression. Donor chimerism was calculated by dividing the 
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number of CD45.2 positive cells by the total number of cells expressing either CD45 
marker ([CD45.2]/[CD45.1+CD45.2]), thus excluding non-hematopoietic cells from the 
analysis. The sample plots shown in Figure 4.6A are from a 1:4 competitive transplant in 
which 2x10
5
 experimental WBM cells were co-transplanted with 8x10
5
 SJL WBM cells. 
Non-diseased
 
Cre
neg
 control mice from that experiment demonstrated ~40% donor 
chimerism in WBM as well as in specific cell types analyzed. Regardless of the 
transplanted ratio, we consistently observed higher than expected donor chimerism (i.e. 
40% vs. 20%), perhaps due to slight errors in cell counting or in slight age differences 
between experimental mice (age-matched) and SJL controls. Importantly, we did not 
observe differences in donor chimerism between Cre
neg 
and H/P;A/E prior to pIpC 
treatment. Following development of the MPD, H/P;A/E recipients displayed significant 
donor expansion of WBM (Figure 4.6B, black bars). This expansion was observed in 
mature myeloid cells (Gr1
+
Mac1
+
), myeloid-restricted progenitors (LK) and stem cells 
(LSK). Importantly, these mice did not have donor expansion of non-myeloid cells 
(B220
+
 cells). This myeloid specific donor expansion suggests that co-expression of H/P 
and A/E in the HSC population shifts the balance between lymphoid and myeloid 
differentiation. We hypothesized that long-term treatment with imatinib would result in 
progressive reduction of the mutant donor cells to below
 
Cre
neg
 control levels. Moreover, 
we theorized that only a rare donor-type cell would persist and that it would have the 
phenotypic characteristics of an HSC. To our surprise, after 14-35 days of imatinib 
therapy, chimeric mice maintained ~60% donor chimerism in WBM which was not 
significantly different from Cre
neg
 control bone marrow (Figure 4.6B, grey bars). While 
the donor chimerism of all cell types in imatinib-treated bone marrow remained slightly 
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higher than Cre
neg
 control donor cells, the only population that remained significantly 
higher than Cre
neg
 controls were the cells in the LSK compartment. Interestingly, spleen 
chimerism dropped significantly below Cre
neg
 levels suggesting that the spleen may be a 
reservoir for overproduced myeloid cells rather than the primary source of the disease. 
These data suggests that under the pressure of tyrosine kinase inhibition, H/P;A/E LICs 
are inhibited from generating the MPD but are not eliminated and in fact revert to normal 
HSC function. Thus, while H/P is the driver of the myeloproliferation, the LIC in the 
H/P;A/E MPD is not addicted to H/P signaling. In this mouse model of CML, tyrosine 
kinase inhibition by imatinib results in suppression of leukemogenesis but not 
suppression of normal hematopoiesis.  
 
LICs do not upregulate H/P transcription to overcome imatinib. 
In vivo persistence of LICs despite TKI treatment in humans is a serious problem that 
prevents complete remission of CML. It has not been proven definitively whether LIC 
persistence is due to insufficient inhibition of tyrosine kinase oncogene signaling or non-
addiction of the LIC to the TK signals. The former possibility includes multiple 
mechanisms by which LICs can suppress or evade tyrosine kinase inhibition. One 
clinically relevant possibility is the emergence of point mutations that confer inhibitor 
resistance. In human Ph
+
 CML, the Bcr/Abl T315I mutation is a common mechanism of 
imatinib resistance
20
. We have demonstrated that the H/P;A/E MPD retains hematologic 
sensitivity to imatinib upon disease relapse. Thus, it seems more plausible that the LIC 
persistence in this model is a result of relative imatinib refractoriness, not resistance. One 
potential mechanism of refractoriness is increased production of the oncogenic kinase to 
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overcome small molecule inhibition. To determine if the LIC in our mouse model of 
CML persists secondary to increased oncogene production, we tested for H/P and A/E 
mRNA levels with qRT-PCR analysis of unfractionated WBM and splenocytes from 
imatinib treated mice.  As compared to vehicle treated WBM, imatinib treated WBM 
expressed equal amounts of H/P transcript. However, H/P transcript levels dropped 4-fold 
in spleen (p<0.05) (Figure 4.7). Two conclusions can be drawn from this finding. First, 
oncogenic tyrosine kinase transcript is still being produced in vivo despite a clear 
hematologic response and normalization of hematopoietic stem/progenitor cell 
frequencies.  This is further “molecular” evidence for LIC persistence consistent with the 
functional (Figure 3A,B) and phenotypic (Figure 3C,D) data presented earlier. Second, at 
the level of unfractionated hematopoietic cells, there is no obvious amplification of H/P 
transcript to explain imatinib refractoriness. In subsequent experiments, we have sorted 
LSK cells from imatinib responding mice and detected levels of H/P not significantly 
greater than untreated mice (data not shown).  
Interestingly, we observed significant increases in A/E transcript in unfractionated 
WBM and spleen of mice responding to imatinib (10-fold, 8-fold respectively, p<0.005, 
Figure 7). In bone marrow, this corresponded with a 4-fold increase in Aml1 transcript 
indicating that the Aml1 promoter itself may be activated. It is unclear whether these 
changes represent a numerical expansion of A/E expressing cells or an LIC-specific 
increase in A/E transcription.  Analysis of A/E expression in different cells did not show 
any such changes. Regardless, these data suggest that co-existing non-tyrosine kinase 
abnormalities may play a role in TKI resistance/refractoriness.  
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LICs are not eliminated by enhanced H/P kinase inhibition. 
Nilotinib is a Bcr/Abl inhibitor with 20-fold more potency against Bcr/Abl than 
imatinib. It is used clinically because it possesses TKI activity against common kinase 
domain point mutants with IM resistance
21
. It is also a potent inhibitor of PDGFβR and in 
vitro work has shown that nilotinib has a lower IC50 than imatinib in TEL/PDGFβR 
transformed Ba/F3 cells
22,23
.  To determine if more potent inhibition of oncogenic H/P 
signaling would lead to enhanced LIC elimination, we treated a cohort of diseased 
chimeric H/P;A/E mice with nilotinib. After 21 days of therapy, nilotinib-treated mice 
displayed a complete hematologic response with normalization of spleen size and 
reduction of leukocytosis (Figure 4.8). Interestingly, WBC count dropped below Cre
neg
 
levels suggesting more potent inhibition of myelopoiesis than imatinib. Cytometric 
analysis of bone marrow and spleen demonstrated reduction of Gr1
+
Mac1
+
 frequency to 
Cre
neg
 levels, similar to the effects observed with imatinib. Unlike the response to 
imatinib, we did not observe a rescue of the HSC depletion associated with the MPD. To 
functionally assess for elimination of the LIC(s), nilotinib therapy was withdrawn from a 
group of mice after 14 days of treatment. All mice in this group relapsed with MPD 
within 7 days of therapy withdrawal (n=3). The relapsed MPD appeared grossly and 
histologically similar to the un-treated disease (data not shown). We conclude from this 
data that more potent inhibition of H/P signaling by nilotinib is not able to effectively 
eliminate the LIC in this mouse model.  
 
LICs do not maintain CD47 upregulation during imatinib treatment. 
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 Another potential mechanism of imatinib refractoriness is LIC evasion of normal 
immunosurveillance. It has recently been shown that normal HSCs upregulate surface 
expression of the phagocytosis resistance marker CD47 in response to hematopoietic 
mobilizing stimuli (LPS, G-CSF etc), and that this protects HSCs from macrophage-
mediated phagocytosis during peripheral migration
24
. The authors of that study 
hypothesized that leukemic stem cells might co-opt this normal physiologic process to 
evade therapy. They found CD47 up-regulated on stem, progenitor and Mac1
+
 cells in an 
MRP8-BcrAbl/Bcl2 transgenic mouse model CML. However those mice do progress to 
AML and it is unclear at what stage CD47 expression was observed. To test this 
hypothesis in the H/P;A/E model of CML, we measured CD47-FITC fluorescence 
intensity on various cell populations of 
 
Cre
neg
 control mice, as well as vehicle and 
imatinib treated H/P;A/E mice.  When normalized to Cre
neg
 control levels, we found 
ubiquitous up-regulation of CD47 staining intensity with the largest increase found in the 
LSK compartment (Figure 4.9, black bars, p<0.005 for all cell populations). However, 
imatinib treatment reduced CD47 expression to Cre
neg
 control levels even in the LSK 
population (grey bars).  In fact, no unique cell population maintained significantly 
increased CD47 expression during imatinib treatment suggesting that protection from 
peripheral phagocytosis is not the principal mechanism of LIC persistence in this mouse 
model of CML.  Because we also observed upregulation of CD47 on CD45.1 recipient 
cells in diseased mice, an extrinsic mobilization effect of the disease was likely (data not 
shown). We conclude that global upregulation of CD47 in the H/P;A/E MPD is 
secondary to a mobilization effect of the disease itself on the bone marrow.  What 
cytokines are produced as a result of the disease to produce mobilization is unknown.  
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Clearly, immune evasion by increasing expression of CD47 is not the cause of LIC 
persistence in this mouse.  
 
Imatinib inhibits hyperproliferation but does not induce apoptosis of LSK cells in 
H/P;A/E MPD. 
 Like tissue stem cells, HSCs have a robust capacity to increase their proliferative 
rate upon insult or injury. This capacity for increased proliferation is balanced by a 
relative state of quiescence during homeostasis to minimize the genetic risks associated 
with cell division. LICs may or may not share these properties with HSCs
25
. We 
hypothesized that a population of leukemogenic cells in the H/P;A/E MPD might display 
abnormally increased proliferative rates despite disease control with imatinib. To test this 
hypothesis, as well as determine the cell types that drive abnormal myeloproliferation, we 
tested for short-term bromodeoxyuridine (BrdU) incorporation. BrdU is incorporated into 
the DNA of cells in S-phase of the cell cycle and a 24 hour window of BrdU exposure 
has been shown to label 6% of long-term HSCs
26
. Diseased chimeric transplant recipients 
(Cre
neg
 or H/P;A/E) were treated for 14-35 days with vehicle or imatinib. Twenty-four 
hours prior to sacrifice, mice were injected intraperitoneally with 1mg of BrdU. Whole 
bone marrow was isolated and stained for surface markers, followed by cell fixation, 
DNAse treatment, BrdU labeling and flow cytometric analysis. Figure 4.10 shows 
representative FACS plots of cells from Cre
neg
 control, vehicle and imatinib treated mice. 
We did not observe any statistically significant change in BrdU incorporation into whole 
bone marrow or LK cells of vehicle treated diseased mice. However, LSK cells from 
these mice displayed an almost 2-fold increase in BrDU incorporation (p=0.042) 
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compared to Creneg controls. This increased proliferation was observed in all of the LSK 
subpopulations analyzed including Flt3
+
 and Flt3
- 
cells as well as CD48
+
 and CD150
+
48
-
 
cells (data not shown). This indicates that a stem-like hematopoietic cell, not a myeloid 
progenitor, is driving the aberrant myeloproliferation. After 14 days of imatinib 
treatment, BrdU incorporation into LSK cells had dropped to levels not significantly 
different from Cre
neg
 mice. This effect was also observed after just 3 days of treatment 
(data not shown). There was no concurrent drop in the proliferation of non-stem 
progenitor cells suggesting that H/P inhibition by imatinib is specific to the stem cell 
compartment. Imatinib treatment did not affect the 24-hour BrdU incorporation of any 
Cre
neg
 cell populations. However, we did observe increased BrdU incorporation into both 
CD45.1 and CD45.2 cells in diseased mice, suggesting an extrinsic hyperproliferative 
effect (data not shown). After 7 days of imatinib withdrawal and subsequent MPD 
relapse, BrdU incorporation into LSK cells increased again. These short term BrdU 
incorporation results indicate that a cell or cells within the LSK compartment are 
hyperproliferative and the increased cell cycle activity is dependent on H/P signaling. 
 Given the striking effect of imatinib on the proliferative rate of mutant LSK cells, 
we wanted to know if an apoptotic response was also being evoked. In vitro data from 
human CML samples indicates that physiologic concentrations of imatinib induce cell 
cycle arrest without inducing apoptosis of CD34
+
 cells
27
. We conducted AnnexinV 
surface staining of bone marrow cells from chimeric mice treated with imatinib for 3 
days. We chose this length of therapy because proliferation of LSK was inhibited but no 
significant changes in gross hematologic response were detected (spleen size, WBC 
count). We did not observe statistically significant changes in AnnexinV
+
 frequency in 
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any cell population (Figure 4.11). This lack of an apoptotic response is consistent with in 
vitro evidence that physiologic concentrations of imatinib are cytostatic, rather than 
cytotoxic.  
 
Induction of HSC cell cycle entry by cyclophosphamide/G-CSF does not increase the 
ability of imatinib to eliminate LICs.  
 Another potential mechanism by which LICs evade TKI-mediated cell death is by 
“hiding” in a quiescent state similar to the mechanism by which normal HSCs avoid 
chemotherapeutic toxicity. It is hypothesized that in this resting state, LICs do not rely on 
oncogenic signaling for survival and thus are able to withstand potent kinase inhibition. 
We wanted to test this hypothesis by inducing LIC cell cycle entry (mobilization) and 
concomitantly inhibiting H/P with imatinib. Based on our previous findings that LICs 
share phenotypic characteristics with HSCs, we used the well-established 
cyclophosphamide/G-CSF regimen (Cy/G) to induce mobilization
12
. To quantify the 
efficacy of this therapeutic combination, we measured donor chimerism at the study 
endpoint. If mobilization exhibited additive effects to TKI therapy, we would expect to 
see a decrease in the proportion of hematopoietic cells that are derived from the mutant 
donor population. We were specifically interested in the effect of this combination 
therapy on the LSK population given our data that donor LSKs are hyperproliferative and 
remain significantly expanded after imatinib therapy.  
  Chimeric mice were induced with pIpC and, following development of MPD, 
were treated as depicted in Figure 4.12A. Mice were first treated with imatinib for 14 
days and hematologic response was confirmed. Mice were then split into two arms, one 
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receiving mock injections, the other receiving a 5-day Cy/G regimen (“mock” and 
“mobilized”, see Methods12).  Imatinib was continued throughout this mock/mobilization 
treatment to avoid interruption of H/P inhibition. Peripheral blood analysis on the day 
after mobilization demonstrated significant myeloid shifts in all mice (data not shown) 
consistent with the ability of G-CSF to induce myeloid differentiation in vitro/vivo. All 
mice were continued on imatinib for 10 days following mobilization to allow for H/P 
inhibition in mobilized LICs.  At the end point mice were sacrificed for analysis of bone 
marrow cells.   
 Gross pathologic analysis of the two treatment groups did not show any 
significant additional therapeutic effect of the Cy/G treatment (Figure 4.12B). Spleen 
size remained unchanged and WBC counts trended down, but were not significantly 
different. There was a modest increase in the frequency of Gr1
+
Mac1
+
 cells in mobilized 
bone marrow. The only significant finding on cytometric analysis was depletion of bone 
marrow HSCs. While it is tempting to interpret this finding as indicative of elimination of 
LICs, the Cy/G regimen had an HSC depleting effect on Cre
neg
 mice as well (data not 
shown). Bone marrow cells were then quantitated for the fraction of cells that were donor 
derived. We did not detect significant differences in donor chimerism between mock and 
mobilized for any of the cell populations analyzed (Figure 4.12C). The donor chimerism 
of both groups (independent of cell type) trended higher than Cre
neg
 control donor 
chimerism. As seen in Figure 4.6B, LSK chimerism was significantly higher in mock 
mice compared to controls (Cre
neg
 vs. Mock, p=0.01). Mobilized mice maintained this 
difference indicating that HSC/LIC mobilization did not eliminate the persistent donor 
LSKs in chimeric mice (Cre
neg
 vs. Mobilized p=0.04). The absence of any clear 
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difference in chimerism between non-mobilized and mobilized groups suggests that 
Cy/G-CSF does not improve the ability of imatinib to eliminate donor LICs. In a separate 
group of mice, AnnexinV+ staining was measured on cells immediately following G-CSF 
treatment (Figure 4.12D). In this experiment, mice were treated with G-CSF alone 
(which has been shown to have HSC mobilizing effects
28
) and stained for apoptotic cells 
24 hours after the final G-CSF injection. Imatinib was administered for 14 days prior to, 
and during the mobilization regimen. We did not detect any differences in the frequency 
of apoptotic cells between mock and mobilized mice in this experiment. These 
experiments suggest that manipulating LICs out of quiescence does not alter the ability of 
imatinib to effectively induce apoptosis and eliminate the tumorigenic cells.  
 
DISCUSSION 
We have previously shown that concomitant expression of H/P and A/E from the 
endogenous mouse Hip1 and Aml1 loci leads to a fully penetrant, rapid onset imatinib-
sensitive MPD
1
. In that study, we found that LICs share phenotypic characteristics with 
HSCs and are not eliminated by imatinib therapy despite a robust hematologic response 
to the drug. We have built on those findings by further characterizing the hematopoietic 
system of H/P;A/E mice and investigating the mechanism of LIC persistence. In the 
present study, we primarily use a chimeric competitive transplantation model of the 
H/P;A/E induced MPD. This system provides unique advantages over the germline 
primary Mx1-Cre H/P;A/E mice. First, it more accurately reflects human leukemias 
because induction of somatic translocations is limited to a fraction of hematopoietic cells. 
Second, it allows for analysis of large cohorts of mice derived from the same primary 
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donor, thus minimizing the variability of pre-existing mutations as well as the variability 
of disease progression. Third, it allows differentiation between the effects of therapies on 
wildtype (i.e. toxic) and mutant (i.e. therapeutic) populations. 
 Using the chimeric transplant system, we have further characterized 
hematopoietic stem and progenitor cells within the MPD. While phenotypic “definitions” 
of various hematopoietic cells are continuously evolving, we used well established 
surface marker combinations
19,29
. As expected, significant alterations within the myeloid 
progenitor compartment were found. The frequency of CMPs and MEPs was drastically 
reduced while the frequency of GMPs remained unchanged. As a fraction of all myeloid 
progenitors, GMPs were significantly increased, indicating a shift in differentiation 
favoring granulocyte production. Following 14 days of imatinib treatment, all myeloid 
progenitor frequencies and ratios returned to wildtype levels. We did not observe an 
increased rate of proliferation of any myeloid progenitor subtypes.  Importantly, limiting 
activation of H/P and A/E to GMPs (but not HSCs) with an MRP8-Cre transgene did not 
lead to development of MPD. Taken together these data indicate that the LIC is unlikely 
to reside in the GMP population. It should be noted that in human blast crisis CML, 
GMPs gain the stem cell property of self-renewal via activation of β-catenin30. We are 
currently conducting GMP transplants from diseased and imatinib-responding mice to 
determine if this progenitor population is capable of initiating and maintaining the MPD 
in recipient mice. 
 In addition to the dramatic progenitor cell alterations described above, we have 
continued to find significant changes within the stem cell compartment. Most 
interestingly, we found a decrease in phenotypic MPPs (Flt3
+
LSK) and LT-HSCs 
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(CD150
+
CD48
-
CD41
-
LSK). While it is difficult to functionally validate the phenotypic 
MPP depletion, we have shown that the LT-HSC depletion is functional as well as 
phenotypic. Importantly, we did not detect any changes in the overall LSK population 
frequencies highlighting the heterogeneity of this phenotype. Furthermore, LSK cells 
from diseased mice were unable to engraft irradiated recipients or transfer disease 
suggesting a decrease in functional HSC/LIC frequency even within this population often 
described as a stem cell. These data emphasize that investigators should take care not 
interpret the LSK phenotype as a surrogate for HSC/LIC function.  
We previously used a transplant assay to prove the persistence of LICs in the 
H/P;A/E mouse. We now describe the more clinically relevant situation of therapy 
interruption. As with CML patients who discontinue imatinib therapy, we have found that 
the H/P;A/E mouse MPD returns within 7 days of imatinib discontinuation
4,31
. The 
relapsed disease retains hematologic sensitivity to imatinib indicating that the persistent 
LICs are not drug resistant clones. Based on these data, and the incomplete 
transplantation of disease, we think that therapy withdrawal in mouse models is a gold 
standard for making qualitative (and perhaps quantitative) conclusions about the efficacy 
of LIC targeting.  
Given the multiple lines of evidence for LIC persistence in vivo, we used the 
chimeric system to interrogate the frequency and behavior of these cells. A priori, our 
hypothesis was that imatinib would lead to near complete elimination of donor type cells 
and that only a rare cell population would remain. This rare population would be the 
primary suspect in our quest to identify the LIC.  Moreover, we predicted that this would 
be a unique cell type which is suppressed from differentiating or self-renewing. This 
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hypothesis presumes that the active LIC is dependent upon H/P signaling for 
leukemogenesis and/or survival. To our surprise, the bone marrow of imatinib-responding 
mice contained very large numbers of donor type cells which express the H/P and A/E 
oncogenes. These cells were distributed across myeloid and lymphoid lineages similar to 
control mice. In fact, donor cells made up a larger component of the bone marrow than 
cells from control Cre
neg
;H/P;A/E mice which do not develop disease. Importantly, there 
was no unique population of mutant donor type cells that persisted (LSK were the only 
cells with statistically significant elevation above control type cells).  In contrast, spleen 
donor chimerism dropped below levels in Cre
neg
 control mice suggesting effective 
clearance of disease from this peripheral collection tissue. The persistence of robust 
levels of cells in which the H/P and A/E oncogenes have been activated suggests to us 
that the LIC(s) in this system is capable of reverting to the functions of its normal 
counterpart, the HSC.  
Despite reversion to HSC-like functions, we found that the LIC (or some other 
donor type cell) is still producing oncogenic transcript (A/E transcript actually increased) 
in the bone marrow. Our data indicate that H/P transcript is not upregulated in stem or 
progenitor cells during imatinib therapy. It is unclear whether this persistent transcript is 
ultimately translated into functional oncoprotein. We are currently testing the activation 
status of tyrosine kinase pathways in specific cell populations. Nonetheless, the 
maintenance of similar levels of H/P transcript suggests two things. First, LICs are not 
being “converted” into HSCs by complete shutdown of the oncogenes responsible for the 
initial myeloproliferation. Second, tyrosine kinase inhibitor refractoriness is not being 
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caused by amplification of fusion tyrosine kinase transcript in this H/P;A/E model of 
MPD.  
Another possible mechanism of LIC persistence is evasion from 
immunosurveillance. Based on previous reports, the hematopoietic surface marker CD47 
is upregulated in myeloid leukemias and, by binding its receptor SIRPα on macrophages, 
provides protection from phagocytosis
24
. In the H/P;A/E induced MPD, CD47 is globally 
upregulated on all hematopoietic cell types tested although most significantly on the LSK 
population. Importantly, surface CD47 returns to wildtype levels upon a response to 
imatinib. This data suggests that immune evasion via persistence of upregulated CD47 
expression is not the principal mechanism of LIC persistence in this mouse model of 
MPD.   
As further evidence of the HSC origin of disease in the H/P;A/E induced MPD, 
short-term BrdU incorporation data demonstrate that a cell or cells within the LSK 
compartment display increased proliferation. This hyper-proliferation is entirely 
dependent on H/P signaling and even minimal tyrosine kinase inhibition led to a return to 
normal. Despite this increased proliferation, we have not yet observed progression of the 
H/P;A/E MPD to  blast crisis. This is in contrast to the JunB knockout mouse model of 
CML which progresses through the chronic, accelerated and blast crisis phases typically 
observed in humans
32
. We are conducting longer-term observation studies of H/P;A/E 
mice to determine if progression occurs. Furthermore, a retroviral insertional mutagenesis 
screen may identify cooperating mutations that induce progression from the indolent, 
treatable chronic phase of CML to the aggressive, less treatable blastic phase.  
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There is a wealth of data using cultured CD34
+
 cells from human CML patients 
that demonstrate therapeutic concentrations of imatinib are principally cytostatic, 
inhibiting the proliferation of primitive progenitors without significantly inducing 
cytotoxicity via apoptosis
27,33
. Here, we corroborate that result in vivo using proliferation 
and cell death assays. More importantly, we demonstrate that this cytostatic rather than 
cytotoxic response to imatinib poses a challenge to achieving absolute elimination of the 
mutant cell populations, a likely source of disease relapse and progression. Here we show 
functional persistence of LICs and unexpectedly, phenotypic persistence of multiple cell 
types containing the H/P and A/E oncogenes. These data support the notion that an LIC is 
not addicted to activated tyrosine kinase signals and thereby is able to revert to essentially 
normal HSC function when under the influence of tyrosine kinase inhibition. This 
independence from oncogenic kinase signaling suggests that therapeutic advances will 
necessarily come from two possible approaches. First, ways to convert the LIC to an 
oncogene-addicted state might allow more effective targeting by imatinib. Second, 
discovery and inhibition of non-kinase pathways that are critical to LIC, but not HSC, 
survival and homeostasis would complement the cytostatic effect of imatinib.  
It is well-established that the most quiescent leukemic cell populations in CML 
are insensitive to imatinib and recent studies have attempted to enhance cell cycle entry 
as a means of improving imatinib sensitivity in vitro
8-10
. This hypothesis was tested 
clinically in a small phase II trial published in 2009
34
.  Imatinib-responding CML patients 
were randomized to three treatment arms: continuous imatinib (cIM), pulsed imatinib 
(pIM) and pulsed imatinib plus G-CSF (pIM/G).  No significant difference in BCR-
ABL/ABL transcript ratio was detected between pIM and pIM/G. Of note, 6 of 30 
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patients in the experimental arms (pIM, pIM/G) exhibited disease progression versus 1 of 
15 in the control arm (not significant, progression defined as loss of 
cytogenetic/molecular remission). A followup study developed a novel mathematical 
model to simulate these clinical results
7
. This theoretical analysis predicted no added 
benefit of G-CSF to imatinib and in fact, an increased risk of mutations leading to IM 
resistance via an increased pool of cycling leukemic stem cells. In vivo validation of these 
limited human results in a clinically relevant mouse model is lacking. We used the 
imatinib-sensitive MPD induced by H/P and A/E to test whether induction of LIC cycling 
by cyclophosphamide/G-CSF enhances sensitivity to tyrosine kinase inhibition in vivo. 
Imatinib treatments were maintained during the mobilization regimen to minimize 
disease relapse. We did not observe any change in LIC sensitivity to imatinib following 
the cyclophosphamide/G-CSF mobilization protocol as determined by AnnexinV staining 
and donor chimerism levels. This result implies that mobilized LICs retain their 
independence from H/P signaling. We are currently conducting trials with other HSC/LIC 
mobilization regimens (arsenic trioxide, IFNγ) to confirm or refute our conclusion that 
induction of cell cycle entry does not alter the in vivo  sensitivity of the H/P;A/E LIC to 
imatinib. It should be noted that none of the mobilized mice displayed re-emergence of 
disease or blastic progression when maintained on IM.  
A recent study using human CML cells and the inducible Bcr/Abl transgenic 
model of CML demonstrated that the combination of imatinib and histone deacetylase 
inhibitors (HDACi) was effective at targeting LICs
35
.  In vitro evidence strongly suggest 
that AML1/ETO recruit HDACs to the Aml1 promoter, thus inhibiting the normal 
transcriptional activity of this critical hematopoietic regulator
36-38
. We have tested the 
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HDACi suberoylanilide hydroxamic acid (SAHA) in the H/P;A/E mouse model of MPD 
and found no hematologic response (data not shown). Furthermore, the combination of 
SAHA and IM showed no added benefit of SAHA to the gross hematologic response 
evoked by IM. However, further evaluation of combination TKI/HDACi therapy on LICs 
is ongoing.    
While the precise immunophenotype of the LIC in the H/P;A/E induced MPD is 
not yet known, we favor the notion that, in the absence of blastic transformation, HSCs 
are the only normal cells capable of self-renewal, and thus must be the ultimate cell of 
origin for the MPD. Surface markers or gene expression changes that distinguish normal 
HSCs from mutant LICs are of paramount importance in developing LIC targeted 
therapies. Because our data indicate that addition of HDAC inhibitors and cellular 
mobilization agents to the imatinib therapy was largely ineffective, we are currently 
studying the molecular differences between HSCs from imatinib treated H/P;A/E mice 
and imatinib treated Cre
neg
;H/P;A/E mice to discover new therapeutic targets. The 
inability to cure CML with imatinib, the toxicities of allogeneic bone marrow transplant  
and the expense and possible side effects of long term imatinib treatment are legitimate 
reasons to pursue novel therapies for elimination of this disease. Identification, 
characterization and targeting of the LICs in H/P;A/E mice will contribute to the 
identification of new molecular targets in CML. 
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Genotype n 
Latency 
(wks) 
Total diseased 
Wildtype 2 - 0 
H/P-KI;Mx1-Cre;Aml1
LSL-A/E
 2 1-6 2 
 
 
Genotype n 
Age 
(wk) 
Total diseased 
Wildtype 3 7 0 
Vav1-Cre;H/P;A/E 3 7 3 
Widltype 2 12 0 
MRP8-Cre; H/P;A/E 2 12 0 
 
 
Table 4.1: Development of MPD depends on expression of H/P and A/E in stem cells 
but not on the order of oncogene activation.  
Top, Incidence and type of disease observed in germline H/P-KI and control mice. A 
cohort of age-matched littermate mice were mutagenized with ENU (+/- G-CSF 
pretreatment) and sacrificed at 1 year. Middle, Incidence and latency of MPD in H/P-
KI;Mx1-Cre;Aml1
LSL-A/E 
mice. Bottom, Incidence and latency of MPD induced by 
activation of H/P and A/E by Vav1Cre and MRP8-Cre transgenes.  
  
Genotype n 
Age   
(yr) 
Liver 
Tumor 
Lethal 
Disease 
Spleen 
>150mg 
Thymus 
>100mg 
Lymph 
Mass 
Total 
w/disease 
Wt 2 <1 0 0 0 0 0 0 (0%) 
H/P-KI 16 <1 0 0 0 0 0 0 (0%) 
Wt 
(ENU) 
6 1 0 0 1 0 0 1 (17%) 
H/P-KI 
(ENU) 
18 1 0 1 2 1 0 5 (28%) 
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Figure 4.1: Stem cells from H/P;A/E mice have decreased reconstituting potential. 
A, 3000 Lin-c-Kit+Sca1+ (LSK) cells were FACS sorted from control (Cre+;+/+;+/+, 
n=1) or diseased (Cre+;H/P;A/E, n=1) primary mice and transplanted into lethally 
irradiated syngenic recipients along with 3x10
5
 wildtype SJL bone marrow cells (5 
recipients each). The average peripheral blood engraftment in various lineages was 
measured 15 weeks after transplant B, Single LT-HSCs (CD150+CD48-CD41-LSK) 
from control or diseased primary mice were directly sorted into cytokine-supplemented 
methylcellulose. Colony formation was assessed after 14 days. Top row, control. Bottom 
row, H/P;A/E diseased.  
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Figure 4.2: Schematic of competitive transplant system  
Bone marrow cells from wildtype CD45.1 (yellow) and experimental CD45.2 (black) 
donor mice is transplanted at a specific ratio (depicted 1:1) into lethally irradiated 
CD45.1 recipients. Following 4-6 weeks of engraftment, mice are treated with pIpC for 2 
weeks and then analyzed for disease and changes in donor chimerism.  
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Figure 4.3: Hematopoietic progenitor cell alterations during H/P;A/E induced MPD 
and normalization with imatinib therapy.   
Competitive transplants were performed as described in Figure 2 using Cre
neg
;H/P;A/E 
donor cells  (Cre
neg
, recipient n=6, no treatment) and Cre
+
;H/P;A/E donor cells (recipient 
n=10). Chimeric recipients were treated with pIpC and developed MPD within 4-6 
weeks. Recipients of Cre
+
;H/P;A/E cells were then treated with vehicle (n=6) or imatinib 
(n=4) for 14-35 days. (A) FACS plots  showing Gr1
+
Mac1
+
 expansion in bone marrow 
and response to imatinib. (B) FACS plots depicting gating for Lin
-
 myeloid progenitor 
cells. (C) Quantification of mature myeloid and progenitor cell alterations in H/P;A/E 
induced MPD. Middle row, myeloid progenitors frequency of live cells, Bottom row, 
myeloid progenitor frequency of LK population. LK=Lin
-
Sca1
-
c-Kit
+
, GMP = 
Granulocyte/Macrophage progenitor, MEP = Megakaryocyte/Erythrocyte progenitor, 
CMP = common myeloid progenitor. *p<0.05, **p<0.005, NS=not significant. Data from 
one of two independent competitive transplants conducted.  
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Figure 4.4: Hematopoietic stem cell phenotypic changes during H/P;A/E induced 
MPD and normalization with imatinib therapy.  
Primary Cre
neg
 or H/P;A/E mice were induced with pIpC and treated with vehicle or 
imatinib for 7-14 days. (Untreated Cre
neg
 n=7, Vehicle n=7, Imatinib n=4). (A) FACS 
plots depicting initial gating for LSKs and subsequent gating for MPPs or LT-HSCs (B) 
Overall frequency of various HSC subpopulations. LSK=Lin-Sca1+c-Kit+, *p<0.05, 
**p<0.005.  
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Figure 4.5: Functional evidence for persistence of MPD-initiating cells during 
imatinib therapy.  
Cre
neg
;H/P;A/E recipients were treated with vehicle (n=12) or imatinib (n=3) for 3 days. 
Cre
+
;H/P;A/E recipients were treated with vehicle for 14-35 days (n=10) or imatinib for 3 
days (IM3, n=8) or 14-21 days (IM14, n=9). One group of Cre
+
;H/P;A/E recipients was 
treated with imatinib for 14-35 days followed by 7 days with no treatments (IMwd, n=8). 
(A) Left, Spleen weight as percent of body mass. Right, Frequency of CD150+CD48-LSK 
(LT-HSC).  (B) Left, Example of white blood cell trend upon interruption of imatinib 
therapy. Right, Example of white blood cell trend when imatinib therapy is initiated 
immediately after pIpC. Gray boxes indicate periods of imatinib treatments.  
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Figure 4.6: Phenotypic evidence for persistence of MPD-initiating cells during 
imatinib therapy.  
Chimeric Cre
neg
;H/P;A/E recipients were treated with imatinib (n=4) for 3 days. 
Cre
+
;H/P;A/E recipients were treated with vehicle (n=3) or imatinib (n=5) for 14 days. 
(A) FACS plots of recipient (CD45.1, y-axis) and donor (CD45.2, x-axis) contributions to 
Gr1
+
Mac1
+
, LK and LSK populations. (B) The proportion of each cell population that is 
donor-derived (calculated as [CD45.2]/[CD45.1+CD45.2]). Bar graph represents 
difference between experimental groups and Cre
neg
 control chimerism. LSK=Lin-Sca1+c-
Kit+, LK=Lin-Sca1-c-Kit+. *p<0.05, **p<0.005, NS=not significant Spleen data are 
from a 2:1 transplant ratio. WBM data are from a 1:4 transplant ratio.  
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Figure 4.7: Oncogene transcription in response to imatinib. 
Expression levels of H/P, A/E, Hip1, and Aml1 were assessed by quantitative PCR in 
whole bone marrow (WBM) cells and splenocytes. The RNA content of samples was 
normalized based on GAPDH and fold-change comparisons were made between imatinib 
(n=3) and Cre
neg
 (n=3) cells (Cre
neg 
cells were set to 1 for purposes of the comparison). 
Data represent mean±SD.  
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Figure 4.8: Enhanced kinase inhibition does 
not eliminate LICs. 
Chimeric recipient mice were treated for 21 days 
with vehicle (Veh, n=3) or nilotinib (NIL, n=3). 
One group was treated with nilotinib for 14 days, 
then withdrawn for 7 days (wd, n=3).  Control 
mice (Cre
neg
, n=3) were not treated.  Spleen 
weight was normalized to body mass. ‡ WBC for 
vehicle treated mice  was too high to accurately 
measure and is reported as 200K/ul for all mice.   
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Figure 4.9: CD47 is upregulated in MPD but returns to baseline with imatinib 
response. 
Chimeric recipients were treated with vehicle or imatinib for 14 days and bone marrow 
cells were stained with CD47-FITC. Left, sample histogram plots of CD47 fluorescence 
intensity within different bone marrow cell populations. Dotted line drawn at Cre
neg
 
median. Right, quantification of mean fluorescence intensity for multiple cell populations 
(relative to Cre
neg
). All vehicle values are significantly greater than Cre
neg
 (*p<0.005), but 
none of the imatinib values are significant. Cre
neg
 n=3, Vehicle n=3, Imatinib n=3. WBM 
= whole bone marrow, Lin
-
 = lineage negative, LK = Lin
-
c-Kit
+
, LSK = Lin
-
c-Kit
+
Sca1
+
, 
LT-HSC = CD150
+
CD48
-
CD41
-
LSK.  
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Figure 4.10: Imatinib inhibits LSK hyperproliferation in H/P;A/E MPD. 
Chimeric recipients were treated with vehicle or imatinib for 14-35 days. 24 hours prior 
to sacrifice, mice were injected with 1mg of BrdU. Top, sample FACS plots of BrdU 
incorporation into WBM or LSK cells. Bottom, Quantification of BrdU incorporation into 
different populations.  Creneg (n=5), Vehicle (n=7), Imatinib (n=6), Withdrawal (n=8). 
*p<0.05 compared to Cre
neg
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Figure 4.11: Imatinib does not induce an apoptotic response in vivo  
Diseased recipient mice were treated with vehicle or imatinib for 3 days (6 doses). Bone 
marrow cells were analyzed for AnnexinV staining one hour after sacrifice. Top, Sample 
FACS plots of apoptotic cells. Bottom, Frequency of AnnexinV+ cells within given 
population. Vehicle n=3, Imatinib n=3.  
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Figure 4.12: Mobilization of LICs does not enhance their sensitivity to imatinib  
A. Treatment schedule for chimeric mice with MPD (Mock n=5, Mobilized n=5) B, Gross 
and cellular analysis of mock and mobilized (Cytoxan/G-CSF) mice: normalized spleen 
weight, WBC, Gr1+Mac1+ frequency, LTHSC frequency  C, Donor chimerism of WBM 
and  specific cell populations.  The only population with significantly different donor 
chimerism was LSK (mock and mobilized). No differences were detectable between 
mock and mobilized mice, with the exception of bone marrow LTHSC frequency.  
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CHAPTER 5 
 
CONCLUSION 
 
A cryptic splicing event partially rescues a targeted knockout of Hip1 
 The focus of this thesis has been investigating the role of the oncogenic fusion 
protein HIP1/PDGFβR in mouse leukemogenesis. Prior to beginning this investigation, I 
participated in the characterization of a Hip1 knockout allele termed Hip1
Δ3-5
, which is 
described in chapter 2. Previously, germline Hip1 and Hip1/Hip1r knockout mice 
generated in our laboratory exhibited severe degenerative phenotypes characterized by 
spinal deformities, weight loss, shortened lifespan and testicular degeneration. This data, 
together with other in vitro data suggests that the HIP1 family plays a critical role in 
cellular survival and homeostasis. The previous knockout mice also exhibited decreased 
tumor formation (number and severity) in the TRAMP mouse model of prostate 
tumorigenesis, suggesting that HIP1 may be necessary for tumor initiation and/or 
progression. This was also suggested by earlier findings of HIP1 overexpression in 
prostate cancer that was predictive of a bad outcome. However, these germline mouse 
findings are difficult to interpret because of the deficiency of HIP1 in all tissues and cell 
types, the severe degenerative phenotypes of affected mice and the possible effects of the 
complex targeting vector on expression of neighboring genes.  
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To resolve these issues, we attempted to generate a conditional Hip1 knockout 
allele. Our approach was to delete the ANTH-coding domain known to be necessary for 
normal HIP1 function in vitro, while simultaneously inducing a nonsense frameshift 
mutation that would lead to a truncated non-functional protein product. Following 
germline recombination of the loxP sites using CMV-Cre transgenic allele, the Hip1
Δ3-
5/Δ3-5 
mouse was predicted to recapitulate most (if not all) aspects of the previously 
described Hip1
null/null
 mouse. As expected, Hip1
Δ3-5/Δ3-5 
mice did display spinal defects 
and male infertility secondary to testicular degeneration, similar to the gross phenotype of 
Hip1
null/null
 mice. However, these mice did not exhibit ophthalmic abnormalities and the 
spinal defects were less severe than the prior knockout. We initially hypothesized that 
these differences might be due to absence of neighboring gene effects of the Hip1
null 
allele.  
To our surprise, Hip1
Δ3-5/Δ3-5
 mice displayed breast and prostate tumor 
susceptibility more comparable to Hip1
+/+
 than to Hip1
null/null 
mice. This striking 
difference, as well as the detection of a truncated protein product in cultured tumor tissue, 
suggested that the Hip1
Δ3-5 
allele was more complex than originally thought. Further 
DNA, RNA and protein analysis demonstrated the presence of a cryptic U12-dependent 
splicing event that inserted an AG dinucleotide to restore the wildtype reading frame and 
produce a nearly full-length HIP1 protein product. We demonstrated that this HIP1Δ3-
5insAG
 
protein product retains clathrin, AP2, lipid and EGFR binding capacity in vitro. 
The expression of this truncated protein was detected in brain, lung, embryonic 
fibroblasts and neoplastic tissue and was notably not detected in other adult tissues that 
normally express HIP1. It remains unclear how expression of the HIP1Δ3-5insAG protein 
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is insufficient to prevent the adult degenerative phenotype but sufficient to restore breast 
and prostate tumorigenesis. One possibility is that the altered tissue expression profile 
includes loss of functional protein product in a critical tissue type. Testing various tissue-
specific Cre alleles should allow dissection of the location and timing of HIP1 necessity 
in cellular homeostasis. Another possibility is that an unknown function of HIP1 is lost in 
the HIP1Δ3-5insAG protein and this function is necessary for normal cellular processes 
but not tumorigenesis. Characterization of the Hip1
Δ3-5 
allele has provided insight into the 
complexity of the Hip1 genetic structure and shed light on one potential mechanism (U12 
splicing) by which a gene targeting event to knockout a protein may be thwarted. Future 
generation of a true conditional knockout of Hip1 will add to the understanding of this 
gene in normal and cancer biology.  
 
Modeling the HIP1/PDGFβR oncogene in mice  
 Mouse models of human cancers are a critical tool for understanding the biology 
of tumorigenesis. Some aspects of tumor biology such as niche effects, 
immunosurveillance and metastasis can only be evaluated in the intact organism. Given 
the scarcity of accurate mouse models of CML, as well as the relative inefficiency of 
CML xenotransplantation, we sought to model H/P-induced human CMML in mice. In 
chapter 3 of this thesis, we describe a conditional knockin of human H/P into the mouse 
Hip1 locus. Unlike the retroviral transduction and transplantation method (BTT), which 
led to a fatal myeloproliferative disorder, endogenous expression of H/P in adult 
hematopoietic cells was insufficient for leukemogenesis. This striking contrast between 
BTT and genetically engineered mouse models has been appreciated for multiple other 
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human oncogenes including Flt3-ITD, AML1/ETO, BCR/ABL and MLL/AF9
1-4
. Chen 
and colleagues attributed this difference to gene dosage and target cell specificity
4
. 
Endogenous expression of Mll-AF9 from the mouse Mll promoter was able to transform 
LSK cells but not GMPs. However, both LSKs and GMPs were susceptible to 
transformation by high-level Mll-AF9 retroviral transduction.  The phenotypic variability 
associated with the various methods of oncogene expression is likely due to a 
combination of the differences in expression level, cell specificity and cooperating 
mutations. Future work with the H/P knockin mouse will elucidate the precise cell types 
that express the fusion oncogene (mRNA and protein) and whether gene dosage is critical 
for MPD. While frank leukemias were not observed in the H/P knockin mouse, it is 
possible that sub-threshold kinase signaling induces subtle hematopoietic changes. More 
sensitive functional assays such as HSC transplants and methylcellulose re-plating assays 
may uncover these subtleties and help identify the mechanism of cooperation with A/E. 
Retroviral insertional mutagenesis (potentially coupled to introduction of Cre) may also 
lead to identification of other cooperating mutations for induction of MPD.  
 The failure of conditional H/P knockin mice to develop disease could be due to 
any of the reasons outlined above, but we favor the notion that additional transforming 
mutations are required for myeloid transformation. Gilliland and others have proposed a 
“2-hit” model of myeloid leukemia in which a mutation in each of two broad classes of 
genes are required: (1) Mutations which confer survival and/or proliferative advantages 
to hematopoietic stem/progenitors and (2) Mutations which interfere with normal 
hematopoietic differentiation
5
. Neoplastic cells from most patients with de novo AML 
express only one mutation from each class, providing indirect epidemiologic evidence for 
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this 2-hit hypothesis
6
. The first class of mutations includes the X/P fusions as well as 
activating mutations in Flt3, N-ras, K-ras and cKit. The second class includes gene 
rearrangements such as CBFβ/SMMHC, PML/RARα, and AML1/ETO (A/E). Extensive 
in vitro and in vivo work has shown that A/E exerts its oncogenic activity by impairing 
the normal function of the hematopoietic transcription factor AML1 (Runx1)
7-10
. 
 Given the lack of a striking phenotype in the H/P knockin mouse (as compared to 
the H/P or T/P retroviral system), we tested the ability of the A/E mutation to cooperate 
with H/P in vivo. BTT studies have shown that co-expression of A/E transforms the 
myeloproliferative disorder induced by T/P or activated FLT3 into blastic leukemia
11,12
. 
To improve upon and compare with this retroviral cooperation, we chose to cross our H/P 
knockin mice with a conditional knockin of A/E which also fails to develop myeloid 
neoplasms in isolation
2,11
. Co-expression of H/P and A/E from their respective mouse 
promoters in the adult hematopoietic system rapidly led to an aggressive MPD, validating 
the cooperation observed in the BTT assay. Two important findings stand out from this 
result. First, the disease induced by H/P and A/E endogenous co-expression is a fully 
differentiated, mature myeloid neoplasm, unlike the immature, blastic T/P;A/E retroviral 
disease. It is possible that this is due to differences between H/P and T/P kinase signaling, 
although it is more likely secondary to the fundamental differences between the model 
systems (direct testing of this will require H/P;A/E retroviral co-transduction). Second, 
the extremely short latency of the disease suggests complete sufficiency of H/P and A/E 
cooperation. Importantly, we have not yet observed blastic transformation in these double 
knockin mice, suggesting that endogenous expression of A/E in stem cells does not 
inhibit hematopoietic differentiation. While this result seems to run contrary to the 
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premise of the 2-hit hypothesis, clearly A/E must induce changes at the cellular or 
molecular level that cooperate with the mitogenic signaling of H/P to induce 
myeloproliferation. In the original report of the A/E conditional knockin, the authors 
describe an enhanced methylcellulose re-plating capacity for A/E expressing cells
2
. It is 
unclear how (or if) this gain of self-renewal occurs in vivo and if it contributes to the 
H/P;A/E disease. Another possibility is that A/E expression potentiates H/P signaling by 
increasing H/P levels or by enhancing expression of downstream targets. Data to support 
this would include cell-specific detection of activated PDGFβR signaling pathways. Yet 
another possibility is that A/E somehow shifts the balance between myeloid and 
lymphoid differentiation. To address these possibilities, we plan to isolate hematopoietic 
stem and progenitor cells from single and double knockin mice after pIpC induction to 
conduct gene expression microarrays and competitive transplants. Further studies of the 
signaling expression patterns in H/P and A/E single knockin mice and the H/P;A/E 
double knockin mouse will hopefully elucidate the mechanism of cooperation between 
these oncogenes.  
 
Characterization of the H/P;A/E mouse model of MPD 
 Chapters 3 and 4 describe the gross and cellular phenotype of the MPD induced 
by H/P and A/E. Similar to human myeloproliferative disorders, the H/P;A/E induced 
MPD is characterized principally by splenomegaly and neutrophilia. This expansion of 
normal appearing neutrophils is a hallmark of MPD and distinguishes it from the more 
aggressive dysplastic forms of acute leukemia. We show that the disease is made up 
principally of Gr1
+
Mac1
+
 granulocytes which completely take over the bone marrow 
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space and spleen. As with other mouse models of MPD, we observed extramedullary 
myelopoiesis in the liver and spleen.  
 We examined the proportions of hematopoietic stem and progenitor cells in the 
H/P;A/E induced MPD and found significant myeloid progenitor alterations. There was a 
near absence of CMPs and MEPs but no changes in GMP frequency. This suggests a shift 
in myeloid differentiation that favors granulocyte production. We also found a profound 
decrease in MPP and LT-HSC frequency. Importantly, chimeric analysis of diseased 
H/P;A/E and wildtype cells demonstrated that the decrease in phenotypic LT-HSCs was 
not restricted to the donor population, suggesting that the chaos caused by rampant 
myeloproliferation has a negative regulatory effect on wildtype HSC survival. This 
extrinsic LT-HSC depletion (phenotypic) will need to be confirmed functionally by 
secondary transplants of the CD45.1 and CD45.2 fractions. Regardless, this non cell-
autonomous HSC depletion is an important aspect of CML that must be accounted for 
when monitoring response to therapy. Using the chimeric transplant system, we 
confirmed donor expansion of all myeloid lineage cells but not lymphoid cells, consistent 
with an MPD.  
 
Targeting the LIC in CML 
 Imatinib has been hailed as the poster-drug of targeted therapy in cancer. 
However, persistence of a CML-initiating cell or cells suggests that imatinib is acting to 
suppress, rather than eliminate disease
13
. Using the H/P;A/E mouse model of MPD, we 
have confirmed the presence of a persistent LIC despite a robust hematologic response to 
tyrosine kinase inhibition. Our data suggest that the mutant HSC is a candidate LIC, but 
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further studies of tumor-initiating capacity are needed to verify this. The imatinib 
sensitive MPD induced by H/P;A/E provides a unique animal model for testing the many 
hypotheses regarding LIC persistence.  
 Figure 5.1 depicts a model of LIC persistence in MPD. At the top is shown a 
simplified hierarchy of normal myeloid development, with dark blue HSCs (cycling 
between quiescent and activated states) differentiating into light blue myeloid progenitors 
which divide into lighter blue terminally differentiated mature myeloid cells. In MPD, an 
LIC (depicted as a dark orange mutant HSC) leads to hyperproduction of light orange 
myeloid progenitors and lighter orange mature myeloid cells. Three possibilities are 
presented for what a response to tyrosine kinase inhibition by imatinib might look like at 
the cellular level. Situation I assumes that myeloid progenitors with the oncogenic kinase 
are the only cells sensitive to elimination by imatinib (mature myeloid cells have a very 
short half-life and are rapidly cleared from the system). In this scenario, LICs circumvent 
(or remain unaffected by) kinase inhibition and continue to aberrantly differentiate and 
self-renew. However, the continued presence of imatinib summarily dispatches the 
overproduced myeloid progenitors, leaving behind a relatively rare (but active) 
population of LICs. Situation II assumes that LICs are sensitive to elimination by 
imatinib (i.e. addicted to oncogenic kinase signaling) when actively cycling, but not 
while quiescent. Thus, imatinib eliminates all cells containing the oncogenic kinase 
except a relatively rare, quiescent population of LICs. In situation III, the LIC and 
mutant progenitors are dependent upon oncogenic kinase signaling for leukemogenesis, 
but not survival. In this scenario, kinase inhibition by imatinib causes reversion to 
relatively normal HSC behavior. The end result is a hematopoietic compartment with a 
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mixed population of wildtype and mutant cells.  In all three of these scenarios, a 
persistent LIC serves as a reservoir for disease relapse upon discontinuation of imatinib.   
 While clearly a gross simplification of the complexity of CML and LIC 
persistence, this model provides a framework for understanding the H/P;A/E response to 
imatinib therapy. We have demonstrated that the H/P;A/E-LIC does not persist secondary 
to insufficient kinase inhibition as use of the more potent TKI nilotinib does not improve 
elimination of the LIC. We have also shown that the LIC does not maintain upregulation 
of the phagocytosis inhibitor CD47 as a means toward immuno-protection. These 
mechanisms can be classified as kinase-dependent and most likely fall into category I of 
LIC persistence. Another kinase-dependent mechanism of LIC refractoriness worthy of 
investigation will be determining if decreased intracellular imatinib concentration, via 
increased efflux or plasma sequestration of the drug is occurring.  
 Scenario II is an intriguing possibility that is supported by some in vitro data 14-16. 
This scenario lends itself to the hypothesis that cell cycle induction and concomitant TKI 
therapy may lead to enhanced LIC elimination. We have shown that HSC-mobilizing 
agents (cyclophosphamide + GCSF) do not enhance H/P;A/E-LIC sensitivity to imatinib 
in vivo. This result is consistent with the limited human data available
16
 as well as 
mathematical modeling of CML kinetics
17,18
. One explanation for our observed data is 
that LICs are resistant to cell cycle induction agents that mobilize wildtype HSCs. 
Another possibility is that mobilized LICs are not addicted to oncogenic H/P signaling. 
Further testing of the combination of imatinib and other mobilization agents is warranted, 
especially the drugs IFNα and arsenic trioxide which have been shown to enhance LIC 
elimination by chemotherapeutic drugs
19,20
.  
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  Using the chimeric transplant system, we have demonstrated that after clearance 
of bulk disease by imatinib, large populations of mutant donor cells persist. These include 
myeloid and lymphoid cells in wildtype ratios, suggesting that the LIC has reverted to 
normal HSC functionality (scenario III). It is unclear if this in vivo response to imatinib 
occurs in human patients with CML. An important inference from these data is that 
targeting of the H/P pathway might be insufficient for elimination of the LIC. Numerous 
other pathways and genes have been implicated in maintenance of the CML-LIC 
including: Pten, PML, Alox5, TGFβ/FoxO, HDACs, Hedgehog, Wnt/β-catenin and 
autophagy
20-27
. Further analysis of the H/P;A/E mouse model of MPD should focus on 
identifying non-kinase pathways that distinguish LICs from HSCs. An unbiased approach 
to this that is in progress is analysis of gene expression profiles of specific stem and 
progenitor cell populations isolated from imatinib-responding mice.  
 This thesis has focused on understanding the role of HIP1 in tumorigenesis and 
modeling the HIP1/PDGFβR human oncogene in mice. We have established a clinically 
relevant model of myeloproliferative disease that is driven by constitutive kinase 
signaling in hematopoietic stem cells. This model will serve as an excellent tool for 
understanding the basic biology of mouse hematopoiesis and tyrosine kinase signaling. 
Furthermore, this mouse provides a platform for analysis of drug responses in both the 
mutant and surrounding non-mutant hematopoietic and niche cells.   
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Figure 5.1: Proposed model for LIC persistence in vivo 
See text for description 
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